10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2010

Or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from              to             .

Commission file number: 000-26727

BioMarin Pharmaceutical Inc.

(Exact name of registrant issuer as specified in its charter)

Delaware	68-0397820
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
105 Digital Drive, Novato, California	94949
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number including area code: (415) 506-6700

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  ¨    No  ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	x		Accelerated filer	¨
Non-accelerated filer	¨	(Do not check if a smaller reporting company)	Smaller reporting company	¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)    Yes  ¨    No  x

Applicable only to issuers involved in bankruptcy proceedings during the preceding five years:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.    Yes  ¨    No  ¨

Applicable only to corporate issuers:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 101,626,704 shares of common stock, par value $0.001, outstanding as of April 23, 2010.

BIOMARIN PHARMACEUTICAL INC.

TABLE OF CONTENTS

		Page
PART I.	FINANCIAL INFORMATION	3
Item 1.	Consolidated Financial Statements (Unaudited)	3
	Consolidated Balance Sheets	3
	Consolidated Statements of Operations	4
	Consolidated Statements of Cash Flows	5
	Notes to Consolidated Financial Statements (Unaudited)	6
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28
Item 3.	Quantitative and Qualitative Disclosure about Market Risk	36
Item 4.	Controls and Procedures	36
PART II.	OTHER INFORMATION	37
Item 1.	Legal Proceedings	37
Item 1A.	Risk Factors	37
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	37
Item 3.	Defaults Upon Senior Securities	37
Item 4.	(Removed and Reserved)	37
Item 5.	Other Information	37
Item 6.	Exhibits	37
SIGNATURE		38

2

PART I. FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except for share and per share data)

	December 31, 2009 (1)			March 31, 2010
ASSETS					(unaudited)
Current assets:
Cash and cash equivalents	$	167,171		$	108,963
Short-term investments		133,506			214,679
Accounts receivable, net		73,540			82,606
Inventory		78,662			79,761
Other current assets		14,848			14,422
Total current assets		467,727			500,431
Investment in BioMarin/Genzyme LLC		441			1,215
Long-term investments		169,849			128,722
Property, plant and equipment, net		199,141			203,949
Intangible assets, net		40,977			77,416
Goodwill		23,722			40,360
Other assets		15,306			14,112
Total assets	$	917,163		$	966,205
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable, accrued liabilities and other current liabilities	$	78,068		$	78,541
Deferred revenue		86			158
Total current liabilities		78,154			78,699
Convertible debt		497,083			497,083
Other long-term liabilities		19,741			45,183
Total liabilities		594,978			620,965
Stockholders’ equity:
Common stock, $0.001 par value: 250,000,000 shares authorized at December 31, 2009 and March 31, 2010; 100,961,922 and 101,551,221 shares issued and outstanding at December 31, 2009 and March 31, 2010, respectively		101			102
Additional paid-in capital		899,950			917,738
Company common stock held by Nonqualified Deferred Compensation Plan		(1,715	)		(1,072	)
Accumulated other comprehensive income		933			4,405
Accumulated deficit		(577,084	)		(575,933	)
Total stockholders’ equity		322,185			345,240
Total liabilities and stockholders’ equity	$	917,163		$	966,205

(1) December 31, 2009 balances were derived from the audited consolidated financial statements.

See accompanying notes to unaudited consolidated financial statements.

3

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three Months Ended March 31, 2009 and 2010

(In thousands, except for per share data, unaudited)

	Three Months Ended March 31,
	2009			2010
Revenues:
Net product revenues	$	71,914		$	84,073
Collaborative agreement revenues		509			201
Royalty and license revenues		1,557			679
Total revenues		73,980			84,953
Operating expenses:
Cost of sales		14,362			17,412
Research and development		34,358			30,097
Selling, general and administrative		28,568			34,000
Intangible asset amortization and contingent consideration		1,093			654
Total operating expenses		78,381			82,163
Income (Loss) from operations		(4,401	)		2,790
Equity in the loss of BioMarin/Genzyme LLC		(547	)		(691	)
Interest income		2,153			1,190
Interest expense		(4,087	)		(2,429	)
Impairment loss on equity investments		(5,853	)		—
Net gain from sale of investments		—			927
Income (loss) before income taxes		(12,735	)		1,787
Provision for income taxes		417			636
Net income (loss)	$	(13,152	)	$	1,151
Net income (loss) per share, basic and diluted	$	(0.13	)	$	0.01
Weighted average common shares outstanding, basic		99,902			101,144
Weighted average common shares outstanding, diluted		99,933			103,720

See accompanying notes to unaudited consolidated financial statements.

4

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Three Months Ended March 31, 2009 and 2010

(In thousands, unaudited)

	Three Months Ended March 31,
	2009			2010
Cash flows from operating activities:
Net income (loss)	$	(13,152	)	$	1,151
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		5,103			5,410
Amortization of discount (premium) on investments		(643	)		1,198
Imputed interest on acquisition obligation		1,077			—
Equity in the loss of BioMarin/Genzyme LLC		547			691
Stock-based compensation		8,534			8,606
Impairment loss on equity investments		5,848			—
Net gain from sale of investments		—			(927	)
Unrealized foreign exchange (gain) loss on forward contracts		1,624			(60	)
Changes in the fair value of contingent acquisition consideration payable		—			654
Excess tax benefit from stock option exercises		(4	)		—
Changes in operating assets and liabilities:
Accounts receivable, net		(7,057	)		(9,066	)
Inventory		(3,260	)		(1,099	)
Other current assets		25,719			2,925
Other assets		(221	)		(871	)
Accounts payable, accrued liabilities and other current liabilities		(4,046	)		(6,483	)
Other long-term liabilities		138			1,049
Deferred revenue		(187	)		72
Net cash provided by operating activities		20,020			3,250
Cash flows from investing activities:
Purchase of property, plant and equipment		(18,737	)		(14,108	)
Maturities and sales of investments		110,100			22,055
Purchase of investments		(112,801	)		(62,956	)
Business acquisitions, net of cash acquired		—			(14,124	)
Investments in BioMarin/Genzyme LLC		—			(1,465	)
Investment in La Jolla Pharmaceutical Company		(6,250	)		—
Net cash used in investing activities		(27,688	)		(70,598	)
Cash flows from financing activities:
Proceeds from ESPP and exercise of stock options		891			9,183
Excess tax benefit from stock option exercises		4			—
Repayment of acquisition obligation		(1,500	)		—
Repayment of capital lease obligations		(48	)		(43	)
Net cash provided by (used in) financing activities		(653	)		9,140
Net decrease in cash and cash equivalents		(8,321	)		(58,208	)
Cash and cash equivalents:
Beginning of period		222,900			167,171
End of period	$	214,579		$	108,963
Supplemental cash flow disclosures:
Cash paid for interest, net of interest capitalized into fixed assets	$	2,057		$	1,822
Cash paid for income taxes		407			254
Stock-based compensation capitalized into inventory		1,303			1,080
Depreciation capitalized into inventory		650			1,466
Supplemental non-cash investing and financing activities disclosures:
Changes in accrued liabilities related to fixed assets		1,996			4,477
Changes in contingent acquisition consideration payable		—			21,110

See accompanying notes to unaudited consolidated financial statements.

5

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2010

(Unaudited)

(1) NATURE OF OPERATIONS AND BUSINESS RISKS

BioMarin Pharmaceutical Inc. (the Company or BioMarin^®) develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. BioMarin selects product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. The Company’s product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme ^® (galsulfase), Kuvan ^® (sapropterin dihydrochloride), Aldurazyme ^® (laronidase) and Firdapse ^TM (amifampridine phosphate).

Through March 31, 2010, the Company had accumulated losses of approximately $575.9 million. Management believes that the Company’s cash, cash equivalents and short-term and long-term investments at March 31, 2010 will be sufficient to meet the Company’s obligations for the foreseeable future based on management’s current long-term business plans and assuming that the Company achieves its long-term goals. If the Company elects to increase its spending on development programs significantly above current long-term plans or enter into potential licenses and other acquisitions of complementary technologies, products or companies, the Company may need additional capital. The Company expects to continue to finance net future cash needs that exceed its operating revenues primarily through its current cash, cash equivalents, short-term and long-term investments, and to the extent necessary, through proceeds from equity or debt financings, loans and collaborative agreements with corporate partners.

The Company is subject to a number of risks, including the financial performance of Naglazyme, Kuvan, Aldurazyme and Firdapse; the potential need for additional financings; its ability to successfully commercialize its product candidates, if approved; the uncertainty of the Company’s research and development efforts resulting in successful commercial products; obtaining regulatory approval for new products; significant competition from larger organizations; reliance on the proprietary technology of others; dependence on key personnel; uncertain patent protection; dependence on corporate partners and collaborators; and possible restrictions on reimbursement, as well as other changes in the health care industry.

(2) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

(a) Basis of Presentation

These unaudited consolidated financial statements include the accounts of BioMarin and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated. These unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information and the Securities and Exchange Commission (SEC) requirements for interim reporting. However, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Management performed an evaluation of the Company’s activities through the filing of this Quarterly Report on Form 10-Q, and has concluded that there are no subsequent events requiring disclosure through that date.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

(c) Cash and Cash Equivalents

The Company treats liquid investments with original maturities of less than three months when purchased as cash and cash equivalents.

6

(d) Investments

The Company determines the appropriate classification of its investments in debt and equity securities at the time of purchase and reevaluates such designation at each balance sheet date. All of the Company’s securities are classified as either held-to-maturity or available-for-sale and reported in short-term investments or long-term investments. Held-to-maturity investments are recorded at amortized cost. Available-for-sale investments are recorded at fair market value, with unrealized gains or losses included in accumulated other comprehensive income or loss, exclusive of other-than-temporary impairment losses, if any. Short-term and long-term investments are comprised of corporate securities, commercial paper, U.S. federal government agency securities, money market funds, equity securities and certificates of deposit. As of March 31, 2010, the Company had no held-to-maturity investments.

(e) Inventory

The Company values inventories at the lower of cost or net realizable value. The Company determines the cost of inventory using the average-cost method. The Company analyzes its inventory levels quarterly and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Expired inventory is disposed of and the related costs are recognized as cost of sales in the consolidated statements of operations.

Manufacturing costs for product candidates are expensed as research and development expenses. The Company considers regulatory approval of product candidates to be uncertain and product manufactured prior to regulatory approval may not be sold unless regulatory approval is obtained. As such, the manufacturing costs for product candidates incurred prior to regulatory approval are not capitalized as inventory. When regulatory approval is obtained, the Company begins capitalizing inventory at the lower of cost or net realizable value.

Stock-based compensation capitalized into inventory for the three months ended March 31, 2009 and 2010, was $1.3 million and $1.1 million, respectively.

(f) Investment in BioMarin/Genzyme LLC and Equity in the Loss of BioMarin/Genzyme LLC

Effective January 1, 2008, the Company restructured its relationship with Genzyme Corporation (Genzyme) (see Note 17 for further information). The Company accounts for its remaining investment in the joint venture between the Company and Genzyme (BioMarin/Genzyme LLC) using the equity method. Accordingly, the Company records an increase in its investment for contributions to the joint venture and a reduction in its investment for its 50% share of any losses of the joint venture or disbursements of profits from the joint venture. Equity in the loss of BioMarin/Genzyme LLC includes the Company’s 50% share of the joint venture’s loss for the period. The investment in BioMarin/Genzyme LLC includes the Company’s share of the net equity of the joint venture.

(g) Property, Plant and Equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the related estimated useful lives, except for leasehold improvements, which are depreciated over the shorter of the useful life of the asset or the lease term. Significant additions and improvements are capitalized, while repairs and maintenance are charged to expense as incurred. Property and equipment purchased for specific research and development projects with no alternative uses are expensed as incurred. See Note 10 for further information on property, plant and equipment balances as of December 31, 2009 and March 31, 2010.

Certain of the Company’s operating lease agreements include scheduled rent escalations over the lease term, as well as tenant improvement allowances. Scheduled increases in rent expense are recognized on a straight-line basis over the lease term. The difference between rent expense and rent paid is recorded as deferred rent and included in other liabilities in the accompanying consolidated balance sheets. The tenant improvement allowances and free rent periods are recognized as a credit to rent expense over the lease term on a straight-line basis.

(h) Revenue Recognition

The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Subtopics ASC 605-15, Revenue Recognition—Products and ASC 605-25, Revenue Recognition—Multiple-Element Arrangements. The Company’s revenues consist of net product revenues from its commercial products, revenues from its collaborative agreement with Merck Serono and other license and royalty revenues. Milestone payments are recognized in full when the related milestone performance goal is achieved and the Company has no future performance obligations related to that payment.

Net Product Revenues—The Company recognizes net product revenue when persuasive evidence of an arrangement exists, the product has been delivered to the customer, title and risk of loss have passed to the customer, the price to the buyer is fixed or determinable and collection from the customer is reasonably assured. Product sales transactions are evidenced by customer purchase orders, customer contracts, invoices and/or the related shipping documents. Amounts collected from customers and remitted to governmental authorities, which are primarily comprised of value-added taxes related to Naglazyme and Firdapse sales in foreign jurisdictions, are presented on a net basis in the Company’s consolidated statements of operations, in that taxes billed to customers are not included as a component of net product revenues.

7

The Company receives a 39.5% to 50% royalty on worldwide net Aldurazyme sales by Genzyme depending on sales volume, which is included in net product revenues in the consolidated statements of operations. The Company recognizes a portion of this amount as product transfer revenue when product is released to Genzyme because all of the Company’s performance obligations are fulfilled at that point and title to, and risk of loss for, the product has transferred to Genzyme. The product transfer revenue represents the fixed amount per unit of Aldurazyme that Genzyme is required to pay the Company if the product is unsold by Genzyme. The amount of product transfer revenue will eventually be deducted from the calculated royalty rate when the product is sold by Genzyme. The Company records the Aldurazyme royalty revenue based on net sales information provided by Genzyme and records product transfer revenue based on the fulfillment of Genzyme purchase orders in accordance with the terms of the related agreements with Genzyme and when the title and risk of loss for the product is transferred to Genzyme. As of December 31, 2009 and March 31, 2010, accounts receivable included $20.3 million and $18.3 million, respectively, of unbilled accounts receivable related to net incremental Aldurazyme product transfers to Genzyme.

The Company sells Naglazyme worldwide, Kuvan in the U.S. and Canada and Firdapse in the EU. In the U.S., Naglazyme and Kuvan are generally sold to specialty pharmacies or end-users, such as hospitals, which act as retailers. The Company also sells Kuvan to Merck Serono at a price near its manufacturing cost, and Merck Serono resells the product to end users outside the U.S., Canada and Japan. The royalty earned from Kuvan product sold by Merck Serono in the EU is included as a component of net product revenues in the period earned and approximates 4%. Outside the U.S., Naglazyme and Firdapse are sold to the Company’s authorized distributors or directly to government purchasers or hospitals, which act as the end-users. The Company records reserves for rebates payable under Medicaid and other government programs as a reduction of revenue at the time product revenues are recorded. The Company’s reserve calculations require estimates, including estimates of customer mix, to determine which sales will be subject to rebates and the amount of such rebates. The Company updates its estimates and assumptions each quarter and records any necessary adjustments to its reserves. The Company records fees paid to distributors as a reduction of revenue.

The Company records allowances for product returns, if appropriate, as a reduction of revenue at the time product sales are recorded. Several factors are considered in determining whether an allowance for product returns is required, including market exclusivity of the products based on their orphan drug status, the patient population, the customers’ limited return rights and the Company’s experience with returns. Because of the pricing of Naglazyme, Kuvan and Firdapse, the limited number of patients and the customers’ limited return rights, most Naglazyme and Kuvan customers and retailers carry a limited inventory. However, certain international customers, usually government entities, tend to purchase larger quantities of product less frequently. Although such buying patterns may result in revenue fluctuations from quarter to quarter, the Company has not experienced any increased product returns or risk of product returns. The Company relies on historical return rates to estimate returns for Aldurazyme, Naglazyme and Kuvan. Genzyme’s return rights for Aldurazyme are limited to defective product. The Company’s products are comparable in nature and sold to similar customers with limited return rights; therefore the Company relies on historical return rates for Aldurazyme, Naglazyme and Kuvan to estimate returns for Firdapse, which has a limited history of product returns. Based on these factors, management has concluded that product returns will be minimal, and the Company has not experienced significant product returns to date. In the future, if any of these factors and/or the history of product returns changes, an allowance for product returns may be required.

The Company maintains a policy to record allowances for doubtful accounts for estimated losses resulting from the inability of its customers to make required payments. As of March 31, 2010, the Company has experienced no significant bad debts and the recorded allowance for doubtful accounts was insignificant.

Collaborative Agreement Revenues—Collaborative agreement revenues from Merck Serono include both license revenue and contract research revenue under the Company’s agreement with Merck Serono, which was executed in May 2005. Nonrefundable up-front license fees where the Company has continuing involvement through research and development collaboration are initially deferred and recognized as collaborative agreement license revenue over the estimated period for which the Company continues to have a performance obligation. The Company’s recognition of license revenue from Merck Serono was completed in 2008. Nonrefundable amounts received for shared development costs are recognized as revenue in the period in which the related expenses are incurred. Contract research revenue included in collaborative agreement revenues represents Merck Serono’s share of Kuvan development costs under the Merck Serono agreement, which are recorded as research and development expenses in the consolidated statements of operations. Allowable costs during the development period must have been included in the pre-approved annual budget in order to be subject to reimbursement or must be separately approved by both parties.

Collaborative agreement revenues totaled $0.5 million and $0.2 million during the three months ended March 31, 2009 and 2010, respectively. Collaborative agreement revenues in each of the first quarters of 2009 and 2010 were comprised of reimbursable development costs for Kuvan.

Royalty and License Revenues—Royalty revenue includes royalties on net sales of products with which the Company has no direct involvement and is recognized based on data reported by licensees or sublicensees. Royalties are recognized as earned in accordance with the contract terms at the time the royalty amount is fixed or determinable based on information received from the sublicensee and at the time collectibility is reasonably assured.

8

Due to the significant role the Company plays in the operations of Aldurazyme and Kuvan, primarily the manufacturing and regulatory activities, as well as the rights and responsibilities to deliver the products to Genzyme and Merck Serono, respectively, the Company elected not to classify the Aldurazyme and Kuvan royalties earned as other royalty revenues and instead to include them as a component of net product revenues.

Royalty and license revenues for the three months ended March 31, 2010 include $0.5 million of Orapred product royalties, a product the Company acquired in 2004 and sublicensed in 2006, and $0.2 million of royalty revenues for 6R-BH4, the active ingredient in Kuvan, sold in Japan. Royalty and license revenues for the three months ended March 31, 2009 included $1.4 million of Orapred product royalties and $0.2 million of royalty revenue for 6R-BH4.

(i) Research and Development

Research and development expenses include expenses associated with contract research and development provided by third parties, product manufacturing prior to regulatory approval, clinical and regulatory costs, and internal research and development costs. In instances where the Company enters into agreements with third parties for research and development activities, costs are expensed upon the earlier of when non-refundable amounts are due or as services are performed unless there is an alternative future use of the funds in other research and development projects. Amounts due under such arrangements may be either fixed fee or fee for service and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the vendors that perform the activities.

The Company believes that regulatory approval of its product candidates is uncertain and does not assume that products manufactured prior to regulatory approval will be sold commercially. As a result, inventory costs for product candidates are expensed as research and development until regulatory approval is obtained in a major market, at which time inventory is capitalized at the lower of cost or net realizable value.

(j) Net Income (Loss) Per Share

Basic net income (loss) per share is calculated by dividing net income/loss by the weighted average shares of common stock outstanding during the period. Diluted net income (loss) per share reflects the potential dilution that would occur if securities or other contracts to issue common stock were exercised or converted into common stock; however, potential common equivalent shares are excluded if their effect is anti-dilutive. Potential shares of common stock include shares issuable upon the exercise of outstanding employee stock option awards, common stock issuable under the Company’s 2006 Employee Stock Purchase Plan (ESPP), restricted stock, contingent issuances of common stock related to convertible debt and through the first quarter of 2009, the portion of acquisition costs that was payable in shares of the Company’s common stock at the Company’s option.

The following represents a reconciliation from basic weighted shares outstanding to diluted weighted shares outstanding and the earnings per share for the three months ended March 31, 2009 and 2010 (in thousands, except per share data):

	Three Months Ended March 31, 2009
	Net Income (Numerator)			Weighted Average Shares Outstanding (Denominator)	Per Share Amount
Basic Net Loss Per Share:
Net Loss	$	(13,152	)	99,902	$	(0.13	)
Effect of dilutive shares:
Common stock held in the Nonqualified Deferred Compensation Plan using the treasury method		(156	)	31
Diluted Net Loss Per Share:
Net Loss	$	(13,308	)	99,933	$	(0.13	)

9

	Three Months Ended March 31, 2010
	Net Income (Numerator)		Weighted Average Shares Outstanding (Denominator)	Per Share Amount
Basic Net Income Per Share:
Net Income	$	1,151	101,144	$	0.01
Effect of dilutive shares:
Stock options using the treasury method			2,041
Potentially issuable restricted common stock			131
Potentially issuable common stock for ESPP purchases			404
Diluted Net Income Per Share:
Net Income	$	1,151	103,720	$	0.01

In addition to the equity instruments included in the table above, the following potential shares of common stock were excluded from the computation as they were anti-dilutive for the three months ended March 31, 2009 and 2010 using the treasury stock method. Excluded from the dilutive shares of common stock were (i) out-of-the-money options to purchase common stock, (ii) potentially issuable restricted stock, (iii) shares of common stock underlying the Company’s convertible debt using the if-converted method whereby the related interest expense for the convertible debt is added to net income for the period and for the three months ended March 31, 2010 (iv) Company common stock issued to the Nonqualified Deferred Compensation Plan (in thousands):

	Three Months Ended March 31,
	2009	2010
Options to purchase common stock	12,137	11,493
Common stock issuable under convertible debt	26,343	26,343
Portion of acquisition payable in common stock at the option of the Company	696	—
Unvested restricted stock units	243	214
Common stock held in the Nonqualified Deferred Compensation Plan using the treasury method	—	60
Potentially issuable common stock for ESPP purchases	137	—
Total	39,556	38,110

(k) Stock-Based Compensation

The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options and ESPP awards. The determination of the fair value of stock-based payment awards using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period for each award. Further, stock-based compensation expense recognized in the consolidated statements of operations is based on awards expected to vest and therefore the amount of expense has been reduced for estimated forfeitures, which are based on historical experience. If actual forfeitures differ from estimates at the time of grant they will be revised in subsequent periods.

If factors change and different assumptions are employed in determining the fair value of stock-based awards, the stock-based compensation expense recorded in future periods may differ significantly from what was recorded in the current period (see Note 3 for further information).

(l) Nonqualified Deferred Compensation Plan

The Company’s Nonqualified Deferred Compensation Plan allows eligible employees, including management and certain highly-compensated employees as designated by the plan’s administrative committee and members of the Company’s Board of Directors (the Board), to make voluntary deferrals of compensation to specified dates, retirement or death. Participants are permitted to defer portions of their salary, annual cash bonus and restricted stock. The Company is not allowed to make additional direct contributions to the Nonqualified Deferred Compensation Plan on behalf of the participants without further action by the Board.

Other current assets and other non-current assets include $1.8 million and $2.3 million, of investments held in trust related to the Company’s Nonqualified Deferred Compensation Plan for certain employees and directors as of December 31, 2009, and March 31, 2010, respectively. All of the investments held in the Nonqualified Deferred Compensation Plan are classified as trading securities and recorded at fair value with changes in the investments’ fair values recognized in earnings in the period they occur. Restricted stock issued into the Nonqualified Deferred Compensation Plan is accounted for similarly to treasury stock in that the value of the employer

10

stock is determined on the date the restricted stock vests and the shares are issued into the Nonqualified Deferred Compensation Plan. The restricted stock issued into the Nonqualified Deferred Compensation Plan is recorded in equity and changes in the fair value of the corresponding liability are recognized in earnings as incurred. The corresponding liability for the Nonqualified Deferred Compensation Plan is included in other current liabilities and other long-term liabilities.

(m) Income Taxes

The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined based on the difference between the financial statement and tax bases of assets and liabilities using tax rates expected to be in effect in the years in which the differences are expected to reverse. A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized. There was a full valuation allowance against net deferred tax assets of $268.1 million at December 31, 2009. Future taxable income and ongoing prudent and feasible tax planning strategies have been considered in assessing the need for the valuation allowance. An adjustment to the valuation allowance would increase or decrease net income/loss in the period such adjustment was made or additional paid-in-capital. For the three months ended March 31, 2009 and 2010, the Company recognized income tax expense of $0.4 million and $0.6 million, respectively. Income tax expense for the three months ended March 31, 2009 and 2010 was primarily related to income earned in certain of the Company’s international subsidiaries, California state income tax and U.S. Federal Alternative Minimum Tax expense.

(n) Foreign Currency and Other Hedging Instruments

The Company has transactions denominated in foreign currencies and, as a result, is exposed to changes in foreign currency exchange rates. The Company manages some of these exposures on a consolidated basis, which results in the netting of certain exposures to take advantage of natural offsets and through the use of foreign currency forward contracts. Gains or losses on net foreign currency hedges are intended to offset gains or losses on the underlying net exposures in an effort to reduce the earnings and cash flow volatility resulting from fluctuating foreign currency exchange rates.

The Company accounts for its derivative instruments as either assets or liabilities on the balance sheet and measures them at fair value. Derivatives that are not defined as hedging instruments are adjusted to fair value through earnings. Gains and losses resulting from changes in fair value are accounted for depending on the use of the derivative and whether it is designated and qualifies for hedge accounting (see Note 14 for further information).

(o) Fair Value of Financial Instruments

The Company discloses the fair value of financial instruments for assets and liabilities for which the value is practicable to estimate. The carrying amounts of all cash equivalents, investments and forward exchange contracts approximate fair value based upon quoted market prices or discounted cash flows. The fair value of trade accounts receivables, accounts payable and other financial instruments approximates carrying value due to their short-term nature.

(p) Contingent Acquisition Consideration Payable

The Company determines the fair value of contingent acquisition consideration payable on the acquisition date using a probability-based income approach utilizing an appropriate discount rate. Contingent acquisition consideration payable is included in accrued expenses and other liabilities on the Company’s consolidated balance sheet. Changes in the fair value of the contingent acquisition consideration payable are determined each period end and recorded in the “Intangible asset amortization and contingent consideration” expense line item on the consolidated statements of operations.

(q) Comprehensive Income (Loss) and Accumulated Other Comprehensive Income (Loss)

Comprehensive income (loss) includes net income/loss and certain changes in stockholders’ equity that are excluded from net income/loss, such as changes in unrealized gains and losses on the Company’s available-for-sale securities, unrealized gains/losses on foreign currency hedges and changes in the Company’s cumulative foreign currency translation account. There were no tax effects allocated to any components of other comprehensive income (loss) during the three months ended March 31, 2009 and 2010 due to the Company’s full valuation allowance against its net deferred tax assets

11

Total comprehensive income was approximately $4.6 million for the three months ended March 31, 2010, compared to comprehensive net loss of $12.2 million for the three months ended March 31, 2009. The fluctuation in accumulated other comprehensive income (loss) is comprised of the following (in thousands):

	Three Months Ended March 31,
	2009			2010
Net unrealized gain (loss) on available-for-sale securities	$	(632	)	$	283
Net unrealized gain on foreign currency hedges		1,932			4,058
Net unrealized loss on equity investments		(337	)		(866	)
Net foreign currency translation loss		—			(3	)
Change in accumulated other comprehensive income (loss)	$	963		$	3,472

(r) Restricted Cash

The Company’s balance of restricted cash amounted to $2.0 million and $2.5 million at December 31, 2009, and March 31, 2010, respectively. Restricted cash is primarily comprised of investments held by the Company’s Nonqualified Deferred Compensation Plan totaling $1.8 million and $2.3 million as of December 31, 2009 and March 31, 2010, respectively, which are included in other current assets and other non-current assets.

(s) Recent Accounting Pronouncements

In April 2010, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2010-17 (ASU 2010-17), Revenue Recognition—Milestone Method (Topic 605), which provides guidance on applying the milestone method to milestone payments for achieving specified performance measures when those payments are related to uncertain future events. ASU 2010-17 is effective for fiscal years and interim periods within those years beginning on or after June 15, 2010 with early adoption permitted. ASU 2010-17 is effective for the Company on January 1, 2011. The Company is currently evaluating the impact, if any, ASU 2010-17 will have on the Company’s consolidated financial statements.

In January 2010, the FASB issued ASU 2010-6, Fair Value Measurements and Disclosures (Topic 820), Improving Disclosures about Fair Value Measurements (ASU 2010-6), which expands fair value disclosure requirements. Transition will be in two phases with expanded disclosures regarding activity for Level 1 and 2 applicable to the Company on January 1, 2010 and expanded disclosures for Level 3 activity effective on January 1, 2011.

In September 2009, the FASB issued ASU 2009-13, Multiple Deliverable Revenue Arrangements (ASU 2009-13), which amended the accounting standards for multiple element arrangements to:

• provide updated guidance on whether multiple deliverables exist, how the elements in an arrangement should be separated and how the consideration should be allocated;

• require an entity to allocate revenue in an arrangement using estimated selling prices (ESP) of each element if a vendor does not have vendor-specific objective evidence of selling price (VSOE) or third-party evidence of selling price (TPE); and

• eliminate the use of the residual method and require a vendor to allocate revenue using the relative selling price method.

ASU 2009-13 is effective for fiscal years beginning after June 15, 2010, which for the Company will be January 1, 2011, with early application permitted. The Company is currently evaluating the impact, if any, ASU 2009-13 will have on the Company’s consolidated financial statements.

(t) Reclassifications and Adjustments

Certain items in the prior year’s consolidated financial statements have been reclassified to conform to the current presentation.

12

(3) STOCK-BASED COMPENSATION

The Company’s stock-based compensation plans include the 2006 Share Incentive Plan and the ESPP. These plans are administered by the Compensation Committee of the Board, which selects persons to receive awards and determines the number of shares subject to each award and the terms, conditions, performance measures and other provision of the award. See Note 3 of the Company’s consolidated financial statements in the Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on February 25, 2010, for additional information related to these stock-based compensation plans.

Determining the Fair Value of Stock Options and Stock Purchase Rights

The fair value of each option award is estimated on the date of grant using the Black-Scholes valuation model and the assumptions noted in the tables below. The expected life of options is based on observed historical exercise patterns. Groups of employees that have similar historical exercise patterns were considered separately for valuation purposes, but none were identified that had distinctly different exercise patterns as of March 31, 2010. The expected volatility of stock options is based upon proportionate weightings of the historical volatility of the Company’s common stock and the implied volatility of traded options on the Company’s common stock for fiscal periods in which there is sufficient trading volume in options on the Company’s common stock. The risk free interest rate is based on the implied yield on a U.S. Treasury zero-coupon issue with a remaining term equal to the expected term of the option. The dividend yield reflects that the Company has not paid any cash dividends since inception and does not intend to pay any cash dividends in the foreseeable future. During the three months ended March 31, 2010, the Company granted 263,850 options with a weighted average option value of $10.75 per option. The assumptions used to estimate the per share fair value of stock options granted and stock purchase rights granted under the Company’s 2006 Share Incentive Plan and ESPP for the three months ended March 31, 2009 and 2010, respectively, are as follows:

	Three Months Ended March 31,
Stock Option Valuation Assumptions	2009			2010
Weighted average fair value of common stock per share	$	12.49		$	20.43
Expected volatility		55	%		52	%
Dividend yield		0.0	%		0.0	%
Expected life		6.0 years			6.2 years
Risk-free interest rate		1.9	%		2.7	%

	Three Months Ended March 31,
Employee Stock Purchase Plan Valuation Assumptions	2009			2010
Fair value of common stock on grant date	$	19.36		$	15.56
Expected volatility		51	%		55	%
Dividend yield		0.0	%		0.0	%
Expected life		6-24 months			6-24 months
Risk-free interest rate		1.1-1.5	%		0.2 – 0.9	%

Restricted Stock Units

Restricted stock units (RSUs) are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. The Company expenses the cost of the RSUs, which is determined to be the fair market value of the shares of common stock underlying the RSUs at the date of grant, ratably over the period during which the vesting restrictions lapse. During the three months ended March 31, 2010, the Company granted 20,000 RSUs with a weighted average fair market value of $20.40 per share.

Stock Option Grants to Non-Employees

During the third quarter of 2009, the Company granted 54,000 stock options to non-employees. The non-employee grants vest over periods from nine months to two years depending on the grant. The unvested portion of the stock options will be re-measured at each reporting period. Total stock-based compensation expense for non-employee stock option grants for the first quarter of 2010 was approximately $88,000.

13

Stock-based Compensation Expense

The compensation expense that has been included in the Company’s consolidated statements of operations for stock-based compensation arrangements for the three months ended March 31, 2009 and 2010, respectively, was as follows (in thousands):

	Three Months Ended March 31,
	2009		2010
Cost of sales	$	564	$	1,028
Research and development expense		2,475		3,182
Selling, general and administrative expense		4,757		4,336
Total stock-based compensation expense	$	7,796	$	8,546

There was no income tax benefit associated with stock-based compensation for the three months ended March 31, 2009 and 2010 because any deferred tax asset resulting from stock-based compensation was offset by additional valuation allowance.

Stock-based compensation of $1.3 million and $1.1 million was capitalized into inventory during the first quarters of 2009 and 2010, respectively. Capitalized stock-based compensation is recognized into cost of sales when the related product is sold.

(4) GOODWILL

The following table represents the changes in goodwill for the quarter ended March 31, 2010 (in thousands):

Balance at December 31, 2009	$	23,722
Goodwill related to the acquisition of LEAD Therapeutics, Inc. (LEAD) (See Note 6)		16,638
Balance at March 31, 2010	$	40,360

The $16.6 million of LEAD goodwill represents $14.0 million of goodwill recognized in connection with the deferred tax liability associated with the indefinite-lived intangible assets acquired and $2.6 million of excess purchase price. See Note 6 for additional discussion.

(5) ACQUISITION OF HUXLEY PHARMACEUTICALS, INC.

On October 23, 2009, the Company acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, which the Company has branded Firdapse, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS) for a total purchase price of $37.2 million. As a result of the acquisition, the Company will be the first to market an approved treatment for LEMS in Europe.

In connection with its acquisition of Huxley, the Company paid $15.0 million upfront for all of the outstanding common stock of Huxley. The Company has also agreed to pay Huxley stockholders additional consideration in future periods up to $42.9 million (undiscounted) in milestone payments if certain annual sales, cumulative sales and development milestones are met. The fair value of the contingent acquisition consideration payments was $22.2 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 6.3%; and (2) a probability adjusted contingency. As March 31, 2010, the range of outcomes and assumptions used to develop these estimates have not changed. In November 2009, the U.S. Food and Drug Administration (FDA) granted Firdapse U.S. orphan status, resulting in a payment of $1.0 million to the former Huxley shareholders. In December 2009, the European Medicines Agency (EMEA) granted marketing approval for Firdapse, which resulted in a payment of $6.5 million in the second quarter of 2010 to the former Huxley shareholders.

14

The following table presents the allocation of the purchase consideration, including the contingent acquisition consideration payable, based on fair value (in thousands):

Cash and cash equivalents	$	483
Intangible assets – IPR&D		36,933
Other assets		179
Total identifiable assets	$	37,595
Accounts payable and accrued expenses		(387	)
Deferred tax liability		(2,460	)
Total liabilities assumed		(2,847	)
Net identified assets acquired	$	34,748
Goodwill		2,460
Net assets acquired	$	37,208

Huxley’s results of operations prior to and since the acquisition date were insignificant compared to the Company’s consolidated financial statements.

The deferred tax liability relates to the tax impact of future amortization or possible impairments associated with the identified intangible assets acquired, which are not deductible for tax purposes. The $2.5 million of goodwill represents the assets recognized in connection with the deferred tax liability and did not result from excess purchase price. In April 2010, the Company and the former Huxley stockholders executed an amendment to the acquisition agreements, which resulted in a $1.0 million reduction to certain of the future milestone payments.

See Note 7 for further discussion of the acquired intangible assets.

(6) ACQUISITION OF LEAD THERAPEUTICS, INC.

On February 10, 2010, the Company acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with a key compound LT-673, now referred to as BMN-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers for a total purchase price of $39.1 million.

In connection with its acquisition of LEAD, the Company paid $18.6 million in cash for all of the outstanding common stock of LEAD. The Company has also agreed to pay LEAD stockholders additional consideration in future periods up to $68.0 million (undiscounted) in milestone payments if certain clinical, development and sales milestones are met. The fair value of the contingent acquisition consideration payments was $20.5 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. Key assumptions include: (1) a discount rate of 6.4%; and (2) a probability adjusted contingency.

The following table presents the allocation of the purchase consideration, including the contingent acquisition consideration payable, based on fair value (in thousands):

Cash and cash equivalents	$	1,187
Prepaid expenses		40
Property, plant and equipment		26
Acquired deferred tax assets		7,788
Intangible assets – IPR&D		36,089
Total identifiable assets	$	45,130
Accounts payable and accrued expenses		(891	)
Deferred tax liability		(13,981	)
Valuation allowance for acquired deferred tax assets		(7,788	)
Total liabilities assumed	$	(22,660	)
Net identifiable assets acquired		22,470
Goodwill		16,638
Net Assets Acquired	$	39,108

The deferred tax liability relates to the tax impact of future amortization or possible impairments associated with the identified intangible assets acquired, which are not deductible for tax purposes. The $16.6 million of goodwill reflects the $14.0 million deferred tax liability recognized in connection with the LEAD acquisition and $2.6 million of goodwill attributable to the synergies expected from the acquisition and other benefits that do not qualify for separate recognition as acquired intangible assets.

15

LEAD’s results of operations prior to and since the acquisition date were insignificant compared to the Company’s consolidated financial statements.

See Note 7 for further discussion of the acquired intangible assets.

(7) INTANGIBLE ASSETS

As of December 31, 2009 and March 31, 2010, intangible assets consisted of the following (in thousands):

	December 31, 2009			March 31, 2010
Intangible assets:
Finite-lived intangible assets	$	35,239		$	35,740
Indefinite-lived intangible assets		6,710			42,799
Gross intangible assets:		41,949			78,539
Less: Accumulated amortization		(972	)		(1,123	)
Net carrying value	$	40,977		$	77,416

Finite-Lived Intangible Assets

The following table summarizes the annual amortization of the finite-lived intangible assets through 2018 (in thousands):

	Net Balance at March  31, 2010		Remaining Life	Annual Amortization
EU marketing rights for Firdapse	$	30,723	10 years	$	3,072
License payment for Kuvan FDA Approval		1,563	4.7 years		332
License payment for Kuvan EMEA Approval		2,331	8.7 years		269
Total	$	34,617		$	3,673

The Firdapse intangible assets consist of the Firdapse product technology purchased as part of the Huxley acquisition in the fourth quarter of 2009. As of December 31, 2009, the gross and net carrying value of the Firdapse product technology was comprised of $30.2 million and $6.7 million related to marketing rights in Europe and the U.S., respectively, which were both in-process research and development assets with indefinite lives as of the purchase date. Subsequently, in December 2009, the EMEA granted marketing approval for Firdapse in the EU. As a result the Company assigned a 10 year useful life to the European product technology, which corresponds to the period of market exclusivity conferred through the orphan drug protection. The EMEA did not enable the commercial launch of Firdapse until April 2010, at which time the Company began amortizing the European product technology at an annual rate of $3.1 million. The increase in the Firdapse intangible assets relates to a $0.5 million license payment made to a third party as a result of the EMEA approval of Firdapse.

Kuvan intangible assets relate to license payments made to third parties as a result of the FDA approval of Kuvan in December 2007 and the EMEA approval in December 2008, which resulted in a $2.7 million addition to the Kuvan intangible assets. At December 31, 2009 and March 31, 2010, Kuvan intangible assets totaled a gross value of $5.0 million. In each of the first quarters of 2009 and 2010, the Company recognized amortization expense related to the Kuvan intangible assets of $0.2 million as a component of cost of sales in the consolidated statements of operations.

16

Indefinite-Lived Intangible Assets

A substantial portion of the assets acquired in the Huxley and LEAD acquisitions consisted of in-process research and development (IPR&D) assets related to both early and late stage drug product candidates. The Company determined that the estimated acquisition-date fair values of the intangible assets related to rights to develop and commercialize the acquired assets as of December 31, 2009 and March 31, 2010, respectivley were as follows (in thousands):

	December 31, 2009		March 31, 2010
In-Process Research and Development
EU marketing rights for Firdapse	$	30,223	$	—
U.S. marketing rights for Firdapse		6,710		6,710
BMN-673 compound acquired through LEAD		—		35,150
Other pre-clinical compounds acquired through LEAD		—		939
Net carrying value	$	36,933	$	42,799

Intangible assets related to IPR&D assets are considered to be indefinite-lived until the completion or abandonment of the associated research and development (R&D) efforts. During the period the assets are considered indefinite-lived, they will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&D assets below their respective carrying amounts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. In estimating fair value of the IPR&D assets, the Company compensated for the differing phases of development of each asset by probability-adjusting its estimation of the expected future cash flows associated with each asset. The Company then determined the present value of the expected future cash flows. The projected cash flows from the IPR&D assets were based on key assumptions such as estimates of revenues and operating profits related to the feasibility and timing of achievement of development, regulatory and commercial milestones, expected costs to develop the IPR&D into commercially viable products and future expected cash flows from product sales. As discussed above, in December 2009, the EMEA granted approval for Firdapse at which time the asset became finite-lived.

(8) SHORT-TERM AND LONG-TERM INVESTMENTS

At December 31, 2009, the principal amounts of short-term and long-term investments by contractual maturity are summarized in the table below (in thousands):

	Contractual Maturity Date For the Years Ending December 31,
	2010		2011		2012		Total Book Value		Unrealized Gain (Loss)			Aggregate Fair Value
Certificates of deposit	$	30,924	$	18,833	$	—	$	49,757	$	(120	)	$	49,637
Corporate securities		57,973		64,735		38,096		160,804		461			161,265
Commercial paper		7,981		—		—		7,981		12			7,993
Equity securities		701		—		—		701		1,052			1,753
U.S. Government agency securities		34,861		47,724		—		82,585		122			82,707
Total	$	132,440	$	131,292	$	38,096	$	301,828	$	1,527		$	303,355

17

At March 31, 2010, the principal amounts of short-term and long-term investments by contractual maturity are summarized in the table below (in thousands):

	Contractual Maturity Date For the Years Ending December 31,
	2010		2011		2012		Total Book Value		Unrealized Gain (Loss)			Aggregate Fair Value
Certificates of deposit	$	26,812	$	23,525	$	983	$	51,320	$	(95	)	$	51,225
Corporate securities		88,696		77,389		44,634		210,719		800			211,519
Commercial paper		14,476		—		—		14,476		6			14,482
Equity securities		204		—		—		204		186			390
U.S. Government agency securities		10,055		45,650		10,020		65,725		60			65,785
Total	$	140,243	$	146,564	$	55,637	$	342,444	$	957		$	343,401

The Company completed an evaluation of its investments and determined that it did not have any other-than-temporary impairments as of March 31, 2010. The investments are placed in financial institutions with strong credit ratings and management expects full recovery of the amortized costs.

At December 31, 2009, the aggregate amounts of unrealized losses and related fair value of investments with unrealized losses were as follows (in thousands). All investments were classified as available-for-sale at December 31, 2009.

	Less Than 12 Months To Maturity					12 Months or More To Maturity					Total
	Aggregate Fair Value		Unrealized Losses			Aggregate Fair Value		Unrealized Losses			Aggregate Fair Value		Unrealized Losses
Certificates of deposit	$	23,744	$	(55	)	$	14,358	$	(69	)	$	38,102	$	(124	)
Corporate securities		12,265		(16	)		45,488		(186	)		57,753		(202	)
U.S. Government agency securities		5,325		(1	)		20,010		(93	)		25,335		(94	)
Total	$	41,334	$	(72	)	$	79,856	$	(348	)	$	121,190	$	(420	)

At March 31, 2010, the aggregate amounts of unrealized losses and related fair value of investments with unrealized losses were as follows (in thousands). All investments were classified as available-for-sale at March 31, 2010.

	Less Than 12 Months To Maturity					12 Months or More To Maturity					Total
	Aggregate Fair Value		Unrealized Losses			Aggregate Fair Value		Unrealized Losses			Aggregate Fair Value		Unrealized Losses
Certificates of deposit	$	26,182	$	(54	)	$	11,937	$	(53	)	$	38,119	$	(107	)
Corporate securities		38,151		(33	)		11,880		(37	)		50,031		(70	)
U.S. Government agency securities		—		—			20,040		(48	)		20,040		(48	)
Total	$	64,333	$	(87	)	$	43,857	$	(138	)	$	108,190	$	(225	)

(9) SUPPLEMENTAL BALANCE SHEET INFORMATION

As of December 31, 2009 and March 31, 2010, inventory consisted of the following (in thousands):

	December 31, 2009		March 31, 2010
Raw materials	$	7,692	$	7,581
Work in process		40,416		41,774
Finished goods		30,554		30,406
Total inventory	$	78,662	$	79,761

18

As of December 31, 2009 and March 31, 2010, other current assets consisted of the following (in thousands):

	December 31, 2009		March 31, 2010
Non-trade receivables	$	7,083	$	4,580
Prepaid expenses		5,202		5,291
Deferred cost of sales		2,232		1,311
Other		331		3,240
Total other current assets	$	14,848	$	14,422

As of December 31, 2009 and March 31, 2010, accounts payable, accrued liabilities and other current liabilities consisted of the following (in thousands):

	December 31, 2009		March 31, 2010
Accounts payable	$	7,567	$	3,276
Accrued accounts payable		28,353		23,692
Accrued vacation		4,652		5,362
Accrued compensation		14,544		8,964
Accrued interest and taxes		2,859		3,415
Accrued royalties		4,740		4,711
Other accrued expenses		1,525		3,346
Accrued rebates		4,786		5,423
Short-term portion of contingent acquisition consideration payable		8,124		18,136
Other		918		2,216
Total accounts payable and accrued liabilities	$	78,068	$	78,541

As of December 31, 2009 and March 31, 2010 other long-term liabilities consisted of the following (in thousands):

	December 31, 2009		March 31, 2010
Long-term portion of deferred rent	$	983	$	969
Long-term portion of capital lease liability		85		42
Long-term portion of contingent acquisition consideration payable		13,089		24,187
Long-term portion of deferred compensation liability		3,124		3,544
Deferred tax liabilities		2,460		16,441
Total other long-term liabilities	$	19,741	$	45,183

19

(10) PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at December 31, 2009 and March 31, 2010 consisted of the following (in thousands):

Category	December 31, 2009			March 31, 2010			Estimated Useful Lives
Leasehold improvements	$	38,059		$	38,554		Shorter of life of asset or lease term
Building and improvements		69,564			73,382		20 years
Manufacturing and laboratory equipment		34,228			40,559		5 years
Computer hardware and software		28,695			29,883		3 to 5 years
Office furniture and equipment		5,529			5,088		5 years
Land		10,056			10,056		Not applicable
Construction-in-progress		74,914			73,181		Not applicable
Total property, plant and equipment, gross	$	261,045		$	270,703
Less: Accumulated depreciation		(61,904	)		(66,754	)
Total property, plant and equipment, net	$	199,141		$	203,949

Depreciation for three months ended March 31, 2009 and 2010 was $3.5 million and $4.8 million, respectively. Depreciation capitalized into inventory for the three months ended March 31, 2009 and 2010 was $0.7 million and $1.5 million, respectively.

Capitalized interest related to the Company’s property, plant and equipment purchases for the three months ended March 31, 2009 and 2010 was $0.1 million and $0.3 million, respectively.

(11) INVESTMENT IN SUMMIT CORPORATION PLC

In July 2008, the Company entered into an exclusive worldwide licensing agreement with Summit Corporation plc (Summit) related to Summit’s preclinical drug candidate SMT C1100 and follow-on molecules (2008 Summit License), which are being developed for the treatment of Duchenne muscular dystrophy. The Company paid Summit $7.1 million for an equity investment in Summit shares and licensing rights to SMT C1100. The initial equity investment represented the acquisition of approximately 5.1 million Summit shares with a fair value at the time of acquisition of $5.7 million, based on public market quotes. The Company’s investment in Summit represents less than 10% of Summit’s outstanding shares.

In March 2009, the Company entered into an asset purchase agreement with Summit. Pursuant to the terms of the asset purchase agreement, the Company purchased certain of Summit’s assets which included the rights, title to and interest in Summit’s preclinical drug candidate SMT C1100, thus terminating the 2008 Summit License. These assets were acquired by issuing a secured promissory note and assuming $56,000 in related liabilities. The promissory note is secured by all of the assets acquired from Summit. The value of the assumed liabilities was expensed in the first quarter of 2009, as the asset acquired does not have an alternative use. Under the secured promissory note, the Company is obligated to make up to $50.0 million in future development and regulatory milestone payments contingent on achieving certain development and regulatory milestones, as well as tiered royalties based on future net sales.

The Company accounts for the Summit shares, which are traded on the London Stock Exchange, as an available-for-sale investment, with changes in the fair value reported as a component of accumulated other comprehensive income/loss, exclusive of other-than-temporary impairment losses, if any. Losses determined to be other-than-temporary are reported in earnings in the period in which the impairment occurs.

As of March 31, 2010, the Company has recognized cumulative impairment charges of $5.5 million for the decline in the investment’s value determined to be other-than-temporary. The impairment charges are comprised of $4.1 million and $1.4 million recognized in December 2008 and March 2009, respectively. The determination that the decline was other-than-temporary is, in part, subjective and influenced by several factors, including: the length of time and the extent to which the market value had been less than the value on the date of purchase, Summit’s financial condition and near-term prospects, including any events that may influence its operations, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for the anticipated recovery in market value.

20

(12) INVESTMENT IN LA JOLLA PHARMACEUTICAL COMPANY

On January 4, 2009, the Company entered into a co-exclusive worldwide (excluding Asia Pacific) licensing agreement with La Jolla Pharmaceutical Company (La Jolla) to develop and commercialize Riquent, La Jolla’s investigational drug for lupus nephritis. The Company paid La Jolla $7.5 million for the license rights and an additional $7.5 million for 339,104 shares of La Jolla’s Series B Preferred Stock. The initial equity investment represents the acquisition of the La Jolla Series B Preferred shares with a fair value of $6.2 million. The $1.3 million paid in excess of the fair value of the shares acquired was allocated to the license fee using the residual method and expensed in the first quarter of 2009, as the license acquired did not have an alternative future use. Research and development expense related to the Company’s agreements with La Jolla in the first quarter of 2009 approximated $8.8 million, and is comprised of the $7.5 million up-front license fee and the $1.3 million premium paid in excess of the preferred stock’s fair value.

On February 12, 2009, the results of the first interim efficacy analysis for the Phase 3 study of Riquent were announced, and the Independent Data Monitoring Board determined that the continuation of the trial was futile. Based on the results of this interim efficacy analysis, the Company and La Jolla decided to stop the study.

On March 26, 2009, the Company terminated its licensing agreement with La Jolla, triggering the preferred stock’s automatic conversion feature at a rate of one preferred share to thirty shares of common stock. Thus, as of the conversion date, the Company held approximately 10.2 million shares of common stock, or approximately 15.5% La Jolla’s outstanding common stock. The Company accounted for the converted La Jolla shares, which were traded on the NASDAQ Stock Exchange, as an available-for-sale investment. The investment was classified as available-for-sale, with changes in the fair value reported as a component of accumulated other comprehensive income/loss, exclusive of other-than-temporary impairment losses, if any. Losses determined to be other-than-temporary were reported in earnings in the period in which the impairment occurs.

In March 2009, the Company recognized an impairment charge of $4.5 million, for the decline in the La Jolla investment’s value, which was determined to be other-than-temporary. The determination that the decline was other-than-temporary was, in part, subjective and influenced by several factors, including: the length of time and the extent to which the market value of La Jolla’s common stock had been less than the value on the date of purchase, La Jolla’s financial condition and near-term prospects, including any events which may influence its operations, and the Company’s intent and ability to hold the investment for a period of time sufficient to allow for the anticipated recovery in market value. Based on the then current market conditions, La Jolla’s current financial condition and its business prospects, the Company determined that its investment in La Jolla was other-than-temporarily impaired and adjusted the recorded amount of the investment to the stock’s market price on March 31, 2009. In June 2009, the Company sold its 10.2 million shares of La Jolla common stock through a series of open market trades, ranging in gross proceeds to the Company of $0.17 to $0.22 per share. In connection with the sale of the La Jolla common stock, the Company recognized a loss of $66,000 on the sale of the equity investment during the second quarter of 2009.

(13) CONVERTIBLE DEBT

In April 2007, the Company sold approximately $324.9 million of Senior Subordinated Convertible Notes due 2017. The debt was issued at face value and bears interest at the rate of 1.875% per annum, payable semi-annually in cash. The debt is convertible, at the option of the holder, at any time prior to maturity or redemption, into shares of Company common stock at a conversion price of approximately $20.36 per share, subject to adjustment in certain circumstances. There is not a call provision included and the Company is unable to unilaterally redeem the debt prior to maturity on April 23, 2017. The Company also must repay the debt if there is a qualifying change in control or termination of trading of its common stock.

In connection with the placement of the April 2007 debt, the Company paid approximately $8.5 million in offering costs, which have been deferred and are included in other assets. In each of the first quarters of 2009 and 2010, the Company recognized amortization of expense of $0.2 million.

In March 2006, the Company sold $172.5 million of Senior Subordinated Convertible Notes due 2013. The debt was issued at face value and bears interest at the rate of 2.5% per annum, payable semi-annually in cash. The debt is convertible, at the option of the holder, at any time prior to maturity or redemption, into shares of Company common stock at a conversion price of approximately $16.58 per share, subject to adjustment in certain circumstances. There is not a call provision included and the Company is unable to unilaterally redeem the debt prior to maturity on March 29, 2013. The Company also must repay the debt if there is a qualifying change in control or termination of trading of its common stock.

In connection with the placement of the March 2006 debt, the Company paid approximately $5.5 million in offering costs, which have been deferred and are included in other assets. They are being amortized as interest expense over the life of the debt, and the Company recognized amortization of expense of $0.2 million in each of the first quarters of 2009 and 2010. Interest expense on the convertible debt for the three months ended March 31, 2009 and 2010 was $2.6 million in both periods.

21

(14) DERIVATIVE INSTRUMENTS AND HEDGING STRATEGIES

The Company uses hedging contracts to manage the risk of its overall exposure to fluctuations in foreign currency exchange rates. All of the Company’s designated hedging instruments are considered to be cash flow hedges.

Foreign Currency Exposure

The Company uses forward foreign exchange contracts to hedge certain operational exposures resulting from changes in foreign currency exchange rates. Such exposures result from portions of its forecasted revenues being denominated in currencies other than the U.S. dollar, primarily the Euro and British Pound.

The Company designates certain of these foreign currency forward contract hedges as hedging instruments and enters into some foreign currency forward contracts that are considered to be economic hedges that are not designated as hedging instruments. Whether designated or undesignated, these forward contracts protect against the reduction in value of forecasted foreign currency cash flows resulting from Naglazyme and Aldurazyme revenues and net asset or liability positions designated in currencies other than the U.S. dollar. The fair values of foreign currency agreements are estimated as described in Note 15, taking into consideration current interest rates and the current creditworthiness of the counterparties or the Company, as applicable. Details of the specific instruments used by the Company to hedge its exposure to foreign currency fluctuations follow below.

At March 31, 2010, the Company had 53 foreign currency forward contracts outstanding to sell a total of 61.5 million Euros with expiration dates ranging from April 30, 2010 through December 31, 2011. These hedges were entered into to protect against the fluctuations in Euro denominated Naglazyme and Aldurazyme revenues. The Company has formally designated these contracts as cash flow hedges and expects them to be highly effective within the meaning of ASC Subtopic 815-30, Derivatives and Hedging- Cash Flow Hedges, in offsetting fluctuations in revenues denominated in Euros related to changes in the foreign currency exchange rates.

The Company also enters into forward foreign currency contracts that are not designated as hedges for accounting purposes. The changes in fair value of these foreign currency hedges are included as a part of selling, general and administrative expenses in the consolidated statements of operations. At March 31, 2010, the Company had one outstanding foreign currency contract to sell 16.0 million Euros that was not designated as a hedge for accounting purposes.

The maximum length of time over which the Company is hedging its exposure to the reduction in value of forecasted foreign currency cash flows through foreign currency forward contracts is through December 31, 2011. Over the next twelve months, the Company expects to reclassify $3.1 million from accumulated other comprehensive income to earnings as related forecasted revenue transactions occur.

At December 31, 2009 and March 31, 2010, the fair value carrying amount of the Company’s derivative instruments were recorded as follows (in thousands):

	Asset Derivatives December 31, 2009			Liability Derivatives December  31, 2009
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments
Foreign currency forward contracts	Other current assets	$	77	Other current liabilities	$	768
Total		$	77		$	768
Derivatives not designated as hedging instruments
Foreign currency forward contracts	Other current assets	$	6	Other current liabilities	$	27
Total		$	6		$	27
Total derivative contracts		$	83		$	795

22

	Asset Derivatives March 31, 2010			Liability Derivatives March  31, 2010
	Balance Sheet Location	Fair Value		Balance Sheet Location	Fair Value
Derivatives designated as hedging instruments
Foreign currency forward contracts	Other current assets	$	3,071	Other current liabilities	$	—
Foreign currency forward contracts	Other assets		168	Other liabilities		—
Total		$	3,239		$	—
Derivatives not designated as hedging instruments
Foreign currency forward contracts	Other current assets	$	—	Other current liabilities	$	56
Total		$	—		$	56
Total derivative contracts		$	3,239		$	56

The effect of derivative instruments on the consolidated statements of operations for the three months ended March 31, 2009 and 2010 was as follows (in thousands):

	Foreign Currency Forward Contracts Three Months Ended March 31,
	2009		2010
Derivatives Designated as Hedging Instruments
Net gain recognized in OCI (1)	$	1,740	$	4,058
Net gain (loss) reclassified from accumulated OCI into income (2)		1,184		274
Net gain (loss) recognized in income (3)		209		86
Derivatives Not Designated as Hedging Instruments
Net gain (loss) recognized in income (4)		1,165		1,317

(1) Net change in the fair value of the effective portion classified in other comprehensive income (OCI)

(2) Effective portion classified as product revenue

(3) Ineffective portion and amount excluded from effectiveness testing classified in selling, general and administrative expense

(4) Classified in selling, general and administrative expense

At December 31, 2009 and March 31, 2010, accumulated other comprehensive income associated with foreign currency forward contracts qualifying for hedge accounting treatment was a loss of $0.7 million and gain of $3.4 million, respectively.

The Company is exposed to counterparty credit risk on all of its derivative financial instruments. The Company has established and maintained strict counterparty credit guidelines and enters into hedges only with financial institutions that are investment grade or better to minimize the Company’s exposure to potential defaults. The Company does not require collateral to be pledged under these agreements.

23

(15) FAIR VALUE MEASUREMENTS

The Company measures certain financial assets and liabilities at fair value on a recurring basis, including available-for-sale fixed income, other equity securities and foreign currency derivatives. The tables below present the fair value of these financial assets and liabilities determined using the following inputs at December 31, 2009 and March 31, 2010 (in thousands).

	Fair Value Measurements at December 31, 2009
	Total		Quoted Price in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash and cash equivalents
Overnight deposits	$	18,761	$	18,761	$	—	$	—
Money market instruments		148,410		—		148,410		—
Total cash and cash equivalents	$	167,171	$	18,761	$	148,410	$	—
Available-for-sale securities
Certificates of deposit (1)	$	49,637	$	—	$	49,637	$	—
Corporate securities (2)		161,265		—		161,265		—
Government agency securities (2)		82,707		—		82,707		—
Commercial paper (2)		7,993		—		7,993		—
Equity securities (3)		1,753		1,361		392		—
Total available-for-sale securities	$	303,355	$	1,361	$	301,994	$	—
Deferred compensation asset (4)	$	1,791	$	—	$	1,791	$	—
Foreign currency derivatives (5)		83		—		83		—
Total	$	472,400	$	20,122	$	452,278	$	—
Liabilities:
Deferred compensation liability (6)	$	3,505	$	1,714	$	1,791	$	—
Foreign currency derivatives (7)		795		—		795		—
Contingent acquisition consideration payable (8)		21,213		—		—		21,213
Total	$	25,513	$	1,714	$	2,586	$	21,213

24

	Fair Value Measurements at March 31, 2010
	Total		Quoted Price in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
Cash and cash equivalents
Overnight deposits	$	18,524	$	18,524	$	—	$	—
Money market instruments		90,439		—		90,439		—
Total cash and cash equivalents	$	108,963	$	18,524	$	90,439	$	—
Available-for-sale securities
Certificates of deposit (1)	$	51,225	$	—	$	51,225	$	—
Corporate securities (2)		211,519		—		211,519		—
Commercial paper (2)		14,482		—		14,482		—
Government agency securities (2)		65,785		—		65,785		—
Equity securities (3)		390		—		390		—
Total available-for-sale securities	$	343,401	$	—	$	343,401	$
Deferred compensation asset (4)	$	2,287	$	—	$	2,287	$	—
Foreign currency derivatives (5)		3,239		—		3,239		—
Total	$	457,890	$	18,524	$	439,366	$	—
Liabilities:
Deferred compensation liability (6)	$	3,693	$	1,406	$	2,287	$	—
Foreign currency derivatives (7)		56		—		56		—
Contingent acquisition consideration payable (8)		42,323		—		—		42,323
Total	$	46,072	$	1,406	$	2,343	$	42,323

(1) At December 31, 2009 and March 31, 2010, 62% and 67% are included in short-term investments in the Company’s consolidated balance sheets, respectively. The remaining balances are included in long-term investments.

(2) These amounts are included in short-term investments and long-term investments in the Company’s consolidated balance sheet. At December 31, 2009, 64% of corporate securities and 58% of government agencies were included in long-term investments and the remaining balances were included in short-term investments. At March 31, 2010, 36% of corporate securities and 53% of government agencies were included in long-term investments and the remaining balances were included in short-term investments.

(3) These amounts are included in short-term investments and long-term investments in the Company’s consolidated balance sheet. At December 31, 2009 and March 31, 2010, 22% and 100%, respectively, are included in long-term investments and the remaining balances are included in short-term investments.

(4) At December 31, 2009 and March 31, 2010, 95% and 100%, respectively of this balance is included in other assets and the remainder of the balance is included in other current assets on the Company’s consolidated balance sheet.

(5) These amounts are included in other current assets on the Company’s consolidated balance sheet. Foreign currency derivatives at December 31, 2009 and March 31, 2010 include forward foreign exchange contracts for the Euro.

(6) At December 31, 2009 and March 31, 2010, 89% and 96%, respectively, was included in other long-term liabilities and the remainder is included in accounts payable and accrued liabilities on the Company’s consolidated balance sheet.

(7) These amounts are included in accounts payable and accrued liabilities on the Company’s consolidated balance sheet.

(8) At December 31, 2009 and March 31, 2010, 62% and 57% of these amounts are included in other long-term liabilities, respectively, and 38% and 43% are included in accrued expenses, respectively. See Notes 6 and 7 for additional discussion.

The Company’s level 2 securities are valued using third-party pricing sources, which generally use interest rates and yield curves observable at commonly quoted intervals of similar assets as observable inputs for pricing. See Note 8 for further information regarding the fair value of the Company’s financial instruments.

The Company’s level 3 liabilities are estimated using a probability-based income approach utilizing an appropriate discount rate. Subsequent changes in the fair value of the contingent acquisition consideration payable will be recorded in the “Intangible asset and contingent consideration” expense line item in the consolidated statements of operations under operating expenses. During the first quarter of 2010, the fair value of the contingent acquisition consideration payable increased by $0.6 million. The following table represents the changes in the Company’s level 3 liabilities for the quarter ended March 31, 2010 (in thousands):

	Contingent Acquisition Payable
Fair value at December 31, 2009	$	21,213
Contingent acquisition consideration payable resulting from the LEAD acquisition		20,456
Change in valuation of contingent consideration payable to former Huxley shareholders		654
Fair value at March 31, 2010	$	42,323

25

As discussed in Notes 6 and 7, the Company acquired intangible assets as a result of Huxley and LEAD acquisitions. The estimated fair value of these long-lived assets was measured using level 3 inputs.

(16) REVENUE AND CREDIT CONCENTRATIONS

The Company considers there to be revenue concentration risks for regions where net product revenue exceeds 10% of consolidated net product revenue. The concentration of the Company’s revenue within the regions below may expose the Company to a material adverse effect if sales in the respective regions were to experience difficulties. The table below summarizes product revenue concentrations based on patient location for Naglazyme, Kuvan and Firdapse and Genzyme’s location for Aldurazyme for the three months ended March 31, 2009 and 2010.

	Three Months Ended March 31,
	2009		2010
Region:
United States	52	%	51	%
Europe	24	%	22	%
Latin America	11	%	13	%
Rest of World	13	%	14	%
Total Net Product Revenue	100	%	100	%

The accounts receivable balances at December 31, 2009 and March 31, 2010 are comprised of amounts due from customers for net product sales of Naglazyme and Kuvan and Aldurazyme product transfer and royalty revenues. On a consolidated basis, the three largest customers accounted for 46% of the Company’s net product revenues during the first quarter of 2010, compared to the first quarter of 2009 during which the three largest customers accounted for 51% of the Company’s net product revenues. On a consolidated basis, the three largest customers accounted for 41%, 16% and 11% of the March 31, 2010 accounts receivable balance, compared to December 31, 2009 when the two largest customers accounted for 49% and 18% of the accounts receivable balance. The Company does not require collateral from its customers, but performs periodic credit evaluations of its customers’ financial condition and requires immediate payment in certain circumstances.

(17) JOINT VENTURE

Effective January 2008, the Company and Genzyme restructured BioMarin/Genzyme LLC. Under the revised structure, the operational responsibilities for the Company and Genzyme did not significantly change, as Genzyme continues to globally market and sell Aldurazyme and the Company continues to manufacture Aldurazyme. The restructuring had two significant business purposes. First, since each party now has full control over its own operational responsibilities, without the need to obtain the approval of the other party, and the parties do not need to review and oversee the activities of the other, it reduces management’s time and effort and therefore improves overall efficiencies. Second, since each party will realize 100% of the benefit of their own increased operational efficiencies, it increases the incentives to identify and implement cost saving measures. Under the previous 50/50 structure, each company shared 50% of the expense associated with the other’s inefficiencies and only received 50% of the benefit of its own efficiencies. Specifically, the Company will be able to realize the full benefit of any manufacturing cost reductions and Genzyme will be able to realize the full benefit of any sales and marketing efficiencies.

Genzyme records sales of Aldurazyme to third party customers and pays the Company a tiered payment ranging from approximately 39.5% to 50% of worldwide net product sales depending on sales volume, which is recorded by the Company as product revenue. The Company recognizes a portion of this amount as product transfer revenue when product is released to Genzyme because all of the Company’s performance obligations are fulfilled at this point and title to, and risk of loss for, the product has transferred to Genzyme. The product transfer revenue represents the fixed amount per unit of Aldurazyme that Genzyme is required to pay the Company if the product is unsold by Genzyme. The amount of product transfer revenue is deducted from the calculated royalty rate when the product is sold by Genzyme. Genzyme’s return rights for Aldurazyme are limited to defective product. Certain research and development activities and intellectual property related to Aldurazyme continue to be managed in the joint venture with the costs shared equally by the Company and Genzyme.

26

The Company presents the related cost of sales and its Aldurazyme-related operating expenses as operating expenses in the consolidated statements of operations. Equity in the loss of BioMarin/Genzyme LLC subsequent to the restructuring includes the Company’s 50% share of the net income/loss of BioMarin/Genzyme LLC related to intellectual property management and ongoing research and development activities.

27

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under securities laws. Many of these statements can be identified by the use of terminology such as “believes,” “expects,” “anticipates,” “plans,” “may,” “will,” “projects,” “continues,” “estimates,” “potential,” “opportunity” and similar expressions. These forward-looking statements may be found in “Overview,” of this Item 2 and other sections of this Quarterly Report on Form 10-Q. Our actual results or experience could differ significantly from the forward-looking statements. Factors that could cause or contribute to these differences include those discussed in “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the Securities and Exchange Commission (SEC) on February 25, 2010 as well as those discussed elsewhere in this Quarterly Report on Form 10-Q. You should carefully consider that information before you make an investment decision.

You should not place undue reliance on these statements, which speak only as of the date that they were made. These cautionary statements should be considered in connection with any written or oral forward-looking statements that we may issue in the future. We do not undertake any obligation to release publicly any revisions to these forward-looking statements after completion of the filing of this Quarterly Report on Form 10-Q to reflect later events or circumstances or the occurrence of unanticipated events.

The following discussion of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and notes to those statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We develop and commercialize innovative biopharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Our product portfolio is comprised of four approved products and multiple investigational product candidates. Approved products include Naglazyme, Aldurazyme, Kuvan and Firdapse.

Naglazyme received marketing approval in the U.S. in May 2005, in the EU in January 2006 and subsequently in other countries. Naglazyme net product revenues for the three months ended March 31, 2009 and 2010 totaled $39.4 million and $48.6 million, respectively.

Aldurazyme, which was developed in collaboration with Genzyme Corporation (Genzyme), has been approved for marketing in the U.S., EU and other countries. Pursuant to our arrangement with Genzyme, Genzyme sells Aldurazyme to third parties and we recognize royalty revenue on net sales by Genzyme. We recognize a portion of the royalty as product transfer revenue when product is released to Genzyme because all obligations related to the transfer have been fulfilled at that point and title to, and risk of loss for, the product has been transferred to Genzyme. The product transfer revenue represents the fixed amount per unit of Aldurazyme that Genzyme is required to pay us if the product is unsold by Genzyme. The amount of product transfer revenue will eventually be deducted from the calculated royalties earned when the product is sold by Genzyme. Aldurazyme net product revenues for the three months ended March 31, 2009 and 2010 were $17.0 million and $14.2 million, respectively.

Kuvan was granted marketing approval in the U.S. and EU in December 2007 and December 2008, respectively. Kuvan net product revenues for the three months ended March 31, 2009 and 2010 totaled $15.5 million and $21.2 million, respectively.

In December 2009, the EMEA granted marketing approval for Firdapse. We launched this product on a country by country basis starting in March 2010. Firdapse net product revenues for the three months ended March 31, 2010 totaled $0.1 million and were comprised solely of named patient sales. Firdapse was launched commercially in Europe in April 2010. We also continue to develop Firdapse for the possible treatment of LEMS in the U.S.

We are conducting clinical trials on several investigational product candidates for the treatment of genetic diseases, including: GALNS, an enzyme replacement therapy for the treatment of Mucopolysaccharidosis Type IV or Morquio Syndrome Type A, (MPS IV A), PEG-PAL, an enzyme substitution therapy for the treatment of phenylketonurics (PKU) for patients who do not respond well to Kuvan and a small molecule for the treatment of Duchenne muscular dystrophy. In September 2009, we initiated a Phase 2 clinical trial to evaluate PEG-PAL in PKU patients. Results from this clinical trial are expected in the third quarter of 2010. In the first half of 2009, we initiated a Phase 1/2 clinical trial of GALNS. We have completed enrollment in this clinical trial and reported results in April 2010. In January 2010, we initiated a Phase 1 clinical trial of our small molecule for the treatment of Duchenne muscular dystrophy. Initial top-line results from this trial are expected in the second quarter of 2010.

28

Key components of our results of operations for the three months ended March 31, 2009 and 2010 include the following (in millions):

	Three Months Ended March 31,
	2009			2010
Total net product revenues	$	71.9		$	84.1
Cost of sales		14.4			17.4
Research and development expense		34.4			30.1
Selling, general and administrative expense		28.6			34.0
Net income (loss)		(13.2	)		1.2
Stock-based compensation expense		7.8			8.5

See “Results of Operations” below for a discussion of the detailed components and analysis of the amounts above. Our cash, cash equivalents, short-term investments and long-term investments totaled $452.4 million as of March 31, 2010, compared to $470.5 million as of December 31, 2009. See “Liquidity and Capital Resources” below for a further discussion of our liquidity and capital resources.

Critical Accounting Policies and Estimates

In preparing our consolidated financial statements in accordance with accounting principles generally accepted in the U.S. and pursuant to the rules and regulations promulgated by the SEC, we make assumptions, judgments and estimates that can have a significant impact on our net income/loss and affect the reported amounts of certain assets, liabilities, revenue and expenses, and related disclosures. We base our assumptions, judgments and estimates on historical experience and various other factors that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates under different assumptions or conditions. On a regular basis, we evaluate our assumptions, judgments and estimates. We also discuss our critical accounting policies and estimates with the Audit Committee of our Board of Directors.

We believe that the assumptions, judgments and estimates involved in the accounting for the valuation and impairment reviews of long-lived assets, revenue recognition and related reserves, income taxes, inventory, research and development expenses, stock-based compensation and business combinations have the greatest impact on our consolidated financial statements, so we consider these to be our critical accounting policies. Historically, our assumptions, judgments and estimates relative to our critical accounting polices have not differed materially from actual results.

Except for our critical accounting policy for the valuation of our contingent acquisition consideration payable noted below, there have been no significant changes in our critical accounting policies and estimates during the three months ended March 31, 2010, as compared to the critical accounting policies and estimates disclosed in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on February 25, 2010.

Valuation of Contingent Acquisition Consideration Payable

Each period we revalue the contingent acquisition consideration payable associated with certain acquisitions to their then fair value and record increases in the fair value as contingent consideration expense and record decreases in the fair value as a reduction of contingent consideration expense. Increases or decreases in the fair value of the contingent acquisition consideration payable can result from changes in assumed discount periods and rates, changes in the assumed timing of when milestones will be achieved and amount of revenue and expense estimates and changes in assumed probability adjustments with respect to regulatory approval. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, future business and economic conditions, as well as changes in any of the assumptions described above, can materially impact the amount of contingent consideration expense that we record in any given period.

Recent Accounting Pronouncements

See Note 2(s) of our accompanying unaudited consolidated financial statements for a full description of recent accounting pronouncements and our expectation of their impact, if any, on our results of operations and financial condition.

29

Results of Operations

Net Income (Loss)

Our net income for the three months ended March 31, 2010 was $1.2 million compared to net loss of $13.2 million for the three months ended March 31, 2009, representing a change of $14.4 million. The change of $14.4 million was primarily a result of the following (in millions):

Net loss for the year period ended March 31, 2009	$	(13.2	)
Increased Naglazyme gross profit		8.0
Increased Kuvan gross profit		4.6
Increased selling, general and administrative expense		(5.4	)
Decreased Aldurazyme gross profit		(3.6	)
Decreased impairment loss on equity investments		5.9
Decreased research and development expense		4.3
Decreased interest expense		1.7
Decreased interest income		(1.0	)
Decreased Orapred royalty revenue		(0.9	)
Gain on the sale of equity investments		0.9
Other individually insignificant fluctuations		(0.1	)
Net income for the period ended March 31, 2010	$	1.2

The increase in selling, general and administrative expense in the first quarter of 2010 is primarily due to increased facility and employee related costs and the continued international expansion of Naglazyme and commercialization of Firdapse in Europe. The decrease in research and development expense is primarily attributed to the absence of the $8.8 million of up-front costs associated with a product licensed from La Jolla in 2009, offset by increased development expenses for our PEG-PAL and Duchenne muscular dystrophy programs. The increase in Naglazyme gross profit in the first quarter of 2010 as compared is the same period in 2009 primarily a result of additional patients initiating therapy outside the U.S. The increase in Kuvan gross profit in the first quarter of 2010 as compared to the same period in 2009 is primarily a result of additional patients initiating therapy in the U.S. The decrease in Aldurazyme gross profit in the first quarter of 2010, as compared to the same period in 2009 is primarily attributed to less shipments of Aldurazyme to Genzyme than Genzyme’s shipments to third parties resulting in lower royalties payable to us and the write-off of approximately $2.1 million of Aldurazyme product for an outdated registration lot as a result of delays in the qualification of a new fill finish vendor during the first quarter of 2010. See below for additional information related to the primary net income/loss fluctuations presented above, including details of our operating expense fluctuations.

Net Product Revenues, Cost of Sales and Gross Profit

The following table shows a comparison of net product revenues for the three months ended March 31, 2009 and 2010 (in millions):

	Three Months Ended March 31,
	2009		2010		Change
Naglazyme	$	39.4	$	48.6	$	9.2
Kuvan		15.5		21.2		5.7
Aldurazyme		17.0		14.2		(2.8	)
Firdapse		—		0.1		0.1
Total Net Product Revenues	$	71.9	$	84.1	$	12.2

Net product revenues for Naglazyme in the first quarter of 2010 totaled $48.6 million, of which $41.2 million was earned from customers based outside the U.S. The impact of foreign currency exchange rates on Naglazyme sales denominated in currencies other than the U.S. dollar was insignificant in the first quarter of 2010. Gross profit from Naglazyme sales in the first quarter of 2010 was approximately $39.3 million, representing gross margins of 81%, compared to gross profits of $31.3 million in the first quarter of 2009, representing gross margins of approximately 80%. The slight increase in gross margins during the first quarter of 2010 as compared to the first quarter of 2009 is primarily due to the impact of improved manufacturing yields.

30

Net product revenue for Kuvan during the first quarter of 2010 was $21.2 million, compared to $15.5 million during the same period in 2009. With the commercial launch of Kuvan in the EU during the first half of 2009, we began receiving a royalty of approximately 4% on net sales of Kuvan from Merck Serono. During the first quarter of 2010, we earned $0.2 million in royalties from Merck Serono on net sales of $4.8 million. Royalties earned from Merck Serono during the first quarter of 2009 were insignificant. Gross profit from Kuvan in the first quarter of 2010 was approximately $17.7 million, representing gross margins of approximately 84%, compared to the first quarter of 2009 when gross profit totaled $13.1 million, representing gross margins of approximately 84%. Both periods reflect royalties paid to third parties of 11%. In accordance with our inventory accounting policy, we began capitalizing Kuvan inventory production costs after U.S. regulatory approval was obtained in December 2007. We expect U.S. gross margins for Kuvan for the foreseeable future to be in the lower 80% range as the pre-approval inventory has been mostly depleted.

Pursuant to our relationship with Genzyme, we record a 39.5% to 50% royalty on worldwide net product sales of Aldurazyme. We also recognize product transfer revenue when product is released to Genzyme and all of our obligations have been fulfilled. Genzyme’s return rights for Aldurazyme are limited to defective product. The product transfer revenue represents the fixed amount per unit of Aldurazyme that Genzyme is required to pay us if the product is unsold by Genzyme. The amount of product transfer revenue will eventually be deducted from the calculated royalty rate when the product is sold by Genzyme.

	Three Months Ended March 31,
	2009		2010			Change
Aldurazyme revenue reported by Genzyme	$	36.8	$	39.9		$	3.1
Royalties due from Genzyme		14.5		15.9			1.4
Incremental (previously recognized) Aldurazyme product transfer revenue		2.5		(1.7	)		(4.2	)
Total Aldurazyme net product revenues	$	17.0	$	14.2		$	(2.8	)
Gross profit	$	13.2	$	9.6		$	(3.6	)

In the first quarter of 2010, Aldurazyme gross margins were 67%, compared to 77% in the first quarter of 2009. Aldurazyme gross margins reflect the profit earned on royalty revenue and net incremental product transfer revenue. The change in gross margins is attributed to a shift in revenue mix between royalty revenue and net product transfer revenues as well as a $2.1 million write-off of an outdated registration lot of Aldurazyme as a result of delays in the qualification of a new fill finish vendor during the first quarter of 2010. In the first quarter of 2010 Aldurazyme net product revenues were solely comprised of royalty revenues, compared to the same period in 2009, when the revenue mix was 85% royalty revenues and 15% net product transfer revenues. In the future, to the extent that Genzyme’s Aldurazyme inventory quantities on hand remain flat, we expect that our total Aldurazyme revenues will approximate the 39.5% to 50% royalties on net product sales by Genzyme. Aldurazyme gross margins are expected to fluctuate depending on the mix of royalty revenue, from which we earn higher gross profit, and product transfer revenue, from which we earn a lower gross profit.

Total cost of sales in the first quarter of 2010 was $17.4 million, compared to $14.4 million in the first quarter of 2009. The increase in cost of sales in the first quarter of 2010 compared the same period in 2009 is attributed to the increase in Naglazyme and Kuvan product sales and the Aldurazyme inventory write-off discussed above.

Collaborative Agreement Revenues

Collaborative agreement revenues for the first quarters of 2009 and 2010 are comprised of contract research revenue under our agreement with Merck Serono, which was executed in May 2005. Contract research revenues are related to shared development costs that are incurred by us, of which approximately 50% is reimbursed by Merck Serono. Our performance obligations related to the initial $25.0 million up-front license payment were completed in December 2008; as such, periods subsequent to December 31, 2008 no longer include amortization of the $25.0 million up-front license payment received from Merck Serono. As shared development spending increases or decreases, contract research revenues will also change proportionately. Reimbursable revenues are expected to increase if PEG-PAL successfully completes Phase 2 clinical trials and Merck Serono exercises its right to co-develop it. The related costs are included in research and development expenses.

Collaborative agreement revenue in the first quarters of 2009 and 2010 were $0.5 million and $0.2 million, respectively. In both periods collaborative agreement revenue was comprised solely of reimbursable Kuvan development costs.

31

Royalty and License Revenues

The following table details the components of royalty and license revenues for the three months ended March 31, 2009 and 2010 (in millions):

	Three Months Ended March 31,
	2009		2010		Change
Orapred product royalties	$	1.4	$	0.5	$	(0.9	)
6R-BH4 royalty revenues		0.2		0.2		—
Total		1.6		0.7		(0.9	)

Royalty and license revenues include Orapred product royalties, a product we acquired in 2004 and sublicensed in 2006, and 6R-BH4 royalty revenues for product sold in Japan. There is no cost of sales associated with the royalty and license revenues recorded during the periods and no related costs are expected in future periods.

Research and Development Expense

Our research and development expense includes personnel, facility and external costs associated with the research and development of our product candidates and products. These research and development costs primarily include preclinical and clinical studies, manufacturing of our product candidates prior to regulatory approval, quality control and assurance and other product development expenses, such as regulatory costs.

Research and development expense decreased by $4.3 million to $30.1 million for the three months ended March 31, 2010, from $34.4 million for the three months ended March 31, 2009. The change in research and development expense for the three months ended March 31, 2010 was primarily a result of the following (in millions):

Research and development expense for period ended March 31, 2009	$	34.4
Absence of license payment related to collaboration with La Jolla Pharmaceutical Company		(8.8	)
Decreased 6R-BH4 development expenses for indications other than PKU		(2.0	)
Increased PEG-PAL development expenses		2.1
Increased Duchenne muscular dystrophy program development expense		1.4
Decreased Prodrug development expenses		(0.9	)
Decreased GALNS for Morquio Syndrome Type A development expense		(0.2	)
Increased stock-based compensation expense		0.7
Increased development expenses related to commercial products		0.7
Increased research and development expenses on early development stage programs		1.6
Increase in non-allocated research and development expenses and other net changes		1.1
Research and development expense for the period ended March 31, 2010	$	30.1

During the first quarter of 2009, we paid La Jolla an up-front license fee for the rights to develop and commercialize La Jolla’s investigational drug, Riquent. We terminated the license agreement with La Jolla in 2009 and there will not be any additional development expense for Riquent. The increase in PEG-PAL development expense is attributed to increased clinical trial activities related to the product candidate. The increase in Duchenne muscular dystrophy program development expense is primarily attributed to increased pre-clinical activities and Phase I clinical trial related to the product candidate. The decrease in 6R-BH4 development expense expenses for indications other than PKU is primarily due to a decline in clinical studies in the first quarter of 2010 compared to the same period in 2009. The increase in stock-based compensation expense is a result of an increased number of options outstanding due to an increased number of employees. The increase in research and development expenses related to commercial products is attributed to long-term Kuvan clinical activities related to post-approval regulatory commitments. The increase in non-allocated research and development expense primarily includes increases in general research costs and research and development personnel costs that are not allocated to specific programs. We expect to continue incurring significant research and development expense for the foreseeable future due to long-term clinical activities related to post-approval regulatory commitments related to our products and spending on our GALNS, PEG-PAL, Duchenne muscular dystrophy and Firdapse programs and our other product candidates.

Selling, General and Administrative Expense

Our selling, general and administrative expense includes commercial and administrative personnel, corporate facility and external costs required to support our commercialized products and product development programs. These selling, general and administrative costs include: corporate facility operating expenses and depreciation; marketing and sales operations; human resources; finance; legal and support personnel expenses and other external corporate costs such as insurance, audit and legal fees.

32

Selling, general and administrative expenses increased by $5.4 million to $34.0 million for the three months ended March 31, 2010, from $28.6 million for the three months ended March 31, 2009. The components of the change for the three months ended March 31, 2010 was primarily include the following (in millions):

Selling, general and administrative expense for the period ended March 31, 2009	$	28.6
Increased Naglazyme sales and marketing expenses		1.0
Increased Firdapse commercial preparation expenses		1.2
Decreased Kuvan commercialization expenses		(1.0	)
Decreased stock-based compensation expense		(0.4	)
Increased depreciation expense		0.4
Increased foreign exchange losses on un-hedged transactions		0.3
Net increase in corporate overhead and other administrative expenses		3.9
Selling, general and administrative expense for the period ended March 31, 2010	$	34.0

The increase in Naglazyme sales and marketing expenses in the first quarter of 2010 is attributed to continued expansion of our international activities. We incurred spending related to the commercialization of Firdapse for the product’s European launch in April 2010. The decrease in Kuvan commercialization expense is attributed to a decline in publication and media development expense for Kuvan during the first quarter of 2010 compared to the same period in 2009. The increase in corporate overhead and other administrative costs during the first quarter of 2010 is primarily comprised of increased employee related costs. We expect selling, general and administrative expenses to increase in future periods as a result of the international expansion of Naglazyme, the European launch of Firdapse and the U.S. commercialization activities for Kuvan.

Intangible Asset Amortization and Contingent Consideration Expense

Intangible asset amortization and contingent consideration expense for the first quarter of 2010 was $0.7 million, compared to $1.1 million in the first quarter of 2009. Intangible asset amortization and contingent consideration expense during the first quarter of 2010 was comprised of the change in fair value of the contingent consideration payable to the former shareholders of Huxley Pharmaceuticals, Inc. (See Note 15 of the accompanying unaudited consolidated financial statements for additional discussion). Amortization of intangible assets for the first quarter of 2009 included three months of amortization expense related to the intangible assets acquired in the Ascent Pediatrics transaction in May 2004, including the Orapred developed and core technology. In June 2009, we completed the purchase of all of the outstanding shares of capital stock of BioMarin Pediatrics II (formerly known as Ascent Pediatrics, Inc. and Medicis Pediatrics, Inc.), a wholly-owned subsidiary of Medicis Pharmaceutical Corporation (Medicis) as required by the original transaction agreement of 2004 for $70.6 million. Medicis’ sole substantive asset was the intellectual property related to the Orapred franchise. Subsequently, we transferred the exclusive intellectual property rights to our sublicense in July 2009.

Equity in the Loss of BioMarin/Genzyme LLC

Equity in the loss of BioMarin/Genzyme LLC includes our 50% share of the joint venture’s loss for the period. BioMarin/Genzyme LLC’s operations consist primarily of certain research and development activities and the intellectual property which are managed by the joint venture with costs shared equally by BioMarin and Genzyme.

Equity in the loss of the joint venture totaled $0.7 million for the three months ended March 31, 2010, compared to $0.5 million for the three months ended March 31, 2009.

Interest Income

We invest our cash, short-term and long-term investments in government and other high credit quality securities in order to limit default and market risk. Interest income totaled $2.2 million and $1.2 million in the three months ended March 31, 2009 and 2010, respectively. The reduced interest yield during the first quarter of 2010 was due to lower market interest rates and decreased levels of cash and investments. We expect that interest income will decline during the remainder of 2010 as compared to 2009 due to reduced interest yields and lower cash and investment balances.

Interest Expense

We incur interest expense on our convertible debt. Interest expense also includes imputed interest expense on the discounted acquisition obligation for the Ascent Pediatrics transaction. Interest expense during the first quarter of 2010 was $2.4 million, compared to the same period of 2009 when interest expense amounted to $4.1 million. Interest expense in the first quarter of 2009 included imputed interest of $1.1 million. Imputed interest will not be incurred in periods subsequent to June 2009 as the Medicis obligation was paid in full in June 2009.

33

Changes in Financial Position

March 31, 2010 Compared to December 31, 2009

From December 31, 2009 to March 31, 2010, our cash, cash equivalents, and short-term and long-term investments decreased by $18.1 million, primarily as a result the acquisition of LEAD Therapeutics, Inc. and capital expenditures, offset by cash flows from operating activities and proceeds from ESPP contributions and stock option exercises. Our accounts receivable increased by $9.1 million due to increased sales of Naglazyme and Kuvan and receivables from Genzyme for Aldurazyme product transfer and royalty revenues. Our net property, plant and equipment increased by approximately $4.8 million from December 31, 2009 to March 31, 2010, primarily as a result of continued expansion and improvements to our facilities during the period. Intangible assets, goodwill and other long-term liabilities increased by approximately $36.4 million, $16.7 million and $25.5 million primarily as a result of the LEAD acquisition. Due to several ongoing facility improvement projects substantially completed in 2009, we expect depreciation expense to increase as the assets are placed into service.

Liquidity and Capital Resources

Cash and Cash Flow

As of March 31, 2010, our combined cash, cash equivalents, short-term and long-term investments totaled $452.4 million, a decrease of $18.1 million from $470.5 million at December 31, 2009.

The decrease in our combined cash, cash equivalents, short-term investments and long-term investments during the first quarter of 2010 was $18.1 million, which was $12.6 million more than the net decrease in the first quarter of 2009 of $5.5 million. The primary items contributing to the decrease in net cash outflow in the first quarter of 2010 were as follows (in millions):

Absence of milestone payment received for Kuvan EMEA approval	$	(30.0	)
Acquisition of LEAD Therapeutics, Inc.		14.1
Increased proceeds from ESPP and stock option exercises		8.3
Absence of investment in La Jolla Pharmaceuticals, Inc.		6.3
Decreased capital asset purchases		4.6
Decreased Orapred acquisition payments		1.5
Increased investments in BioMarin/Genzyme LLC		(1.5	)
Net increase in cash provided by operating activities, including net payments for working capital, and other		12.3
Total increase in net cash outflow	$	(12.6	)

The net decrease in operating spend includes increases in cash receipts from net revenues, partially offset by increases in cash payments made for operating activities, such as research and development and sales and marketing efforts, as discussed in “Results of Operations” above. Decreased capital purchases reflect the substantial completion of our manufacturing facilities at our Novato, California campus in the second half of 2009. Net payments for working capital in the first quarter of 2010, primarily includes decreased inventory build of $2.2 million, increased accounts receivable build of $2.0 million and decreased reduction of other current assets of $22.8 million. The decrease in other current assets reduction is primarily attributed to the receipt of the Merck Serono $30.0 million milestone payment earned in December 2008 related to the EMEA approval of Kuvan in January 2009.

On October 23, 2009, we acquired Huxley, which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease LEMS for a total purchase price of $37.2 million, of which $15.0 million was paid in cash and $22.2 million is contingent acquisition consideration payable, of which $1.0 million was paid in the fourth quarter of 2009 and $6.5 million was paid in April 2010. In connection with the acquisition, we agreed to pay Huxley stockholders additional consideration in future periods of up to $41.9 million (undiscounted) in milestone payments if certain annual sales, cumulative sales and U.S. development milestones are met.

On February 10, 2010, we acquired LEAD, which has the key compound, LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of patients with rare, genetically defined cancers for a total purchase price of $39.1 million, of which $18.6 million was paid in cash and $20.5 million is contingent acquisition consideration payable. We paid $3.0 million of the $18.6 million in cash during December 2009. In connection with the acquisition, we agreed to pay LEAD stockholders additional consideration in future periods of up to $68.0 million (undiscounted) in milestone payments if certain clinical, development and sales milestones are met.

We expect that our net cash outflow in 2010 related to capital asset purchases will decrease significantly compared to 2009. The expected decrease in capital asset purchases primarily reflects the substantial completion of our manufacturing facility and the related spending on manufacturing and laboratory equipment.

34

We have historically financed our operations primarily by the issuance of common stock and convertible debt and by relying on equipment and other commercial financing. During 2010, and for the foreseeable future, we will be highly dependent on our net product revenue to supplement our current liquidity and fund our operations. We may in the future elect to supplement this with further debt or equity offerings or commercial borrowing. Further, depending on market conditions, our financial position and performance and other factors, in the future we may choose to use a portion of our cash or cash equivalents to repurchase our convertible debt or other securities.

Funding Commitments

We expect to fund our operations with our net product revenues from our commercial products; cash; cash equivalents; short-term and long-term investments supplemented by proceeds from equity or debt financings; and loans or collaborative agreements with corporate partners, each to the extent necessary. We expect our current cash, cash equivalents, and short-term and long-term investments will meet our operating and capital requirements for the foreseeable future based on our current long-term business plans and assuming that we are able to achieve our long-term goals. This expectation could also change depending on how much we elect to spend on our development programs and for potential licenses and acquisitions of complementary technologies, products and companies.

Our investment in our product development programs and continued development of our existing commercial products has a major impact on our operating performance. Our research and development expenses for the three months ended March 31, 2009 and 2010 and for the period since inception (March 1997 for the portion not allocated to any major program) represent the following (in millions):

	Three Months Ended March 31,				Since Program Inception
	2009		2010
Naglazyme	$	2.3	$	2.2	$	134.6
Kuvan		2.6		3.0		104.3
GALNS for Morquio Syndrome Type A		4.1		3.9		38.0
6R-BH4 for indications other than PKU		3.1		0.2		46.7
PEG-PAL		2.3		4.4		46.8
Not allocated to specific major current projects		12.1		16.4		257.9
	$	26.5	$	30.1	$	628.3

We cannot estimate the cost to complete any of our product development programs. Additionally, except as disclosed under “Overview” above, we cannot estimate the time to complete any of our product development programs or when we expect to receive net cash inflows from any of our product development programs. Please see “Risk Factors ” in our Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on February 25, 2010, for a discussion of the reasons that we are unable to estimate such information, and in particular the following risk factors included in such Annual Report on Form 10-K “ —If we fail to maintain regulatory approval to commercially market and sell our drugs, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished, and the capital necessary to fund our operations will be increased;” “—To obtain regulatory approval to market our products, preclinical studies and costly and lengthy preclinical and clinical trials are required and the results of the studies and trials are highly uncertain;” “—If we are unable to successfully develop manufacturing processes for our drug products to produce sufficient quantities at acceptable costs, we may be unable to meet demand for our products and lose potential revenue, have reduced margins or be forced to terminate a program;” “—If we fail to compete successfully with respect to product sales, we may be unable to generate sufficient sales to recover our expenses related to the development of a product program or to justify continued marketing of a product and our revenue could be adversely affected;” and “—If we do not achieve our projected development goals in the timeframes we announce and expect, the commercialization of our products may be delayed and the credibility of our management may be adversely affected and, as a result, our stock price may decline. ”

We may elect to increase our spending above our current long-term plans and may be unable to achieve our long-term goals. This could increase our capital requirements, including: costs associated with the commercialization of our products; additional clinical trials and the manufacturing of Naglazyme, Aldurazyme, Kuvan and Firdapse; preclinical studies and clinical trials for our other product candidates; potential licenses and other acquisitions of complementary technologies, products and companies; general corporate purposes; and working capital.

Our future capital requirements will depend on many factors, including, but not limited to:

• our ability to successfully market and sell Naglazyme, Kuvan and Firdapse;

• Genzyme’s ability to continue to successfully market and commercialize Aldurazyme;

• the progress, timing, scope and results of our preclinical studies and clinical trials;

35

• the time and cost necessary to obtain regulatory approvals and the costs of post-marketing studies which may be required by regulatory authorities;

• the time and cost necessary to develop commercial manufacturing processes, including quality systems and to build or acquire manufacturing capabilities;

• the time and cost necessary to respond to technological and market developments;

• any changes made to or new developments in our existing collaborative, licensing and other commercial relationships or any new collaborative, licensing and other commercial relationships that we may establish; and

• whether our convertible debt is converted to common stock in the future.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that are currently material or reasonably likely to be material to our financial position or results of operations.

Borrowings and Contractual Obligations

In April 2007, we sold approximately $324.9 million of senior subordinated convertible debt due April 2017. The debt was issued at face value and bears interest at the rate of 1.875% per annum, payable semi-annually in cash. The debt is convertible, at the option of the holder, at any time prior to maturity, into shares of our common stock at a conversion price of approximately $20.36 per share, subject to adjustment in certain circumstances. There is a no call provision included and we are unable to unilaterally redeem the debt prior to maturity in 2017. We also must repay the debt if there is a qualifying change in control or termination of trading of our common stock. In March 2006, we sold approximately $172.5 million of senior subordinated convertible notes due 2013. The debt was issued at face value and bears interest at the rate of 2.5% per annum, payable semi-annually in cash. There is a no call provision included and we are unable to unilaterally redeem the debt prior to maturity in 2013. The debt is convertible, at the option of the holder, at any time prior to maturity, into shares of our common stock at a conversion price of approximately $16.58 per share, subject to adjustment in certain circumstances. However, we must repay the debt prior to maturity if there is a qualifying change in control or termination of trading of our common stock. Our $497.1 million of convertible debt will impact our liquidity due to the semi-annual cash interest payments and the scheduled repayments of the debt.

We have contractual and commercial obligations under our debt, operating leases and other obligations related to research and development activities, purchase commitments, licenses and sales royalties with annual minimums. Information about these obligations as of March 31, 2010 is presented in the table below (in thousands).

	Payments Due by Period
	2010		2011		2012 -2013		2014-2015		2016 and Thereafter		Total
Convertible debt and related interest	$	8,246	$	10,401	$	190,853	$	12,183	$	334,012	$	555,695
Operating leases		3,247		4,037		6,495		2,238		2,378		18,395
Research and development and purchase commitments		24,977		8,853		5,806		3,446		4,049		47,131
Total	$	36,470	$	23,291	$	203,154	$	17,867	$	340,439	$	621,221

We are also subject to contingent payments related to various development activities totaling approximately $268.7 million, which are due upon achievement of certain regulatory and licensing milestones, and if they occur before certain dates in the future.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Our market risks at March 31, 2010 have not materially changed from those in Item 7A of our Annual Report on Form 10-K for the year ended December 31, 2009, which was filed with the SEC on February 25, 2010.

Item 4. Controls and Procedures

(a) Controls and Procedures

An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the Exchange Act)) as of the end of the period covered by this report.

36

Based on the evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports that we filed or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

(b) Change in Internal Controls over Financial Reporting

There were no changes in our internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act, during our most recently completed quarter that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

None.

Item 1A. Risk Factors

In the three months ended March 31, 2010, there have not been any material changes from the risk factors previously disclosed in Part 1, Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, which was filed with the SEC on February 25, 2010.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults upon Senior Securities.

None.

Item 4. (Removed and Reserved).

Item 5. Other Information.

None.

Item 6. Exhibits.

10.1#	Stock Purchase Agreement by and among BioMarin Pharmaceutical Inc., and LEAD Therapeutics Inc. and the stockholders of LEAD Therapeutics, Inc. dated February 4, 2010. Portions of this document have been redacted pursuant to a request for confidential treatment filed pursuant to the Freedom of Information Act.
31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Certification accompanies this report and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of §18 of the Securities Exchange Act of 1934, as amended.

# Confidential treatment registered for a portion of this document. Omitted parts have been filed separately with the SEC.

37

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOMARIN PHARMACEUTICAL INC.
Dated: April 30, 2010	By	/s/    JEFFREY H. COOPER
		Jeffrey H. Cooper, Senior Vice President, Chief Financial Officer
		(On behalf of the registrant and as principal financial officer)

38

Exhibit Index

10.1#	Stock Purchase Agreement by and among BioMarin Pharmaceutical Inc., and LEAD Therapeutics Inc. and the stockholders of LEAD Therapeutics, Inc. dated February 4, 2010. Portions of this document have been redacted pursuant to a request for confidential treatment filed pursuant to the Freedom of Information Act.
31.1	Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. This Certification accompanies this report and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed for purposes of §18 of the Securities Exchange Act of 1934, as amended.

# Confidential treatment registered for a portion of this document. Omitted parts have been filed separately with the SEC.

39

EX-10.1

Exhibit 10.1

EXECUTION COPY

CONFIDENTIAL TREATMENT REQUESTED

Redacted portions are indicated by [****].

Redacted portions filed separately with

Confidential Treatment Application.

STOCK PURCHASE AGREEMENT

by and among

BIOMARIN PHARMACEUTICAL INC.,

LEAD THERAPEUTICS, INC.,

Each of the Parties Identified on Schedule A Attached Hereto

and

ARTHUR PAPPAS,

as the

EQUITYHOLDER REPRESENTATIVE

Dated as of February 4, 2010

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

TABLE OF CONTENTS

		Page
ARTICLE I. DEFINITIONS		2
1.1.	Defined Terms	2
1.2.	Other Terms	19
1.3.	Interpretation	19
ARTICLE II. PURCHASE AND SALE		20
2.1.	Purchase and Sale of Shares	20
2.2.	Closing	22
2.3.	Treatment of Company Options, Company Warrants and Company Notes	22
2.4.	Working Capital Adjustment	23
2.5.	Indemnification Escrow Amount	26
2.6.	Working Capital Escrow Amount	27
2.7.	Distribution of Bonus Amount	27
2.8.	Rights to Future Payments	28
2.9.	Escheat	28
2.10.	Withholding Rights	29
2.11.	Equityholder Representative	29
2.12.	Additional Actions	33
2.13.	Tax Forms	33
ARTICLE III. REPRESENTATIONS AND WARRANTIES OF THE COMPANY		34
3.1.	Organization of the Company	34
3.2.	Subsidiaries	34
3.3.	Authorization	34
3.4.	Capitalization	35
3.5.	Title to Properties and Assets	36
3.6.	Absence of Certain Activities or Changes	37
3.7.	Material Contracts	37
3.8.	Compliance with Other Instruments	38
3.9.	Financial Statements	38
3.10.	Liabilities	39
3.11.	Taxes	39
3.12.	Environmental Matters	41
3.13.	Employee Benefits	41
3.14.	Compliance with Law	44
3.15.	Permits	44
3.16.	Consents and Approvals	44
3.17.	Litigation	45
3.18.	Labor Matters	45
3.19.	Intellectual Property	46
3.20.	Transactions with Certain Persons	48

i

TABLE OF CONTENTS

(continued)

		Page
3.21.	Insurance	48
3.22.	Certain Business Practices	49
3.23.	No Brokers	49
3.24.	Books and Records	49
3.25.	Bank Accounts	49
3.26.	FDA and Related Matters	49
3.27.	State Takeover Statutes	51
3.28.	Disclosure	51
ARTICLE IV. REPRESENTATIONS AND WARRANTIES EACH SELLER		51
4.1.	Organization of Certain Sellers	51
4.2.	Authorization	51
4.3.	No Conflict; Required Filings and Consents	52
4.4.	No Brokers	52
4.5.	The Shares	52
ARTICLE V. REPRESENTATIONS AND WARRANTIES OF BUYER		53
5.1.	Organization	53
5.2.	Authorization	53
5.3.	Compliance with Other Instruments	53
5.4.	Consents and Approvals	54
5.5.	Litigation	54
5.6.	No Brokers	54
5.7.	Available Funds	54
ARTICLE VI. ADDITIONAL AGREEMENTS		54
6.1.	Conduct of Business by the Company	54
6.2.	Confidentiality; Access to Information; No Modification of Representations, Warranties or Covenants	57
6.3.	Public Disclosure	58
6.4.	Regulatory Filings; Reasonable Efforts	59
6.5.	Notification of Certain Matters	60
6.6.	No Solicitation	61
6.7.	Takeover Statutes	62
6.8.	Closing Date Allocation Schedule	62
ARTICLE VII. POST-CLOSING COVENANTS OF ALL PARTIES		62
7.1.	Indemnification of Directors and Officers	62

ii

TABLE OF CONTENTS

(continued)

		Page
7.2.	Tax Matters	62
7.3.	Employee Benefits	64
7.4.	Development and Commercialization of the Development Products	66
ARTICLE VIII. CONDITIONS TO OBLIGATIONS		66
8.1.	Conditions to the Obligations of Each Party	66
8.2.	Conditions to the Company’s Obligations	66
8.3.	Conditions to the Obligations of Buyer	67
ARTICLE IX. INDEMNIFICATION		68
9.1.	Survival of Representations	68
9.2.	Indemnification	69
9.3.	Notice of Claims	69
9.4.	Third Person Claims	70
9.5.	Limitation on Indemnity; Payments Out of Milestone Payment Amounts	71
9.6.	Remedies	72
ARTICLE X. TERMINATION, AMENDMENT AND WAIVER		72
10.1.	Termination	72
10.2.	Notice of Termination; Effect of Termination	73
10.3.	Expenses	73
ARTICLE XI. MISCELLANEOUS		73
11.1.	Binding Effect; Assignment	73
11.2.	Notices	74
11.3.	Choice of Law	75
11.4.	Entire Agreement; Amendments and Waivers	75
11.5.	Counterparts	76
11.6.	Severability	76
11.7.	Schedules	76
11.8.	No Third Party Beneficiaries	76
11.9.	Specific Performance	76
11.10.	No Strict Construction	76
11.11.	Submission to Jurisdiction; Waivers; Consent to Service of Process	76
11.12.	WAIVER OF JURY TRIAL	77
11.13.	Release	77

iii

LIST OF EXHIBITS

Exhibit A	Form of Escrow Agreement [**portions redacted**]
Exhibit B	Form of Release for Participating Service Providers
Exhibit C	Option Holder Consent Agreement
Schedule A	Sellers
Schedule B	Initial Allocation Schedule [**portions redacted**]
Schedule C	Continuing Employees
Schedule 1.1(a)	Assumed Current Liabilities [**portions redacted**]
Schedule 1.1(b)	Sample Future Payment Allocation Schedule [**portions redacted**]

STOCK PURCHASE AGREEMENT

This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of February 4, 2010, is entered into by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“Buyer”), LEAD Therapeutics, Inc., a Delaware corporation (the “Company”), the parties listed on Schedule A hereto (each a “Seller” and collectively the “Sellers”) and Arthur Pappas, acting in his capacity as Equityholder Representative in connection with the transactions contemplated by this Agreement (the “Equityholder Representative”). (Hereafter, Buyer, the Company, each Seller and the Equityholder Representative shall sometimes be referred to as the “Parties”).

RECITALS

WHEREAS, each Seller owns the number and type of shares of Common Stock (as such term is defined herein) or Series A Preferred Stock (as such term is defined herein, and together with the Common Stock, the “Shares”) of the Company set forth opposite such Seller’s name on the Initial Allocation Schedule (as such term is defined herein);

WHEREAS, each Seller holds the Company Options, Company Notes and Company Warrants (as such terms are defined herein) set forth opposite such Seller’s name on the Initial Allocation Schedule;

WHEREAS, in addition to the Sellers, the Initial Allocation Schedule sets forth each other holder of Company Options, Company Notes and Company Warrants and the Company Options, Company Note and Company Warrants held by them (each such holder together with each Seller, an “Equityholder”);

WHEREAS, the Common Stock, Series A Preferred Stock, Company Options, Company Notes and Company Warrants set forth on the Initial Allocation Schedule represent all of the issued and outstanding Equity Participations (as defined herein) of the Company;

WHEREAS, the Sellers wish to sell to the Buyer, and the Buyer wishes to purchase from the Sellers, the Shares, upon the terms and subject to the conditions set forth herein; and

WHEREAS, certain capitalized terms used in this Agreement are defined in Article I of this Agreement.

1

AGREEMENT

NOW THEREFORE, in consideration of the respective covenants and promises contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereto agree as follows:

ARTICLE I.

DEFINITIONS

1.1. Defined Terms. As used herein, the terms below shall have the following meanings. Any of such terms, unless the context otherwise requires, may be used in the singular or plural, depending upon the reference.

“Acquisition Proposal” means, other than the transactions contemplated by this Agreement, any offer, proposal or inquiry relating to, or any Person’s indication of interest in, (i) any merger consolidation or other form of business combination with or involving the Company, (ii) the sale, license, disposition or acquisition of all or any material portion of the business or assets of the Company, including the grant of any license to any Intellectual Property of the Company, other than non-exclusive licenses granted to contract research organizations or other independent contractors in the Ordinary Course of Business, (iii) the issuance, grant, disposition or acquisition of (A) any Company Capital Stock or other equity security of the Company (other than the issuance of Common Stock to employees of the Company upon the exercise of Company Options or upon conversion of the Company’s outstanding Series A Preferred Stock or the Series A Preferred Stock issuable upon conversion of the Company Notes or exercise of the Company Warrants and the issuance of Series A Preferred Stock upon the conversion of Company Notes or exercise of Company Warrants), (B) any option, call, warrant or right to acquire any Equity Participations of the Company (other than the grant of Company Options to Company employees by the Company pursuant to its existing option plans in the Ordinary Course of Business) or (C) any security, instrument or obligations that is or may become convertible into or exchangeable for any Company Capital Stock or other equity security of the Company, in each case of (A), (B) and (C) constituting fifteen percent (15%) or more of the equity interest (by vote or value) of the Company, or (iv) any combination of the foregoing.

“Adjusted Current Liabilities” means (A) Current Liabilities less (B) Assumed Current Liabilities.

“Affiliate” means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by or is under common control with such Person; as used in this definition, “control” shall mean (a) the ownership of more than twenty-five percent (25%) of the voting securities or other voting interest of any Person (including attribution from related parties), or (b) the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through ownership of voting securities, by contract or otherwise.

“Agreement” has the meaning set forth in the Preamble.

“Applicable Law(s)” means, with respect to any Person, any federal, state, local or other domestic or foreign statute, law, ordinance, rule, regulation, order, writ, injunction, judgment, award, decree or other requirement of any Governmental Authority applicable to such Person or any of such Person’s property and assets or such Person’s officers, directors, employees, consultants or agents in their capacity as such Person’s officers, directors, employees, consultants or agents, respectively.

2

“Assumed Current Liabilities” shall mean (a) all liabilities evidenced by an invoice from Shanghai Chempartner Co., Ltd., dated January 21, 2010 attached as Exhibit 1 to Schedule 1.1(a), and incurred in connection with a rat pharmacokinetic study for LT-00673ts/02 and LF00673 (Quotation #: CPB-2009-Q4-046)(LEAD study#LT_673_PKA_005) and (b) the liabilities incurred on or after February 1, 2010 listed on Schedule 1.1(a) (which Schedule, subject to Buyer’s consent, not to be unreasonably withheld, may be updated by the Company should the Closing Date occur after February 10, 2010), and in each case of (a) and (b), whether or not such current liabilities have been paid.

“Benefit Plan(s)” has the meaning set forth in Section 3.13(a).

“Bonus Amount” means $800,000.

“Business Day” means a day other than a Saturday, Sunday or other day on which commercial banks in San Francisco, California or New York, New York are authorized or required by law to close.

“Buyer” has the meaning set forth in the Preamble.

“Buyer Indemnified Parties” has the meaning set forth in Section 9.2(a)(i).

“Buyer Liquidation Event” means and shall be deemed to be occasioned by, or to include, (i) the merger or consolidation of Buyer by means of any transaction or series of related transactions with or into another entity, provided that the applicable transaction shall not be deemed a Buyer Liquidation Event unless Buyer’s stockholders constituted immediately prior to such transaction do not hold more than 50% of the voting power of the surviving or acquiring entity immediately following such transaction; (ii) any transaction or series of related transactions to which Buyer is a party in which in excess of fifty percent (50%) of Buyer’s voting power is transferred; provided that a Buyer Liquidation Event shall not include any transaction or series of related transactions principally for bona fide equity financing purposes in which cash is received by Buyer or Indebtedness of Buyer is cancelled or converted or a combination thereof occurs; or (iii) a sale, pledge exclusive license or other disposition of all or substantially all of the assets of Buyer to a Person that Buyer does not hold at least fifty percent (50%) of the voting power of or to a Person in which the stockholders of Buyer immediately prior to such transaction do not hold at least 50% of the voting power immediately following such transaction

“Buyer Promissory Note” means that certain convertible promissory note issued by the Company in favor of Buyer, dated December 11, 2009.

“Cap Amount” means the sum of (a) the Indemnification Escrow Amount and (b) 40% of any and all Milestone Payment Amounts payable to the Equityholders pursuant to this Agreement.

“CERCLA” has the meaning set forth in Section 3.12.

3

“Change of Control Payments” means the aggregate amount of all change of control, bonus, termination, retention, severance, forgiveness of Indebtedness, increase in benefits or other similar payments or Liabilities (A) that are accrued, incurred or payable by the Company prior to, at or after the Closing pursuant to any Benefit Plan or Contract of the Company or any plan, program, agreement and other arrangement set forth on Schedule 3.13(f) or 3.13(g), in each case as in effect as of the Closing, or (B) that are otherwise obligations of the Company that are accrued or incurred prior to or at the Closing, whether payable prior to, at or after Closing, in the case of each of clauses (A) and (B) above, to any Person as a result of or connection with any of the transactions contemplated by this Agreement (alone or in combination with any other event). Notwithstanding the foregoing, Change of Control Payments shall not include the Bonus Amount.

“Claim” has the meaning set forth in Section 11.13(a).

“Claim Notice” has the meaning set forth in Section 9.3(a).

“Closing” has the meaning set forth in Section 2.2.

“Closing Date” has the meaning set forth in Section 2.2.

“Closing Date Allocation Schedule” means a schedule, prepared by the Company and the Equityholder Representative and dated as of the Closing Date, setting forth, for each Equityholder: (a) such Equityholder’s name and address; (b) the number of shares of Common Stock held by such Equityholder; (c) the number of shares of Common Stock subject to Company Options held by such Equityholder immediately prior to the Closing Date; (d) the number of shares of Series A Preferred Stock subject to Company Warrants held by such Equityholder immediately prior to the Closing Date; (e) the number of shares of Series A Preferred Stock held by such Equityholder; (f) the portion of the Closing Payment Amount to be paid to such Equityholder by Buyer at the Closing (which amount shall be calculated in accordance with the provisions of the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing as if the transactions contemplated hereby constitute a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing), Applicable Law, and the terms and conditions of this Agreement); (g) such Equityholder’s pro rata share of the amounts to be held in the Indemnification Escrow Account; (h) such Equityholder’s election to receive such payment by check or by wire transfer; and (i) for Equityholders electing to receive payment by check, delivery instructions for such check, or for Equityholders electing to receive payment by wire transfer, wire transfer instructions for such wire transfer. The Closing Date Allocation Schedule shall include any interim updates made in accordance with Section 6.9.

“Closing Date Balance Sheet” means an unaudited balance sheet of the Company as of 5:00 p.m. Pacific Standard Time on the Closing Date (without giving effect to the transactions contemplated by this Agreement), prepared in accordance with GAAP, consistently applied.

“Closing Date Net Working Capital” means (A) Current Assets less (B) Adjusted Current Liabilities.

4

“Closing Payment Amount” means (a) $14,200,000, plus (b) the Estimated Net Working Capital Excess Amount set forth on the Estimated Net Working Capital Adjustment Statement, if any, minus (b) the Estimated Net Working Capital Deficiency Amount, set forth on the Estimated Net Working Capital Adjustment Statement, if any, minus (c) the Indemnification Escrow Amount, minus (d) the Working Capital Escrow Amount and, minus (e) the Equityholder Representative’s Fund Amount.

“COBRA” has the meaning set forth in Section 7.3(a).

“Code” means the Internal Revenue Code of 1986, as amended, and the rules and regulations promulgated thereunder.

“Common Stock” means the common stock, par value $0.001, of the Company.

“Company” has the meaning set forth in the Preamble.

“Company 401(k) Plan” has the meaning set forth in Section 7.3(d).

“Company Capital Stock” means the Common Stock and the Series A Preferred Stock.

“Company Disclosure Schedule” has the meaning set forth in Article III.

“Company Indemnified Parties” has the meaning set forth in Section 9.2(a)(ii).

“Company Notes” shall mean the Company’s Convertible Promissory Notes issued pursuant to that certain Convertible Note and Warrant Purchase Agreement, dated as of April 28, 2009.

“Company Option” means each outstanding stock option to purchase Common Stock granted under the Company Option Plan.

“Company Option Plan” means the Company’s Amended and Restated 2006 Equity Incentive Plan.

“Company Partner” has the meaning set forth in Section 3.26(b).

“Company Warrants” shall mean the Company’s Preferred Stock Purchase Warrants issued pursuant to that certain Convertible Note and Warrant Purchase Agreement, dated as of April 28, 2009.

“Conclusive Net Working Capital Adjustment Statement” has the meaning set forth in Section 2.4(e).

“Conclusive Net Working Capital Statement” has the meaning set forth in Section 2.4(e).

“Confidentiality Agreement” has the meaning set forth in Section 6.2(a).

5

“Continuing Employees” has the meaning set forth in Section 7.3(a).

“Contract” means, with respect to any Person, any agreement, understanding, contract, note, bond, deed, mortgage, lease, sublease, license, sublicense, instrument, commitment, promise, undertaking or other legally binding arrangement, whether written or oral: (a) to which such Person is a party; (b) by which such Person or any of its assets is or may become bound or under which such Person has, or may become subject to, any obligation; or (c) under which such Person has or may acquire any right or interest.

“Court Order” means any judgment, decision, consent decree, injunction, ruling or order of any federal, state, local or other domestic or foreign court or Governmental Authority that is binding on any Person or its property.

“Covered Parties” has the meaning set forth in Section 9.2(a)(ii).

“Current Assets” the Company’s total current assets as of 5:00 p.m. Pacific Standard Time on the Closing Date; provided, however, when computing Current Assets, current assets shall exclude any long term restricted cash or cash received after the date of the Most Recent Balance Sheet in respect to the disposal of equipment or other tangible assets (if any),

“Current Liabilities” means the Company’s total current Liabilities as of 5:00 p.m. Pacific Standard Time on the Closing Date (other than deferred Tax Liabilities that reflect timing differences between book and tax accounting), in each case determined in accordance with GAAP, consistently applied and applying the same accounting principles and methodologies used to prepare the Most Recent Balance Sheet; provided, however, when computing Current Liabilities, the following adjustments shall be made: (a) subject to clause (d), current Liabilities shall include any and all Indebtedness of the Company outstanding at the Closing to the extent not already included as a current Liability; (b) current Liabilities shall include any Transaction Expenses not paid by the Company prior to the Closing to the extent not already included as a current Liability; (c) current Liabilities shall include, without duplication, an allowance for doubtful accounts receivable determined in accordance with GAAP consistently applied; (d) current Liabilities shall not include any amounts due or owed under the Buyer Promissory Note or the Company Notes, which Company Notes shall be settled or converted into shares of Series A Preferred Stock immediately prior to the Closing, (e) current Liabilities shall not include the Bonus Amount, (f) current Liabilities shall not include Change of Control Payments, (g) current Liabilities shall not include any unpaid employer Taxes attributable to Change of Control Payments and payments in respect of Company Options in connection with the transactions contemplated by this Agreement, and (h) current Liabilities shall not include any fees, costs, payments and expenses for severance or other termination pay or benefits paid, or payable, upon termination of employees of the Company pursuant to Section 7.3(a) under any Contract, Benefit Plan or other arrangement of the Company.

“D&O Indemnified Parties” has the meaning set forth in Section 7.1(a).

“D&O Tail” has the meaning set forth in Section 7.1(c).

“Damages” has the meaning set forth in Section 9.2(a)(i).

6

“Deductible Amount” has the meaning set forth in Section 9.5(a).

“Default” means (a) any actual breach, violation or default, (b) the existence of circumstances or the occurrence of an event that with the passage of time or the giving of notice or both would constitute a breach, violation or default or (c) the existence of circumstances or the occurrence of an event that, with or without the passage of time or the giving of notice or both, would give rise to a right of termination, renegotiation or acceleration.

“Development Compound” means any PARP Development Compound or any Non-PARP Development Compound.

“Development Product” means any product containing a Development Compound as an active pharmaceutical ingredient.

“DGCL” means the Delaware General Corporation Law.

“Dispute Notice” has the meaning set forth in Section 2.11(h).

“Disputed Items” has the meaning set forth in Section 2.4(c).

“Dose Escalation Study Milestone” means [****]

“Dose Escalation Study Subsequent Payment Amount” means [****]

“Dose Escalation Study Subsequent Payment Date” means [****]

“Drug Regulatory Agency” means the FDA, or any other Governmental Authority that has jurisdiction over the safety, efficacy, reliability, manufacturing, labeling, marketing, or advertising of drug products.

“EMEA” means the European Medicines Agency and any successor agency thereto.

“Employee Loans” has the meaning set forth in Section 3.7(a).

“Encumbrance” means any claim, lien, pledge, option, charge, easement, security interest, deed of trust, mortgage, conditional sales agreement, encumbrance, preemptive right, right of first refusal, restriction or other right of third parties, whether voluntarily incurred or arising by operation of law, and includes any agreement to give any of the foregoing in the future.

“End Date” has the meaning set forth in Section 10.1(b).

“Environmental Claim” means, in respect of any Person, (i) any and all administrative, regulatory or judicial actions, suits, Court Orders, decrees, demands, directives, claims, Encumbrances, proceedings or written notices of noncompliance or violation by any Person, alleging potential presence or release of, or exposure to, any Hazardous Materials at any location, whether or not owned, operated, leased or managed by such Person, or (ii) any and all indemnification, cost recovery, compensation or injunctive relief resulting from the presence or release of, or exposure to, any Hazardous Materials.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

7

“Environmental Law” has the meaning set forth in Section 3.12.

“Equity Participations” means any (a) share, quota, security, participation right and any other present or future right entitling the holder, absolutely or contingently (through the exercise of any subscription, conversion, exchange, option or similar right), to participate in the revenues, dividends or equity appreciation of another Person, including capital stock, membership interests, units, performance units, options, warrants, company appreciation rights, interests in “phantom” stock plans, restricted or contingent stock or profits interests, voting securities, stock appreciation rights or equivalents, stock loan purchase plans, convertible debentures or stock bonus plans and (b) commitments to issue any of the foregoing.

“Equityholder” has the meaning set forth in the recitals.

“Equityholder Representative” has the meaning set forth in the Preamble.

“Equityholder Representative’s Costs” has the meaning set forth in Section 2.11(e).

“Equityholder Representative’s Fund” has the meaning set forth in Section 2.11(f).

“Equityholder Representative’s Fund Amount” means two hundred fifty thousand dollars ($250,000).

“ERISA” has the meaning set forth in Section 3.13(a).

“ERISA Affiliate” means, with respect to any Person, any other Person that, together with such first Person, would be treated as a single employer under Section 414 of the Code.

“Escrow Agent” has the meaning set forth in Section 2.5(a).

“Escrow Agreement” has the meaning set forth in Section 2.5(a).

“Escrow Earnings” has the meaning set forth in Section 2.5(c).

“Estimated Net Working Capital” has the meaning set forth in Section 2.4(a).

“Estimated Net Working Capital Adjustment Statement” has the meaning set forth in Section 2.4(a).

“Estimated Net Working Capital Deficiency Amount” has the meaning set forth in Section 2.4(a).

8

“Estimated Net Working Capital Excess Amount” has the meaning set forth in Section 2.4(a).

“Estimated Net Working Capital Statement” has the meaning set forth in Section 2.4(a).

“FDA” means the United States Food and Drug Administration or any successor agency.

“Financial Statements” has the meaning set forth in Section 3.9(a).

“First E.U. Commercial Sale” means the first commercial sale of a PARP Development Product in the European Union, following applicable and required governmental marketing approval or governmental clearance for marketing thereof to an unaffiliated third party in an arms’ length transaction (but excluding sales pursuant to any compassionate use program, patient assistance program or similar arrangements).

“First PARP Milestone” means [****]

“First PARP Subsequent Payment Amount” means $[****].

“First PARP Subsequent Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of the First PARP Subsequent Payment Amount in accordance with Section 2.1(f).

“First U.S. Commercial Sale” means the first commercial sale of a PARP Development Product in the United States, following applicable and required governmental marketing approval or governmental clearance for marketing thereof to an unaffiliated third party in an arms’ length transaction (but excluding sales pursuant to any compassionate use program, patient assistance program or similar arrangements).

“Fourth PARP Milestone” means [****]

“Fourth PARP Subsequent Payment Amount” means $[****]

“Fourth PARP Subsequent Payment Date” means the fifteenth (15th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of the Fourth PARP Subsequent Payment Amount in accordance with Section 2.1(i).

“Future Payment Allocation Schedule” means a schedule, prepared by the Equityholder Representative with respect to the applicable Future Payment Amount setting forth, for each Equityholder: (a) such Equityholder’s name and address; (b) the number of shares of each class of Company Capital Stock held by such Equityholder as of the Closing; (c) the number of shares of Common Stock subject to Company Options held by such Equityholder immediately prior to the Closing Date; (d) the number of shares of Series A Preferred Stock

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

9

subject to Company Warrants held by such Equityholder immediately prior to the Closing Date; (e) the portion of such Future Payment Amount to be paid to such Equityholder by Buyer (which amount shall be calculated in accordance with the provisions of the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing as if the transactions contemplated hereby constitute a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing), Applicable Law, and the terms and conditions of this Agreement); (f) such Equityholder’s election to receive such payment by check or by wire transfer, and (g) for Equityholders electing to receive payment by check, delivery instructions for such check, or for Equityholders electing to receive payment by wire transfer, wire transfer instructions for such wire transfer. Each such schedule shall be prepared taking into account any and all portions of the Purchase Price previously paid to each Equityholder, including any amounts that may be released to Equityholders from the Equityholder Representative’s Fund. By way of example and for illustrative purposes only, the calculation of certain Future Payment Allocation Schedules in connection with certain Future Payment Amounts, under the assumptions set forth in Schedule 1.1(b), is set forth on Schedule 1.1(b).

“Future Payment Amounts” means each of (a) the Milestone Payment Amounts, if any, (b) the Unallocated Bonus Amount, if any, (c) amounts required to be released to the Equityholders from the Indemnification Escrow Account, if any, (d) amounts required to be released to the Equityholders from the Working Capital Escrow Account, if any, and (e) the right of the Equityholders to receive the Working Capital Excess Amount, if any.

“GAAP” means generally accepted United States accounting principles consistently applied over all relevant periods.

“Governmental Authority” means any: (i) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of any nature; (ii) federal, state, local, municipal, foreign or other government; or (iii) governmental or quasi governmental authority of any nature (including any governmental division, department, agency, Regulatory Authority, commission, instrumentality, official, organization, unit, body or Person and any court or other tribunal).

“Grant Date” has the meaning set forth in Section 3.4(e).

“Hazardous Materials” has the meaning set forth in Section 3.12.

“HSR Act” means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

“IND” means an Investigational New Drug application filed with the FDA, or the equivalent documentation filed or submitted to the applicable Regulatory Authority in any jurisdiction outside the United States for the purposes of commencing human clinical trials of a pharmaceutical compound in accordance with Applicable Laws in the relevant jurisdiction (including a clinical trial authorization).

10

“Indebtedness” means (without duplication), as to any Person, (a) all obligations for the payment of principal, interest, penalties, fees or other Liabilities for borrowed money (including guarantees and notes payable), incurred or assumed, (b) all obligations of such Person for the deferred purchase price of property or services (other than current trade payables incurred in the Ordinary Course of Business), (c) any obligations to reimburse the issuer of any letter of credit, surety bond, debentures, promissory notes, performance bond or other guarantee of contractual performance, in each case to the extent drawn or otherwise not contingent, (d) all obligations of such Person as lessee under leases that have been or should be, in accordance with GAAP, recorded as capital leases, (e) all indebtedness of third parties secured by an Encumbrance on property owned or acquired by such Person, (f) any obligation that, in accordance with GAAP, would be required to be reflected as debt on the balance sheet of such Person, (g) all obligations of such Person to purchase, redeem, retire, defease or otherwise acquire for value any capital stock of such Person or any warrants, rights or options to acquire such capital stock, valued, in the case of redeemable preferred stock, at the greater of its voluntary or involuntary liquidation preference plus accrued and unpaid dividends, and (h) all Indebtedness of others referred to in clauses (a) through (h) above guaranteed directly or indirectly in any manner by such Person, or in effect guaranteed directly or indirectly by such Person through an agreement to pay or purchase such Indebtedness, to advance or supply funds for the payment or purchase of such Indebtedness or otherwise to assure a creditor against loss, in each case including all accrued interest and prepayment penalties, if any.

“Indemnification Escrow Account” has the meaning set forth in Section 2.5(a).

“Indemnification Escrow Amount” means $[****]

“Indemnification Escrow Release Date” means the date that is fifteen (15) months following the Closing.

“Indemnifying Party” has the meaning set forth in Section 9.3(a).

“Initial Allocation Schedule” means a schedule, prepared by the Company and attached hereto as Schedule B, setting forth, for each Equityholder as of the date of this Agreement: (a) such Equityholder’s name and address; (b) the number and type of Equity Participations of the Company held by such Equityholder, (c) the number of shares of each class of Company Capital Stock subject to Company Options or Company Warrants held by such Equityholder as of the date hereof (and the exercise price thereof); (d) the principal amount of Company Notes, if any, held by such Equityholder and the number of Shares of Company Capital Stock into which the Company Notes held by such Equityholder are convertible, (e) with respect to the Company Options, whether such Company Option is a nonqualified stock option or incentive stock option, (f) with respect to the Company Options, whether the optionee is an employee of the Company as of the date of this Agreement and any restrictions on exercise or sale of such Company Option or underlying shares (other than any restrictions contained in the agreements listed on Schedule 3.4(d)), (g) the estimated portion of the Closing Payment Amount to be paid to such Equityholder by Buyer at the Closing (which amount shall be calculated in accordance with the provisions of the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing as if the transactions contemplated hereby constitute a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation as

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

11

amended and in effect as of immediately prior to the Closing), Applicable Law, and the terms and conditions of this Agreement), and (h) such Equityholder’s estimated pro rata share of the amounts to be held in the Indemnification Escrow Account.

“Initiation” means the first dosing of the first human patient or subject in a clinical trial.

“Instrument” has the meaning set forth in Section 2.11(c).

“Intellectual Property” means patents and patent applications and other similar rights granted by a Governmental Authority with respect to an invention, trademarks, service marks, trade names, trade dress, domain names, copyrights, trade secrets, inventions, technology, discoveries, know-how, software, formulae, processes, confidential and proprietary information and similar proprietary rights and registrations and applications for registration for any of the foregoing granted or recognized by any Governmental Authority.

“IRS” has the meaning set forth in Section 3.13(d).

“Knowledge” of the Company means [****]

“Leased Real Property” has the meaning set forth in Section 3.5(c).

“Liability” means any direct or indirect liability, Indebtedness, obligation, commitment, expense, claim, deficiency, guaranty or endorsement of or by any Person of any type, known or unknown, and whether accrued, absolute, contingent, matured, unmatured or other, including “off-balance sheet” Liabilities.

“Material Adverse Effect” shall mean any event, change, circumstance, effect, development or state of facts (whether specific to the applicable party or generally applicable to multiple parties), violation, inaccuracy or other matter that has, or would, individually or in the aggregate with other events, reasonably be expected to have or give rise to, a material adverse effect on or material adverse change to (a) the condition (financial or otherwise), business, results of operations, assets, Liabilities, capitalization or financial performance of the party making the representations and warranties, or (b) the ability of such party to consummate the transactions contemplated by this Agreement or to perform any of its obligations under this Agreement; provided, however, that any adverse effects attributable to any of the following as they relate to the Company shall not be deemed to constitute, and the following shall not be taken into account in determining whether there has been or will be, a Material Adverse Effect on the Company: (i) conditions affecting the industries in which the Company participates or the U.S. economy as a whole or affecting the financial or securities markets in the United States or any foreign markets where the Company has operations (other than those that disproportionately affect the Company relative to similarly situated industry participants), (ii) the public announcement or pendency of this Agreement or any of the transactions contemplated herein, or (iii) changes in Applicable Law or GAAP (or any interpretation thereof) (other than those that disproportionately affect the Company relative to similarly situated industry participants).

“Material Contracts” has the meaning set forth in Section 3.7(a).

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

12

“Milestone” means any of the First PARP Milestone, Second PARP Milestone, Third PARP Milestone, Fourth PARP Milestone, Non-PARP Phase 2 Milestone(s), Non-PARP Phase 3 Milestone(s), Non-PARP Sublicensing Milestone(s) or the Dose Escalation Study Milestone.

“Milestone Diligent Efforts” has the meaning set forth in Section 7.4(a).

“Milestone Payment Amounts” means the First PARP Subsequent Payment Amount, if any, the Second PARP Subsequent Payment Amount, if any, the Third PARP Subsequent Payment Amount, if any, the Fourth PARP Subsequent Payment Amount, if any, each Non-PARP Phase 2 Payment Amount, if any, each Non-PARP Phase 3 Payment Amount, if any, each Non-PARP Sublicensing Payment Amount, if any and the Dose Escalation Study Subsequent Payment Amount, if any.

“Most Recent Balance Sheet” has the meaning set forth in Section 3.9.

“NDA” means a new drug application filed with the FDA for authorization to market a pharmaceutical product, or its equivalent in any country or territory.

“Net Tax Benefit” has the meaning set forth in Section 9.2(b).

“Net Working Capital Adjustment Statement” has the meaning set forth in Section 2.4(b).

“Net Working Capital Deficiency Amount” has the meaning set forth in Section 2.4(b).

“Net Working Capital Excess Amount” has the meaning set forth in Section 2.4(b).

“Net Working Capital Statement” has the meaning set forth in Section 2.4(b).

“Neutral Arbitrator” has the meaning set forth in Section 2.4(d).

“New Equityholder Representative Account” has the meaning set forth in Section 2.14(f).

“Non-PARP Development Compound” means [****]

“Non-PARP Development Product” means any product containing a non-PARP Development Compound.

“Non-PARP Phase 2 Milestone” means [****]

“Non-PARP Phase 2 Payment Amount” means [****]

“Non-PARP Phase 2 Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of any Non-PARP Phase 2 Milestone in accordance with Section 2.1(j).

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

13

“Non-PARP Phase 3 Milestone” means [****]

“Non-PARP Phase 3 Payment Amount” means [****]

“Non-PARP Phase 3 Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of any Non-PARP Phase 3 Payment Amount in accordance with Section 2.1(k).

“Non-PARP Sublicensing Milestone” means [****]

“Non-PARP Sublicensing Payment Amount” means [****]

“Non-PARP Sublicensing Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of any Non-PARP Sublicensing Payment Amount in accordance with Section 2.1(l).

“Ordinary Course of Business” or “Ordinary Course” or any similar phrase means the ordinary course of the Company’s business, consistent with the past practice of the Company.

“PARP” means poly (ADP-ribose) polymerase.

“PARP Development Compound” means a PARP inhibitor, in each case that is developed by the Company, any Affiliate of Buyer or the Company, any licensee of Buyer, the Company or its Affiliates or any third party that has assumed the obligations as set forth in and in accordance with Section 7.4(c) and is included in or covered by the Intellectual Property owned or controlled by the Company as of the Closing Date and any Related Compounds thereof.

“PARP Development Product” means any product containing a PARP Development Compound.

“Participating Service Providers” has the meaning set forth in Section 2.7(a).

“Participating Service Providers Certificate” has the meaning set forth in Section 2.7(a).

“Parties” has the meaning set forth in the Preamble.

“Payable Consideration” means the sum of (a) the Closing Payment Amount plus (b) the Net Working Capital Excess Amount, if any, plus (c) the Unallocated Bonus Amount, if any, plus (d) any Indemnification Escrow Amount plus interest or other income earned thereon that may be distributed to Equityholders pursuant to Section 2.5(b) and the Escrow Agreement, plus (e) any Remaining Working Capital Escrow Amount plus interest or

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

14

other income earned thereon that may be distributed to Equityholders pursuant to Section 2.6(b) and the Escrow Agreement, plus (f) the Equityholder Representative’s Fund Amount plus interest or other income earned thereon that may be distributed to Equityholders pursuant to Section 2.11(f), plus (g) any Milestone Payment Amount with respect to which a Milestone has occurred, plus (h) any Tax Refund Amount.

“Permits” means all licenses, permits, franchises, approvals, authorizations, easements, variances, consents or orders of, or filings with, any Governmental Authority, whether foreign, federal, state or local, or any other Person, necessary for the conduct of, or relating to, the operation of the Company’s business.

“Permitted Encumbrances” means (a) liens, taxes, assessments and other governmental charges, in each case, not yet due and payable or which are being contested in good faith by appropriate proceedings and are reserved for in full on the Most Recent Balance Sheet or reserved for in full since the date of the Most Recent Balance Sheet in accordance with GAAP, (b) statutory, mechanics’, laborers’ and materialmen liens arising in the Ordinary Course of Business for sums not yet due, (c) statutory and contractual landlord liens under leases pursuant to which the Company is a lessee and not in Default, (d) with regard to real property, any and all matters of record as of the date of this Agreement in the jurisdiction where the real property is located including restrictions, reservations, covenants, conditions, oil and gas leases, and mineral severances, in each case that do not impair the use of such real property in the operation of the Company’s business, (e) with regard to real property, any easements, rights-of-way, building or use restrictions, prescriptive rights, encroachments, protrusions, rights and party walls in each case that do materially impair the use of such real property in the operation of the Company’s business; (f) liens securing rental payments under capital lease arrangements to the extent they are imposed only upon the leased equipment; (g) pledges or deposits made in the Ordinary Course of Business which do not in the aggregate materially detract from the value of the related assets or properties or materially impair the use thereof in the operation of the Company’s business; and (h) the Buyer Promissory Note.

“Person” means any person or entity, whether an individual, trustee, corporation, partnership, limited partnership, limited liability company, trust, unincorporated organization, business association, firm, joint venture or Governmental Authority.

“Phase 1 Clinical Study” means a clinical study for clinical trials in which a product is administered to a sufficient number of human subjects to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of such product and establish an appropriate dose range, as more precisely defined by 21 C.F.R. §312.21(a) (or its successor regulation) and corresponding rules and regulations in other countries. A first-in-human study or any study for which a primary endpoint is directed to safety shall be considered a Phase 1 Clinical Study.

“Phase 2 Clinical Study” means a clinical study for clinical trials in which a product is administered to a sufficient number of patients to obtain initial information on efficacy in patients being studied, as more precisely defined by 21 C.F.R. §312.21(b) (or its successor regulation) and corresponding rules and regulations in other countries. A first-in-human study or any study for which a primary endpoint is directed to safety shall not be considered a Phase 2 Clinical Study.

15

“Phase 3 Clinical Study” means that portion of the clinical development program which provides for the continued trials of a product on sufficient numbers of patients to establish the safety and efficacy of a product for the desired claims and indications, as more precisely defined by 21 C.F.R. § 312.21(c) (or its successor regulation) and corresponding rules and regulations in other countries and that is designed to support an NDA without further clinical studies.

“Post-Closing Tax Period” means any Tax period beginning after the Closing Date and that portion of any Straddle Period beginning after the Closing Date.

“Pre-Closing Tax Period” means any Tax period ending on or before the Closing Date and that portion of any Straddle Period ending on and including the Closing Date.

“Pre-Closing Taxes” means (i) Taxes of the Company for the Pre-Closing Tax Period; and (ii) Taxes of the Company resulting from the several Liability of the Company pursuant to Treasury Regulations Section 1.1502-6(a) by reason of the Company’s having been included in a consolidated or affiliated group prior to the Closing; provided, however, in each of (i) and (ii) that any Taxes reflected as a liability in Closing Date Net Working Capital shall not constitute Pre-Closing Taxes. For purposes of this Agreement, where it is necessary to apportion Taxes of the Company for a Straddle Period between the Pre-Closing Tax Period and the Post-Closing Tax Period, such Taxes shall be apportioned, in the case of real property, personal property or similar ad valorem Taxes, prorated on the basis of the number of days elapsed in the portion of such period ending on the Closing Date and the portion of such period beginning on the day following the Closing Date, respectively, or, in the case of all other such Taxes, on the basis of an interim closing of the books on the Closing Date.

“Proceeding” has the meaning set forth in Section 3.17.

“Purchase Price” has the meaning set forth in Section 2.1.

“Regulatory Approval” means, with respect to each Development Product, any approval (including a pricing approval if required), registration, license or authorization from any Regulatory Authority in a particular country or regulatory jurisdiction required to market and sell such Development Product and/or its components in such country or regulatory jurisdiction.

“Regulatory Authority” means any applicable government regulatory agency or authority responsible for granting Regulatory Approvals for Development Products, including the FDA and any corresponding national or regional regulatory authorities.

“Related Compound” means any polymorph, solvate, ester, salt, crystalline form or hydrate of a specified compound.

16

“Related Party” means: (a) each 10% or greater Stockholder; (b) each individual who is, or who was at the time of the entry into the transaction or the creation of the interest in question an officer or director of the Company; (c) each member of the immediate family of each of the Persons referred to in clauses “(a)” or “(b)” above; and (d) each Person that is, or that was at the time of the entry into the transaction or the creation of the interest in question an Affiliate of a 10% or greater Stockholder.

“Releasees” has the meaning set forth in Section 11.13(a).

“Releasors” has the meaning set forth in Section 11.13(a).

“Remaining Working Capital Escrow Account” has the meaning set forth in Section 2.6(b).

“Representative” means, with respect to any Person, any officer, director, principal, attorney, agent, employee or other representative of such Person.

“Resolution Period” has the meaning set forth in Section 2.4(c).

“Second PARP Milestone” means [****]

“Second PARP Subsequent Payment Amount” means $[****].

“Second PARP Subsequent Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of the Second PARP Subsequent Payment Amount in accordance with Section 2.1(g).

“Securities Act” means the Securities Act of 1933, as amended.

“Seller” as the meaning set forth in the Preamble.

“Series A Preferred Stock” means the Company’s Series A Preferred Stock, par value $0.001 per share.

“Series A Preferred Stock Agreements” means the Amended and Restated Series A Preferred Stock Purchase Agreement, dated as of October 31, 2007, by and among the Company and the other parties named therein, the Amended and Restated Investors’ Rights Agreement, dated October 31, 2007, by and among the Company and the other parties named therein, Amended and Restated Voting Agreement, dated October 31, 2007, by and among the Company and the other parties named therein and Amended and Restated Right of First Refusal and Co-Sale Agreement, dated October 31, 2007, by and among the Company and the other parties named therein.

“Shares” has the meaning set forth in the Recitals.

“Specified Buyer Benefit Plans” has the meaning set forth in Section 7.3(b).

“Stockholder(s)” means holders of Company Capital Stock.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

17

“Straddle Period” means any Tax period beginning before or on and ending after the Closing Date.

“Subsidiary” when used with respect to any Person, shall mean any entity, corporation or other organization, whether incorporated or unincorporated, at least a majority of the securities or other interests of which having by their terms ordinary voting power to elect a majority of the Board of Directors or others performing similar functions with respect to such corporation or other organization is directly or indirectly owned or controlled by such Party or by any one or more of its Subsidiaries, or by such Person and one or more of its Subsidiaries.

“Supermajority” has the meaning set forth in Section 2.11(b).

“Target Net Working Capital” means [****]

“Tax” (including with correlative meaning, the terms “Taxes” and “Taxable”) means all taxes and duties and similar governmental charges, levies, imposts or withholdings (including net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties, value added or other taxes) whenever and by whatever Governmental Authority imposed, and whether of the United States or a foreign, state or local jurisdiction, together with in any such case any interest, fines, penalties, surcharges and charges incidental or relating to the imposing of any of such Taxes and any additions to tax or additional amounts with respect thereto.

“Tax Claim” has the meaning set forth in Section 7.2(e).

“Tax Refund Amount” has the meaning set forth in Section 7.2(d).

“Tax Return” means any return, declaration, report, statement, information statement and other document required to be filed with a Governmental Authority with respect to Taxes.

“Third PARP Milestone” means [****]

“Third PARP Subsequent Payment Amount” means [****]

“Third PARP Subsequent Payment Date” means the fifteenth (15^th) Business Day following the Buyer’s receipt of the Future Payment Allocation Schedule relating to the distribution to Equityholders of the Third PARP Subsequent Payment Amount in accordance with Section 2.1(h).

“Transaction Expenses” means, without duplication (a) fees, costs, payments and expenses of the Company incident to the participation in or response to the investigation, review and inquiry conducted by Buyer and its Representatives with respect to the business of the Company (and the furnishing of information to Buyer and its Representatives in connection with such investigation and review) or any other similar investigation, review or inquiry by any other Person or its Representatives in connection with an Acquisition Proposal since September

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

18

30, 2009; the negotiation, preparation, drafting, review, execution, delivery or performance of this Agreement or any Contract or other instrument delivered or to be delivered in connection with the transactions contemplated hereby or any similar Contract or other document in connection with any Acquisition Proposal at any time since September 30, 2009; the preparation and submission of any filing or notice required to be made or given in connection with any of the transactions contemplated hereby, or the obtaining of any consent, waiver or approval required to be obtained in connection with any of the transactions contemplated hereby, including legal and accounting fees, investment banking fees, and related disbursements in connection with any of the foregoing and (b) the Company’s share of transfer taxes, if any, contemplated by Section 7.2(b). Notwithstanding the foregoing, Transaction Expense shall not include (a) the Bonus Amount, (b) any Change of Control Payments, (c) any fees, costs, payments and expenses for severance or other termination pay or benefits paid, or payable, upon termination of employees of the Company pursuant to Section 7.3(a) under any Contract, Benefit Plan or other arrangement of the Company and (d) any unpaid employer Taxes attributable to Change of Control Payments and payments in respect of Company Options in connection with the transactions contemplated by this Agreement.

“Unallocated Bonus Amount” has the meaning set forth in Section 2.7(a).

“WARN Act” has the meaning set forth in Section 3.18(h).

“Worker” or “Workers” means any individual performing services for the Company in the capacity of an employee and/or independent contractor.

“Working Capital Dispute Notice” has the meaning set forth in Section 2.4(c).

“Working Capital Escrow Account” has the meaning set forth in Section 2.6(a).

“Working Capital Escrow Amount” means [****]

1.2. Other Terms. Other terms may be defined elsewhere in the text of this Agreement and, unless otherwise indicated, shall have such meaning indicated throughout this Agreement.

1.3. Interpretation. (a) In this Agreement, unless the context otherwise requires, references:

(i) to the Recitals, Articles, Sections, Exhibits or Schedules are to a Recital, Article or Section of, or Exhibit or Schedule to, this Agreement;

(ii) to any agreement (including this Agreement), contract, statute or regulation are to the agreement, contract, statute or regulation as amended, modified, supplemented or replaced from time to time, and to any section of any statute or regulation are to any successor to the section;

(iii) to any Person include any successor to that Person or permitted assigns of that Person; and

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

19

(iv) to this Agreement are to this Agreement and the exhibits and schedules to it, taken as a whole.

(b) The table of contents and headings contained herein are for reference purposes only and do not limit or otherwise affect any of the provisions of this Agreement.

(c) Whenever the words “include,” “includes” or “including” are used in this Agreement, they shall be deemed to be followed by the words “without limitation.”

(d) Whenever the words “herein” or “hereunder” are used in this Agreement, they shall be deemed to refer to this Agreement as a whole and not to any specific Section, unless otherwise indicated.

(e) The terms herein defined in the singular shall have a comparable meaning when used in the plural, and vice versa. The masculine, feminine and neuter genders used herein shall include each other gender.

(f) The terms “dollars” and “$” shall mean dollars of the United States of America.

(g) It is understood and agreed that neither the specifications of any dollar amount in this Agreement nor the inclusion of any specific item in the Schedules or Exhibits is intended to imply that such amounts or higher or lower amounts, or the items so included or other items, are or are not material, and neither Party shall use the fact of setting of such amounts or the fact of the inclusion of such item in the Schedules or Exhibits in any dispute or controversy between the Parties as to whether any obligation, item or matter is or is not material for purposes hereof.

ARTICLE II.

PURCHASE AND SALE

2.1. Purchase and Sale of Shares. Upon the terms and subject to the conditions of this Agreement, at the Closing, Sellers shall sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to Buyer, free of any Encumbrances, all of the Shares, and Buyer shall purchase the Shares. The aggregate purchase price (the “Purchase Price”) payable by Buyer for the Shares and for the cancellation of Company Options in accordance with Section 2.3(a) and Company Warrants in accordance with Section 2.3(c) shall consist of the following:

(a) the Closing Payment Amount, payable by Buyer to the Equityholders at the Closing (with the portion of the Closing Payment Amount payable to each Equityholder determined as set forth on the Closing Date Allocation Schedule); plus

20

(b) the aggregate amount of any Unallocated Bonus Amount, payable in accordance with Section 2.7(b) (with the portion of the Unallocated Bonus Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such Unallocated Bonus Amount); plus

(c) the aggregate amount of any cash required to be released from the Working Capital Escrow Account in accordance with Section 2.6(b), payable as and when such cash is required to be released from the Working Capital Escrow Account (with the portion of the amount released from the Working Capital Escrow Account that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such amount released from the Working Capital Escrow Account); plus

(d) the aggregate amount of the Net Working Capital Excess Amount, if any, payable as required by Section 2.4(g); plus

(e) the aggregate amount of any cash required to be released from the Indemnification Escrow Account in accordance with the Escrow Agreement, payable as and when such cash is required to be released from the Indemnification Escrow Account (with the portion of the amount released from the Indemnification Escrow Account that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such amount released from the Indemnification Escrow Account); plus

(f) the First PARP Subsequent Payment Amount, if any, payable on the First PARP Subsequent Payment Date (with the portion of the First PARP Subsequent Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to the First PARP Subsequent Payment Amount); plus

(g) the Second PARP Subsequent Payment Amount, if any, payable on the Second PARP Subsequent Payment Date (with the portion of the Second PARP Subsequent Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to the Second PARP Subsequent Payment Amount); plus

(h) the Third PARP Subsequent Payment Amount, if any, payable on the Third PARP Subsequent Payment Date (with the portion of the Third PARP Subsequent Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to the Third PARP Subsequent Payment Amount); plus

(i) the Fourth PARP Subsequent Payment Amount, if any, payable on the Fourth PARP Subsequent Payment Date (with the portion of the Fourth PARP Subsequent Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to the Fourth PARP Subsequent Payment Amount); plus

(j) each Non-PARP Phase 2 Payment Amount, if any, payable on each Non-PARP Phase 2 Payment Date (with the portion of each Non-PARP Phase 2 Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such Non-PARP Phase 2 Payment Amount); plus

(k) each Non-PARP Phase 3 Payment Amount, if any, payable on each Non-PARP Phase 3 Payment Date (with the portion of each Non-PARP Phase 3 Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such Non-PARP Phase 3 Payment Amount); plus

21

(l) each Non-PARP Sublicensing Payment Amount, if any, payable on each Non-PARP Sublicensing Payment Date (with the portion of each Non-PARP Sublicensing Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to such Non-PARP Sublicensing Payment Amount); plus

(m) the Dose Escalation Study Subsequent Payment Amount, if any, payable on the Dose Escalation Study Subsequent Payment Date (with the portion of the Dose Escalation Study Subsequent Payment Amount that is payable to each Equityholder determined as set forth on a Future Payment Allocation Schedule related to the Dose Escalation Study Subsequent Payment Amount).

2.2. Closing. Subject to the terms and conditions of this Agreement, the sale and purchase of the Shares contemplated by this Agreement shall take place at a closing (the “Closing”) at the offices of Jones Day, 3161 Michelson Drive, Irvine, California at 9:01 a.m. Pacific Standard Time on the later of February 10, 2010 or second Business Day following the day upon which the last of the conditions set forth in Article VIII (other than those that by their terms are to be satisfied or waived at the Closing itself) is satisfied or waived in writing, or at such other time, date and location as the Parties hereto agree in writing. All Closing transactions shall be deemed to take place simultaneously and no one of them shall be deemed to have occurred until all shall have occurred. The Closing shall occur at the time the Closing Payment Amount is paid by Buyer. All Closing transactions shall be deemed to take place simultaneously and no one of them shall be deemed to have occurred until all shall have occurred. The date on which the Closing occurs is referred to herein as the “Closing Date.”

2.3. Treatment of Company Options, Company Warrants and Company Notes.

(a) Treatment of Company Options. Prior to the execution of this Agreement, the Board of Directors of the Company (or, if appropriate, any committee thereof) has adopted appropriate resolutions and taken all other actions necessary to provide that each Company Option heretofore granted under the Company Option Plan or otherwise, whether or not currently vested or exercisable immediately prior to the Closing Date, and which remains outstanding immediately prior to the Closing Date, shall, at the Closing, be cancelled, no longer be outstanding and cease to represent the right to acquire shares of Common Stock and in consideration for such cancellation, each holder of a Company Option (whether vested or unvested at the time of such Company Option’s cancellation) shall have the right to receive the amounts payable to such Company Option holder in accordance with Section 2.1. For the avoidance of doubt, each Company Option shall, as of the Closing, be extinguished, shall no longer be outstanding and shall cease to represent the right to acquire shares of Common Stock.

(b) Treatment of Company Notes. Each holder of a Company Note hereby agrees that such Company Note, to the extent outstanding immediately prior to the Closing, shall effective as of immediately prior to the Closing be converted into shares of Series A Preferred Stock in accordance with the terms of such Company Note and shall, as of the Closing, be extinguished, shall no longer be outstanding and shall cease to represent the right to acquire any

22

shares of Company Capital Stock. The Company has delivered to Buyer executed true and correct copies of agreements with the requisite holders of Company Notes pursuant to which such holders have agreed to elect to convert such Company Notes immediately prior to the Closing.

(c) Treatment of Company Warrants. Prior to the execution of this Agreement, the Board of Directors and the holders of the Company Warrants have taken all actions necessary to provide that each Company Warrant which remains outstanding immediately prior to the Closing shall no longer be outstanding and shall cease to represent the right to acquire shares of Series A Preferred Stock or Common Stock and in consideration for such action, each holder of a Company Warrant shall have the right to receive the amounts payable to such Company Warrant holder in accordance with Section 2.1.

2.4. Working Capital Adjustment.

(a) Not more than ten (10) nor later than three (3) days prior to the Closing Date, the Company shall have caused to be prepared and delivered to Buyer (i) the Company’s reasonable and good faith estimated Closing Date Balance Sheet, (ii) a statement (the “Estimated Net Working Capital Statement”) setting forth the Company’s reasonable and good faith estimate of the Closing Date Net Working Capital and the components and calculations thereof, by reference to the foregoing Closing Date Balance Sheet and (iii) a statement (the “Estimated Net Working Capital Adjustment Statement”) setting forth the calculation of the amount by which the estimated Closing Date Net Working Capital as shown on the Estimated Net Working Capital Statement (the “Estimated Net Working Capital”) either (A) exceeds the Target Net Working Capital (such amount, the “Estimated Net Working Capital Excess Amount”) or (B) is less than the Target Net Working Capital (such amount, the “Estimated Net Working Capital Deficiency Amount”). The estimated Closing Date Balance Sheet, Estimated Net Working Capital Statement and Estimated Net Working Capital Adjustment Statement delivered pursuant to this Section 2.4(a) shall be accompanied by all relevant backup materials and schedules, in detail reasonably acceptable to Buyer.

(b) Within ninety (90) calendar days following the Closing Date, the Company shall cause to be prepared and delivered to the Equityholder Representative (i) a Closing Date Balance Sheet, (ii) a statement (the “Net Working Capital Statement”) setting forth the Closing Date Net Working Capital and the components and calculations thereof, by reference to the Closing Date Balance Sheet and (iii) a statement (the “Net Working Capital Adjustment Statement”) setting forth the calculation of the amount by which the Closing Date Net Working Capital as shown on the Net Working Capital Statement either (A) exceeds the Estimated Net Working Capital (as such amount may be adjusted below, the “Net Working Capital Excess Amount”) or (B) is less than the Estimated Net Working Capital (as such amount may be adjusted below, the “Net Working Capital Deficiency Amount”). The Closing Date Balance Sheet, Net Working Capital Statement and Net Working Capital Adjustment Statement delivered pursuant to this Section 2.4(b) shall be accompanied by all relevant backup materials and schedules, in detail consistent with the materials and detail provided by the Company pursuant to Section 2.4(a).

23

(c) After receipt of the Net Working Capital Statement and the Net Working Capital Adjustment Statement, the Equityholder Representative shall have thirty (30) calendar days to review the Net Working Capital Statement and the Net Working Capital Adjustment Statement. The Company shall give, or cause to be given, to the Equityholder Representative reasonable access during standard working hours to all documents, records and the employees of the Company used in their preparation to the extent such employees are employed by the Company at such time. Not later than thirty (30) calendar days following the date of receipt of the Net Working Capital Statement and the Net Working Capital Adjustment Statement, the Equityholder Representative shall provide the Company with a notice (a “Working Capital Dispute Notice”) listing those items, if any, to which the Equityholder Representative takes exception, which notice shall also (i) specifically identify, and provide a reasonably detailed explanation of the basis upon which the Equityholder Representative has delivered such list, including the applicable provisions of this Agreement on which the dispute set forth in such Working Capital Dispute Notice is based, (ii) set forth the amount of Closing Date Net Working Capital that the Equityholder Representative has calculated based on the information contained in the Net Working Capital Statement and (iii) specifically identify the Equityholder Representative’s proposed adjustment(s). Unless the Equityholder Representative delivers the Working Capital Dispute Notice to the Company setting forth the specific items disputed by the Equityholder Representative on or prior to the thirtieth (30^th) day following the Equityholder Representative’s receipt of the Net Working Capital Statement and the Net Working Capital Adjustment Statement, the Equityholder Representative on behalf of the Equityholders shall be deemed to have accepted and agreed to the Net Working Capital Statement and the Net Working Capital Adjustment Statement and such statements (and the calculations contained therein) shall be final, binding and conclusive. If the Equityholder Representative timely provides the Company with a Working Capital Dispute Notice, the Equityholder Representative and the Company shall, within fifteen (15) days following receipt of such Working Capital Dispute Notice by the Company (the “Resolution Period”), use good faith efforts to resolve their differences with respect to the items specified in the Working Capital Dispute Notice (the “Disputed Items”), and all other undisputed items (and all calculations relating thereto) shall be final, binding and conclusive. Any written resolution by the Equityholder Representative and the Company during the Resolution Period as to any Disputed Items shall be final, binding and conclusive.

(d) If the Equityholder Representative and the Company do not resolve all Disputed Items by the end of the Resolution Period, then all Disputed Items remaining in dispute shall be submitted within fifteen (15) days following the expiration of the Resolution Period to an accounting firm of national reputation that is independent of Buyer, the Company or any Equityholder that is an entity and that is reasonably acceptable to both the Equityholder Representative and the Company to resolve the remaining matters in dispute (the “Neutral Arbitrator”), and such firm shall be the Neutral Arbitrator for all purposes of this Section 2.4(d). The Neutral Arbitrator shall act as an arbitrator to determine only those Disputed Items remaining in dispute, consistent with this Section 2.4, and shall request a statement from each of the Equityholder Representative and the Company regarding such remaining Disputed Items. The Neutral Arbitrator shall consider only those Disputed Items that the Equityholder Representative on the one hand and the Company on the other hand are unable to resolve. In resolving any disputed item, the Neutral Arbitrator may not assign a value to any item greater

24

than the greatest value for such item claimed by any Party or less than the smallest value for such item claimed by any Party. The scope of the disputes to be arbitrated by the Neutral Arbitrator is limited to whether the preparation of the Net Working Capital Statement and the Net Working Capital Adjustment Statement were prepared in accordance with this Agreement, and whether there were mathematical errors in the preparation of the Net Working Capital Statement and the Net Working Capital Adjustment Statement, and the Neutral Arbitrator is not to make any other determination. All fees and expenses relating to the work, if any, to be performed by the Neutral Arbitrator shall be allocated between the Equityholder Representative and the Company in the same proportion that the aggregate amount of the Disputed Items so submitted to the Neutral Arbitrator that is unsuccessfully disputed by such Party (as finally determined by the Neutral Arbitrator) bears to the total amount of such Disputed Items so submitted by such Party. In addition, the Parties shall give the Neutral Arbitrator access to all documents, records and employees as reasonably necessary to perform its function as arbitrator. The Neutral Arbitrator shall deliver to the Equityholder Representative and the Company a written determination (such determination to include a work sheet setting forth all material calculations used in arriving at such determination and to be based solely on information provided to the Neutral Arbitrator by the Equityholder Representative and the Company) of the Disputed Items submitted to the Neutral Arbitrator within thirty (30) days following receipt of such Disputed Items (or as soon thereafter as practicable), which determination, absent manifest error, shall be final, binding and conclusive, and judgment may be entered on the award. If either the Equityholder Representative or the Company fails to submit a statement regarding any Disputed Items submitted to the Neutral Arbitrator within the time determined by the Neutral Arbitrator or otherwise fails to give the Neutral Arbitrator access as reasonably requested, then the Neutral Arbitrator shall render a decision based solely on the evidence timely submitted and the access afforded to the Neutral Arbitrator by the Equityholder Representative and the Company.

(e) The final, binding and conclusive Net Working Capital Statement and Net Working Capital Adjustment Statement, in each case, based either upon agreement by the Equityholder Representative and the Company, the written determination delivered by the Neutral Arbitrator in accordance with this Section 2.4 or the Equityholder Representative’s failure to notify the Company, in accordance with this Section 2.4, of its objections to either the Net Working Capital Statement or the Net Working Capital Adjustment Statement (or any calculations contained therein) shall be the “Conclusive Net Working Capital Statement” and the “Conclusive Net Working Capital Adjustment Statement,” respectively.

(f) If there is a Net Working Capital Excess Amount, the Equityholder Representative shall prepare a Future Payment Allocation Schedule showing the portion of the Net Working Capital Excess amount to be paid to each Equityholder and deliver such Future Payment Allocation Schedule to Buyer. Within ten (10) Business Days following Buyer’s receipt of such Future Payment Allocation Schedule, Buyer shall pay to each Equityholder the portion of the Net Working Capital Excess Amount set forth opposite such Equityholder’s name on such Future Payment Allocation Schedule in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Future Payment Allocation Schedule; provided, however, that no amount shall be payable pursuant to this Section 2.4(f) unless the aggregate Net Working Capital Excess Amount exceeds $[****], in which case the full Net Working Capital Excess Amount shall be paid.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

25

(g) If there is a Net Working Capital Deficiency Amount, the Equityholder Representative shall within ten (10) Business Days following the determination of the Conclusive Net Working Capital Statement, instruct the Escrow Agent to release to the Company from the Working Capital Escrow Account (or if the funds in the Working Capital Escrow Account are insufficient, then first from the Working Capital Escrow Account until the Working Capital Escrow Account has been fully depleted and then from the Indemnification Escrow Account) an amount equal to the Net Working Capital Deficiency Amount in immediately available funds by check or by wire transfer to such bank account or accounts as the Company may specify; provided, however, that no amount shall be payable pursuant to this Section 2.4(g) unless the aggregate Net Working Capital Deficiency Amount exceeds [****], in which case the full Net Working Capital Deficiency Amount shall be paid.

(h) Any Net Working Capital Excess Amount shall be deemed to be an increase in the Purchase Price and any Net Working Capital Deficiency Amount shall be deemed to be a decrease in the Purchase Price for purposes of this Agreement. Absent fraud or willful misconduct in the preparation of the Estimated Net Working Capital Statement or Estimated Net Working Capital Adjustment Statement, neither the Equityholder Representative nor any Equityholder shall have any responsibility for any amount of the Net Working Capital Deficiency other than by means of deductions from the Working Capital Escrow Account or the Indemnification Escrow Account.

2.5. Indemnification Escrow Amount.

(a) Indemnification Escrow Amount. At the Closing, Buyer shall deposit the Indemnification Escrow Amount into an escrow account (the “Indemnification Escrow Account”) to be established by Buyer with Wells Fargo Bank, National Association (the “Escrow Agent”) to be held by the Escrow Agent, pursuant to the terms of an escrow agreement substantially in the form attached hereto as Exhibit A (the “Escrow Agreement”). Buyer shall be treated for Tax purposes as the owner of all amounts held in the Indemnification Escrow Account unless and until such amounts are released therefrom, in which case such amounts shall be treated for Tax purposes as having been paid by Buyer to the Party to whom such amounts are released.

(b) Release of Indemnification Escrow Amount. Following the Indemnification Escrow Release Date, each Equityholder shall be entitled to receive that portion of the Indemnification Escrow Amount then remaining in the Indemnification Escrow Account, if any, that is determined in accordance with the Escrow Agreement.

(c) Escrow Agent Fees and Expenses. Any fees and expenses of the Escrow Agent shall be paid one half by Buyer and one half by the Equityholder Representative (for the account of the Equityholders), with amounts attributed to the Equityholder Representative and known at the Closing to be included in Transaction Expenses. During the period in which the Indemnification Escrow Amount (including any Retained Escrow Amount) is retained in the Escrow Account, all interest or other income earned from the investment of the Indemnification Escrow Amount (the “Escrow Earnings”) shall be retained as additional amounts in the Escrow Account and shall be reported for tax purposes as income of Buyer, provided that within five (5) Business Days following the end of each calendar quarter, forty-five percent (45%) of the Escrow Earnings relating to each such calendar quarter shall be automatically released to Buyer and shall no longer be part of the Indemnification Escrow Account.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

26

2.6. Working Capital Escrow Amount.

(a) Working Capital Escrow Amount. At the Closing, Buyer shall deposit the Working Capital Escrow Amount into an escrow account (the “Working Capital Escrow Account”) to be established by Buyer with the Escrow Agent to be held by the Escrow Agent, pursuant to the terms of the Escrow Agreement, to serve as a source of payment for any Net Working Capital Deficiency Amount payable to Buyer pursuant to the terms of Section 2.4(g). Buyer shall be treated for Tax purposes as the owner of all amounts held in the Working Capital Escrow Account unless and until such amounts are released therefrom, in which case such amounts shall be treated for Tax purposes as having been paid by Buyer to the Party to whom such amounts are released.

(b) Release of Working Capital Escrow Amount. Within three (3) Business Days following the payment of the Net Working Capital Deficiency Amount, if any, or the determination of the Conclusive Net Working Capital Statement showing a Net Working Capital Excess Amount, if any, Buyer shall notify the Equityholder Representative in writing of the amount remaining in the Working Capital Escrow Account (the “Remaining Working Capital Escrow Amount”). The Equityholder Representative shall prepare a Future Payment Allocation Schedule showing the portion of the Remaining Working Capital Escrow Amount to be paid to each Equityholder and deliver such Future Payment Allocation Schedule to Buyer and the Escrow Agent. Within ten (10) Business Days following Buyer’s and Escrow Agent’s receipt of such Future Payment Allocation Schedule, the Escrow Agent shall distribute to each Equityholder the portion of the Remaining Working Capital Escrow Amount set forth opposite such Equityholder’s name on such Future Payment Allocation Schedule in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Future Payment Allocation Schedule.

2.7. Distribution of Bonus Amount.

(a) Prior to the execution of this Agreement, the Company has delivered to Buyer a certificate (the “Participating Service Providers Certificate”) signed by the President and Chief Executive Officer of the Company setting forth the names of those employees and consultants of the Company (the “Participating Service Providers”) who are entitled to receive, subject to the terms set forth in any notice provided by the Company in writing to the Participating Service Providers, as consideration for executing and delivering the release contemplated by this Section 2.7(a) and attached hereto as Exhibit B, a portion of the Bonus Amount as set forth on such Participating Service Provider Certificate. Prior to the Closing, the Company has delivered to each Participating Service Provider for execution a general release of all claims against the Company in the form attached hereto as Exhibit B. With respect to each Participating Service Provider who executes a general release of all claims against the Company in the form attached hereto as Exhibit B within forty-five (45) days following the delivery of such release to the Participating Service Provider, and does not revoke such release, following the expiration of any revocation period provided by Applicable Law, Buyer shall, as soon as reasonably practicable, subject to the immediately following sentence, pay and distribute to each

27

such Participating Service Provider, each in his or her capacity as a current or former service provider of the Company, as the case may be, who complies with the procedures set forth in this Section 2.7(a) the portion of the Bonus Amount as set forth on the Participating Service Provider Certificate for such Participating Service Provider. For the avoidance of doubt, the Bonus Amount shall not be distributed to a Participating Service Provider until the general release of claims executed by such Participating Service Provider becomes effective following the expiration of any applicable revocation period. In the event a Participating Service Provider fails to execute within forty-five (45) days following the Closing or revokes such release during any applicable revocation period, then such Participating Service Provider shall not receive any portion of the Bonus Amount. The aggregate portion of the Bonus Amount that is not payable to all Participating Service Providers is referred to herein as the “Unallocated Bonus Amount”.

(b) Promptly following the determination of the Unallocated Bonus Amount, Buyer shall notify the Equityholder Representative as to the Unallocated Bonus Amount. The Equityholder Representative shall prepare a Future Payment Allocation Schedule showing the portion of the Unallocated Bonus Amount to be paid to each Equityholder and deliver such Future Payment Allocation Schedule to Buyer. Within ten (10) Business Days following Buyer’s receipt of such Future Payment Allocation Schedule, Buyer shall pay to each Equityholder the portion of the Unallocated Bonus Amount set forth opposite such Equityholder’s name on such Future Payment Allocation Schedule in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Future Payment Allocation Schedule.

2.8. Rights to Future Payments. The right of each Equityholder to receive the Future Payment Amounts, if any, or his, her or its portion of the Equityholder Representative’s Fund Amount, if any, shall not be evidenced by a certificate or other instrument. The right of each Equityholder to receive the Future Payment Amounts, if any, and the Equityholder Representative’s Fund Amount, if any, may not be offered, sold, pledged, assigned or otherwise transferred by a Equityholder except by operation of law or by will or intestate succession; provided, however, if a Equityholder is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act and a non-natural Person, such Equityholder may offer, sell, pledge, assign or otherwise transfer its interest in the Future Payment Amounts and the Equityholder Representative’s Fund Amount, if any, provided that such Equityholder’s transferee, assignee or pledgee is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act and agrees to be bound by the restrictions on transfer set forth in this Section 2.8 and provided, that such Equityholder delivers an opinion of counsel in a form that is reasonably acceptable to the Company stating that such offer, sale, pledge, assignment or other transfer will be effected pursuant to a transaction that is exempt from registration under the Securities Act.

2.9. Escheat. Neither Buyer nor the Company shall be Liable to any Equityholder for any portion of the Purchase Price delivered to a public official pursuant to any applicable abandoned property escheat or similar law. If any amounts payable to a Equityholder have not been claimed by such Equityholder for a period of twelve (12) months following the date such payment is due (or immediately prior to such earlier date on which any Purchase Price would otherwise escheat to or become the property of any Governmental Authority), any such Purchase Price shall, to the extent permitted by Applicable Law, become the property of the Company, free and clear of all claims or interest of any Person previously entitled thereto.

28

2.10. Withholding Rights. Each of Buyer or the Company shall be entitled to deduct and withhold from the Closing Payment Amount and any Future Payment Amount or any amount otherwise payable pursuant to this Agreement such amounts as it is required to deduct and withhold with respect to the making of such payment under the Code, or any provision of United States federal, state or local, or any foreign, Tax law. To the extent that amounts are so withheld and paid over to or deposited with the relevant Governmental Authority by Buyer or the Company, as the case may be, such amounts shall be treated for all purposes of this Agreement as having been paid to the applicable Person in respect of which such deduction and withholding were made.

2.11. Equityholder Representative.

(a) Appointment. As used in this Agreement, the term “Equityholder Representative” shall mean Arthur Pappas, or any Person appointed as a successor Equityholder Representative pursuant to Section 2.11(b) hereof. Arthur Pappas hereby accepts his, her or its appointment as the initial Equityholder Representative. Effective upon Closing, without any further action by any other Person, the Equityholder Representative shall be appointed and constituted in respect of each Equityholder, as his, her or its agent, to act in his, her or its name, place and stead, as such Equityholder’s attorney-in-fact, as more fully set forth in Section 2.11(c).

(b) Election and Replacement. From and after the Closing until the date when all obligations under this Agreement have been discharged (including all indemnification obligations under Article IX hereof), Sellers who were entitled to receive in excess of seventy-two percent (72)% of the Closing Payment Amount payable to the former holders of Series A Preferred Stock (the “Supermajority”), may, from time to time upon written notice to the Equityholder Representative and Buyer, remove any Equityholder Representative (including any appointed by Buyer as provided below) or appoint a new Equityholder Representative to fill any vacancy created by the death, incapacitation, resignation or removal of any Equityholder Representative. If the Supermajority is required to but has not appointed a successor Equityholder Representative to fill any vacancy within ten (10) Business Days from written notice from Buyer to all former holders of Series A Preferred Stock and a request by Buyer to appoint a successor Equityholder Representative, Buyer shall have the right to appoint an Equityholder Representative to fill any such vacancy from the directors of the Company prior to the Closing, and shall use commercially reasonable efforts to advise all Equityholders of such appointment by written notice; provided, however, that a Supermajority shall thereafter retain the right to remove the Equityholder Representative or appoint a new Equityholder Representative pursuant to this Section 2.11(b). A copy of any appointment by the Supermajority of any successor Equityholder Representative shall be provided to Buyer promptly after it shall have been effected. Each successor Equityholder Representative shall have all of the power, authority, rights and privileges conferred by this Agreement upon the original Equityholder Representative, and the term “Equityholder Representative” as used herein shall be deemed to include any successor Equityholder Representative.

29

(c) Authority. The Equityholder Representative shall be authorized, on behalf of the Equityholders, (i) to determine the occurrence of any Milestone, (ii) to resolve any disputes related to the occurrence of any Milestone or the payment of any Future Payment Amount, including the authorization to demand arbitration in accordance with the terms of this Agreement and to comply with Court Orders and awards of arbitrators related thereto, (iii) to resolve any disputes related to any matters arising from Section 7.4, (iv) to discuss, negotiate, resolve and fully and finally settle on behalf of the Equityholders any claims for indemnification by Buyer under Article IX hereof, including the authorization to comply with Court Orders with respect to any such claim for indemnification, (v) to review the Net Working Capital Statement and the Net Working Capital Adjustment Statement, deliver a Working Capital Dispute Notice and discuss, negotiate, resolve and fully and finally settle on behalf of Equityholders any disputes with respect to the Closing Date Net Working Capital pursuant to Section 2.4 hereof, (vi) to take any action, including litigating, defending or enforcing any actions, and to make, deliver and sign any certificate, notice, consent or instrument required or permitted to be made or delivered under this Agreement or under the documents referred to in this Agreement (an “Instrument”) which the Equityholder Representative determines in his or her discretion to be necessary, appropriate or desirable, and, in connection therewith (provided however if any individual Equityholder is named in such litigation, such Equityholder shall have the right to tender defense), (vii) to hire or retain, at the sole expense of the Equityholder, such counsel, investment bankers, accountants, representatives and other professional advisors as he or she determines in his or her sole and absolute discretion to be necessary, advisable or appropriate in order to carry out and perform his or her rights and obligations hereunder, (viii) to act as disbursement agent for any payments to the D&O Indemnified Parties pursuant to Section 7.1, and (ix) to receive all documents, certificates and notices and make all determinations on behalf of the Equityholders required under this Agreement. A decision, act, consent or instruction of the Equityholder Representative shall constitute a decision of the Equityholders, and shall be final, binding and conclusive upon the Equityholders, as the case may be. Any Party receiving an Instrument from the Equityholder Representative shall have the right to rely in good faith upon such Instrument, and to act in accordance with the Instrument without independent investigation. The Equityholder Representative shall promptly, and in any event within two (2) Business Days, provide written notice to each Equityholder of any action taken on behalf of the Equityholders by the Equityholder Representative pursuant to the authority delegated to the Equityholder Representative under this Section 2.11.

(d) No Liability of Equityholder Representative or Buyer. The Equityholder Representative shall determine the amounts to be paid to each Equityholder as set forth on the Initial Allocation Schedule and each Future Payment Allocation Schedule in accordance with the certificate of incorporation of the Company as amended and in effect immediately prior to the Closing as if the transactions contemplated hereby constitute a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing) and Applicable Law. Notwithstanding the foregoing, neither the Equityholder Representative (nor any of the directors, officers, agents or employees of Equityholder Representative, if applicable) shall be Liable to any Equityholder or any other Person for any error of judgment, or any action taken, suffered or omitted to be taken, or any calculation made or performed under this Agreement, except in the case of the Equityholder Representative’s fraud, gross negligence or willful misconduct. The Equityholder

30

Representative may consult with legal counsel, independent public accountants and other experts selected by the Equityholder Representative and shall not be Liable to any Equityholder for any action taken or omitted to be taken or any calculation made or performed under this Agreement in good faith in accordance with the advice of such counsel, accountants or experts. As to any matters not expressly provided for in this Agreement, the Equityholder Representative shall not be required to exercise any discretion or take any action. Neither Buyer, the Company nor any of their Affiliates shall have any Liability to any of the Equityholders or otherwise arising out of the acts or omissions of the Equityholder Representative or any disputes among the Equityholders or between the Equityholders and the Equityholder Representative. Buyer may rely entirely on its dealings with, and notices to and from, the Equityholder Representative to satisfy any obligations it may have under this Agreement or otherwise to the Equityholders.

(e) Indemnity; Costs and Expenses. Each Equityholder shall, in proportion to the portion of the Purchase Price plus the Equityholder Representative’s Fund Amount, if any, then previously received by such Equityholder (or if no portion of the Purchase Price and the Equityholder Representative’s Fund Amount has been paid, in proportion to the portion of the Closing Payment Amount to which such Equityholder is entitled), indemnify and defend the Equityholder Representative and hold the Equityholder Representative harmless against any loss, damage, cost, Liability or expense incurred without fraud, gross negligence or willful misconduct by the Equityholder Representative and arising out of or in connection with the acceptance, performance or administration of the Equityholder Representative’s duties under this Agreement. Any Liabilities, losses, penalties, fines, claims, damages, out-of-pocket costs or expenses (including costs of defending claims prior to the final adjudication or settlement of such claims) incurred by or reasonably expected to be incurred by the Equityholder Representative in connection with the acceptance, performance and administration of his or her duties as the Equityholder Representative pursuant to this Agreement (including the hiring of legal counsel, accountants or auditors and other advisors pursuant to the terms of this Agreement but excluding any of the foregoing arising out of the Equityholder Representative’s fraud, gross negligence or willful misconduct) and all fees payable hereunder to the Equityholder Representative by the Equityholder (“Equityholder Representative’s Costs”), shall be paid as follows: (i) first by recourse to the Equityholder Representative’s Fund; and (ii) if such amounts held in the Equityholder Representative’s Fund are insufficient to pay for such Equityholder Representative’s Costs, then by recourse to any Future Payments distributable to Equityholders; and (iii) if such amounts are insufficient to pay such Equityholder Representative’s Costs, then by recourse directly to the Equityholders (in proportion to the portion of the Purchase Price plus the Equityholder Representative’s Fund Amount, if any, then previously received by each such Equityholder, or if no portion of the Purchase Price and Equityholder Representative’s Fund Amount has been paid, in proportion to the portion of the Closing Payment Amount to which such Equityholder is entitled).

(f) Deposit of Equityholder Representative’s Fund Amount. At the Closing, Buyer shall deposit with the Equityholder Representative the Equityholder Representative’s Fund Amount, which shall be held by the Equityholder Representative in trust solely for the purpose of paying the expenses if any, incurred by the Equityholder Representative in connection with this Agreement (the “Equityholder Representative’s Fund”). The deposit of the Equityholder Representative’s Fund Amount by Buyer with the Equityholder Representative

31

shall discharge Buyer’s obligations with respect to such amount, and Buyer shall not have responsibility or Liability for the manner in which the Equityholder Representative administers the Equityholder Representative’s Fund, or for causing or ensuring that all or any portion of the Equityholder Representative’s Fund Amount is ultimately paid or distributed to the Equityholders. Upon the Equityholder Representative’s determination to release the Equityholder Representative’s Fund Amount then remaining, if any, such remaining Equityholder Representative’s Fund Amount shall be distributed to Equityholders in accordance with the certificate of incorporation of the Company as amended and in effect immediately prior to the Closing as if the transactions contemplated hereby constitute a Deemed Liquidation Event (as defined in the Company’s certificate of incorporation as amended and in effect as of immediately prior to the Closing) and Applicable Law.

(g) Access to Information. Within thirty (30) days after the Equityholder Representative’s request following the end of a calendar year, Buyer shall provide to the Equityholder Representative a written report concerning the status of any unachieved Milestones during the previous calendar. At the request of the Equityholder Representative, upon reasonable notice and at a reasonable time and location, the Equityholder Representative shall be entitled to ask, and have answered, reasonable questions arising from their review of such annual updates provided by Buyer. Buyer shall promptly (but no later than five (5) Business Days following the achievement of a Milestone) notify the Equityholder Representative of the achievement of any Milestone, provided that a press release issued by Buyer describing the achievement of such Milestone shall constitute such notice. Promptly thereafter, the Equityholder Representative will prepare a Future Payment Allocation Schedule showing the portion of the Milestone Payment Amount to be paid to each Equityholder and deliver such Future Payment Allocation Schedule to Buyer.

(h) Dispute Resolution.

(1) In the event that the Equityholder Representative shall dispute the purported occurrence or non-occurrence of a Milestone or a request for indemnification or setoff under Article IX, then the Equityholder Representative shall provide written notice to Buyer (the “Dispute Notice”) specifying the amount disputed and the basis for the dispute, together with supporting documentation reflecting the analysis and justification thereof. Buyer and the Equityholder Representative shall thereafter attempt to resolve the dispute as set forth in this Section 2.11(h).

(2) The Equityholder Representative and Buyer shall attempt to resolve any dispute arising out of or relating to this Agreement promptly by negotiation in good faith between the Equityholder Representative and an executive officer of Buyer who has authority to settle the dispute. Each Party shall give the other Party involved written notice of any dispute not resolved in the Ordinary Course of Business. Within seven (7) days following delivery of such notice, the Party receiving notice shall submit to the other a written response thereto. The notice and the response shall include: (i) a statement of each Party’s position(s) regarding the matter(s) in dispute and a summary of arguments in support thereof, and (ii) the name and title of the executive officer who will represent Buyer and any other Person who will accompany that executive officer, in the case of Buyer, or the name of the agent who will represent the Equityholders and any other Person who will accompany that agent, in the case of the Equityholders.

32

(3) Within fourteen (14) days following delivery of the notice delivered pursuant to Section 2.11(h)(2), the Equityholder Representative and the designated executive officer of Buyer shall meet at a mutually acceptable time and place, and thereafter, as often as they reasonably deem necessary, to attempt to resolve the dispute. All reasonable requests for information made by one Party to the other shall be honored in a timely fashion. All negotiations conducted pursuant to this Section 2.11(h) (and any of the Parties’ submissions in contemplation hereof) shall be kept confidential by the Parties and shall be treated by the Parties and their representatives as compromise and settlement negotiations under the Federal Rules of Evidence and any similar state rules.

(4) In the event that the Equityholder Representative and Buyer are unable to resolve any dispute arising out of this Agreement in accordance with provisions (1), (2) and (3) of this Section 2.11(h) within six months after delivery of any Dispute Notice, Buyer and the Equityholder Representative shall submit such dispute for final adjudication to the applicable court sitting in the State of Delaware in accordance with Section 11.12.

2.12. Additional Actions. If, at any time after the Closing, the Company shall consider or be advised that any deeds, bills of sale, assignments, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm of record or otherwise in the Company its right, title or interest in, to or under any of the rights, properties or assets of Buyer or the Company or otherwise to carry out this Agreement, the officers and directors of the Company shall be authorized to execute and deliver, in the name and on behalf of Buyer or the Company, as the case may be, all such deeds, bills of sale, assignments and assurances and to take and do, in the name and on behalf of Buyer or the Company, as the case may be, all such other actions and things as may be necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and under such rights, properties or assets in the Company or otherwise to carry out this Agreement. If, at any time after the Closing, the Company shall consider or be advised that any information or documentation is necessary or desirable for the delivery of the Purchase Price from Buyer or the Company to the Equityholders or to otherwise carry out the terms of the Agreement, the Equityholder Representative shall use its reasonable best efforts to obtain such information or documentation from such Equityholders on behalf of Buyer and the Company.

2.13. Tax Forms. The parties acknowledge if an Equityholder has not delivered to Buyer a current and properly executed IRS Form W-9 or appropriate IRS Form W-8 prior to any payment of Payable Consideration or any amount otherwise payable pursuant to this Agreement, Buyer may withhold amounts from such payment pursuant to Section 2.10 if such withholding is required under the Code, or any provision of United States federal, state or local, or any foreign Tax law.

33

ARTICLE III.

REPRESENTATIONS AND WARRANTIES OF THE COMPANY

As a material inducement to Buyer to enter into this Agreement, except as disclosed in the disclosure schedule delivered Buyer by the Company concurrently herewith (the “Company Disclosure Schedule”) (it being understood that the Company Disclosure Schedule shall be arranged in sections corresponding to the sections contained in this Agreement, and the disclosures in any section of the Company Disclosure Schedule shall qualify the representations in the corresponding section of this Article III and shall be deemed made in any other section or sections of the Company Disclosure Schedule to the extent the relevance of such disclosures is readily apparent from the text of such disclosure), the Company hereby makes the following representations and warranties to Buyer.

3.1. Organization of the Company. The Company is a corporation duly organized and validly existing and in good standing under the laws of the State of Delaware with full corporate power and corporate authority to conduct its business as it is presently being conducted, to own, lease or operate, as applicable, its assets and properties, and to perform all its obligations under its Contracts. Schedule 3.1 sets forth each jurisdiction in which the Company is duly qualified to do business as a foreign corporation and the Company is in good standing in each jurisdiction where the character of its properties owned, leased or operated or the nature of its activities make such qualification necessary, except where the failure to be so qualified or in good standing would not have a Material Adverse Effect on the Company. Copies of the certificate of incorporation and bylaws of the Company, and all amendments thereto, have heretofore been delivered to Buyer and are accurate and complete as of the date hereof. The Company is not in violation of its certificate of incorporation or bylaws.

3.2. Subsidiaries. The Company does not have and has not ever had any Subsidiaries and does not otherwise own or control, directly or indirectly, or hold any rights to acquire, any capital stock or any other securities, interests or investments (other than investments that constitute cash or cash equivalents) in any other corporation, partnership, trust, joint venture, association, or other Person.

3.3. Authorization. The Company has all requisite power and authority, and has taken all action necessary, to execute, deliver and perform this Agreement, to consummate the transactions contemplated hereby and to perform its obligations hereunder. The execution and delivery of this Agreement and the consummation by the Company of the transactions contemplated hereby have been duly approved by the Board of Directors of the Company and no other proceeding on the part of the Company or the Stockholders is necessary to authorize this Agreement and the transactions contemplated hereby. This Agreement has been duly executed and delivered by the Company and is the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights generally and except insofar as the availability of equitable remedies may be limited by Applicable Law. Section 2115 of the California General Corporation Law does not apply to the Company or the transactions contemplated by this Agreement.

34

3.4. Capitalization.

(a) The authorized capital stock of the Company consists of thirty four million five hundred thousand (34,500,000) shares of Common Stock and twenty two million (22,000,000) shares of Preferred Stock. As of the date of this Agreement and without giving effect to the transactions contemplated hereby, there are issued and outstanding 2,112,500 shares of Common Stock and 10,500,000 shares of Preferred Stock. All of the issued and outstanding shares of Common Stock and Series A Preferred Stock are, and each share of Common Stock or Series A Preferred Stock that may be issued pursuant to the Company Options, Company Warrants or Company Notes will be, if and when issued in accordance with the respective terms thereof, duly authorized, validly issued, fully paid and non-assessable. No claim has been made or, to the Company’s Knowledge, threatened against the Company asserting that any Person other than a Person listed on the Initial Allocation Schedule is the holder or beneficial owner of, or has the right to acquire beneficial ownership of, any stock of, or any other voting or Equity Participation in the Company. Except as set forth on Schedule 3.4(a), there are (i) no accrued and unpaid dividends on any of the Shares and (ii) no commitments to issue additional shares of Common Stock or Series A Preferred Stock. The Company does not hold any Equity Participations of the Company in its treasury.

(b) Except as set forth on the Initial Allocation Schedule, there are no (i) shares of Company Capital Stock outstanding, (ii) other Equity Participations of the Company outstanding, (iii) other Contracts pursuant to which the Company is or may become obligated to issue, sell, transfer, purchase, return or redeem or otherwise acquire Equity Participations of the Company or any other Person or to provide funds to, make an investment in, or contribute capital to, any Person, (iv) Equity Participations of the Company reserved for issuance for any purpose, (v) agreements pursuant to which registration rights in the Shares have been granted, (vi) to the Company’s Knowledge, stockholder agreements, whether written or verbal, among any current or former Stockholders of the Company or (vii) statutory or contractual preemptive rights or rights of first refusal with respect to the Shares.

(c) The Company has not violated any applicable federal or state securities laws or any other Applicable Law in connection with the offer, sale or issuance of any of its capital stock. Except as set forth on Schedule 3.4(c), there are no Contracts of the Company or, to the Company’s Knowledge, Contracts between any of the Equityholders, with respect to the voting or transfer of Equity Participations of the Company.

(d) Schedule 3.4(d) lists each Contract of the Company relating to the Company Options, Company Notes and the Company Warrants. The Company has provided Buyer with a true and accurate copy of each Contract identified on Schedule 3.4(d).

(e) With respect to the Company Options, (i) each grant of a Company Option was duly authorized no later than the date on which the grant of such Company Option was by its terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the Board of Directors of the Company, or a committee thereof, or a duly authorized delegate thereof, and any required approval by the stockholders of the Company by the necessary number of votes or written consents, and material terms of such grant were communicated to the recipient of such grant within a reasonable time following the Grant Date,

35

(ii) each such grant was made in accordance with the terms of and pursuant to the Company Option Plan and all Applicable Law, (iii) the per share exercise price of each Company Option was not less than the fair market value of a share of Common Stock on the Grant Date; (iv) each such grant was properly accounted for in all material respects in accordance with GAAP in the financial statements (including the related notes) of the Company and in accordance with all Applicable Laws, and (v) no modifications have been made to any such grants after the Grant Date.

(f) The Initial Allocation Schedule is true, complete and accurate as of the date hereof, and the payments to Equityholders described therein are the correct payments to be made to the Equityholders in accordance with the Company’s certificate of incorporation, Applicable Law, and this Agreement, and each Equityholder’s pro rata share of the amounts to be held in the Indemnification Escrow Account is accurately reflected therein based on the assumptions set forth therein.

(g) The Closing Date Allocation Schedule, when delivered to Buyer and the Paying Agent, will be true, complete and accurate as of the Closing, and the payments to Equityholders described therein will be the correct payments to be made to the Equityholders in accordance with the Company’s certificate of incorporation, Applicable Law, and this Agreement, and each Equityholder’s pro rata share of the amounts to be held in the Indemnification Escrow Account is accurately reflected therein based on the assumptions set forth therein.

(h) Each Future Payment Allocation Schedule, when delivered to Buyer, will be true, complete and accurate as of the date of delivery of such Future Payment Allocation Schedule, and the payments to Equityholders described therein will be the correct payments to be made to the Equityholders in accordance with the Company’s certificate of incorporation, Applicable Law, and this Agreement in connection with such Future Payment Amount.

(i) The distribution of the Purchase Price pursuant to the Closing Date Allocation Schedule and each applicable Future Allocation Schedule will not be in conflict with, or constitute a violation of, the certificate of incorporation of the Company in effect immediately prior to the Closing. No holder of any Equity Participation of the Company will be entitled to receive any consideration with respect to any Equity Participations of the Company except as set forth in, with respect to the Closing Payment Amount, the Closing Date Allocation Schedule or, with respect to any Future Payment Amount, the applicable Future Payment Allocation Schedule.

3.5. Title to Properties and Assets.

(a) The Company has good and valid title to or, in the case of leased properties or properties held under license, a good and valid leasehold or license interest in, all of its properties and assets. The assets, properties and rights of the Company constitute all of the assets, properties and rights which are necessary for the operation of the Company’s business as currently conducted. The Company holds title to each material property and asset which it purports to own, free and clear of any Encumbrances other than Permitted Encumbrances. Notwithstanding the foregoing, the representations in this Section 3.5 do not apply to Intellectual Property rights, which are subject to the representations and warranties contained in Section 3.19.

36

(b) All of the tangible assets of the Company are in all material respects in reasonably serviceable operating condition and repair (giving due account to the age and length of use of same, ordinary wear and tear excepted) and are adequate for the conduct of its business in substantially the same manner as it has heretofore been conducted.

(c) Schedule 3.5(c) sets forth a true and complete list of all real property leased by the Company (collectively, the “Leased Real Property”), including the location of, and a brief description of the nature of the activities conducted on, such Leased Real Property. The Company has a valid leasehold interest in the Leased Real Property, free and clear of all Encumbrances, except Permitted Encumbrances. To the Company’s Knowledge, no Person other than the Company has any right to use, occupy or lease all or any portion of the Leased Real Property. The Company has all certificates of occupancy and Permits of any Governmental Authority necessary for its current use and operation of the Leased Real Property, except to the extent that any such Permits are held by the landlord and/or owner of such Leased Real Property, and the Company has complied in all material respects with the conditions of such certificates of occupancy and other Permits. To the Knowledge of the Company, no Default has occurred in the due observance of any Permit applicable to the Leased Real Property

(d) The Company does not own, and never has owned, any real property.

3.6. Absence of Certain Activities or Changes. Since the date of the Most Recent Balance Sheet Date through the date of this Agreement, the Company has conducted its operations in the Ordinary Course of Business and there has been no: (i) Material Adverse Effect on the Company or (ii) action taken which, if taken after the date of this Agreement without Buyer’s consent, would violate the provisions of Section 6.1(b) of this Agreement.

3.7. Material Contracts.

(a) All Contracts, Indebtedness (including all evidences of Indebtedness owed to the Company by any officer, director or employee of the Company (collectively the “Employee Loans”)), Liabilities and other obligations to which the Company is a party or by which it is bound that: (i) are material to the conduct and operations of its business and its properties, (ii) require the Company to provide in-kind consideration, (iii) contain covenants (A) to indemnify or hold harmless any Person or (B) not to (or otherwise restricting or limiting the Company’s ability to) compete in any line of business or geographical area (including any covenant not to compete with respect to the manufacture, marketing, distribution or sale of any product or product line), solicit any customer of any Person, solicit or hire any employee, consultant or independent contractor of any Person or transact business or deal in any other manner with any other Person, (iv) involve real property, (v) involve a joint venture, strategic alliance, partnership, or limited liability company relationship, (vi) govern or relate to Indebtedness, including guarantees for money borrowed by others, (vii) are material customer or supplier agreements of the Company, (viii) obligate the Company to develop any product or technology, (ix) relate to the acquisition or disposition of any material assets, (x) relate to any rights or obligations to undertake the development or commercialization of any pharmaceutical

37

product, (xi) require, or would reasonably be expected to result in, payments by the Company in excess of $50,000 per annum, (xii) results in any Person holding a power of attorney from the Company, (xiii) relate to the Development Products, the Development Compounds or any related products or product candidates, (xiv) contain a “change of control” or similar provision (other than any Benefit Plan), (xv) involve the payment of royalties or other amounts calculated upon the revenues or income of the Company or income or revenues related to any product or Intellectual Property of the Company, (xvi) involve any Governmental Authority, or (xvii) are not terminable upon ninety or fewer days notice without penalty or additional Liabilities (collectively and together with the Contracts identified on Schedule 3.5(c) and Schedule 3.19(b), the “Material Contracts”) are listed in Schedule 3.7(a) and complete and accurate copies and all amendments thereto of such Contracts, Indebtedness, Liabilities and other obligations have been provided to Buyer.

(b) Each Material Contract is in full force and effect except for Contracts which have expired by their terms in the Ordinary Course of Business. All of the Material Contracts are valid, binding and enforceable against the Company in accordance with their terms except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting enforcement of creditors’ rights generally and except insofar as the availability of equitable remedies may be limited by Applicable Law. The Company is not in Default under any Material Contract in any material respect. To the Company’s Knowledge, no other party is in Default under such Material Contracts in any material respect and, to the Company’s Knowledge, no event has occurred and no condition or state of facts exists which, with the passage of time or the giving of notice or both, would constitute a Default under any Material Contract. No written notice of any claim of Default under a Material Contract has been given to the Company. To the Company’s Knowledge, the Company has not waived any of its rights under any Material Contract. The Company is not currently paying liquidated damages in lieu of performance under any Material Contract.

3.8. Compliance with Other Instruments. The execution, delivery and performance of and compliance with this Agreement and the consummation of the transactions contemplated hereby will not (i) result in a violation of, or be in conflict with or constitute a violation of, the certificate of incorporation or bylaws of the Company, or (ii) assuming the consents and approvals referred to in Section 3.16 are duly obtained, result in a violation of, or be in conflict with or constitute, with or without the passage of time or the giving of notice or both, a Default under, result in a violation of, or conflict with any Applicable Laws, Court Orders or Permits applicable to the Company or (iii) violate, conflict with, result in a material Default under, or give to any Person any rights of termination or acceleration under any Contract of the Company, or result in the creation of any Encumbrance (other than a Permitted Encumbrance) upon any of the properties, assets or Equity Participations of the Company.

3.9. Financial Statements.

(a) The Company has heretofore furnished to Buyer (a) copies of the audited balance sheet of the Company as of December 31, 2006, 2007 and 2008, together with the related statements of operations, stockholders’ equity (deficit) and cash flows for the periods then ended and the notes thereto, accompanied by the reports thereon of PricewaterhouseCoopers

38

LLP, (b) copies of the unaudited balance sheets of the Company as of December 31, 2009 (the “Most Recent Balance Sheet”), together with the related unaudited statements of operations, stockholders’ equity (deficit), and cash flow for the period then ended, and the notes thereto (all the financial statements referred to in clauses (a) and (b) above being hereinafter collectively referred to as the “Financial Statements”). The Financial Statements, including the notes thereto, (i) were prepared in accordance with GAAP applied on a consistent basis throughout the periods covered thereby without modification of the accounting principles used in the preparation thereof (except as otherwise stated in the applicable footnotes), (ii) present fairly in all material respects the financial position, results of operations and changes in financial position of the Company as of such dates and for the periods then ended (subject, in the case of the unaudited interim Financial Statements described in clause (b) above, to normal immaterial year-end audit adjustments consistent with prior periods), and (iii) were prepared in accordance with the books of account and other financial records of the Company.

(b) Buyer has been provided with the audit reports of PricewaterhouseCoopers LLP in respect of the audited Financial Statements. The Company has not withheld any information from the auditors, which, if disclosed would reasonably be expected to have caused the auditors to qualify their audit report or to refuse to issue their report with respect to any of the audited Financial Statements. No auditor to the Company has ever declined or indicated its inability to issue an opinion with respect to any financial statements of the Company.

(c) The Company maintains a system of internal control over financial reporting that is adequate to permit preparation of the financial statements of the Company in accordance with GAAP. There have been no instances of fraud by the Company or, to the Knowledge of the Company, its officers, whether or not material, that occurred during any period covered by the Financial Statements.

3.10. Liabilities. The Company has no Liabilities of any nature which are not shown or provided for on the Most Recent Balance Sheet, except for (a) Liabilities incurred or accrued in the Ordinary Course of Business since the date of the Most Recent Balance Sheet, (b) Liabilities arising from matters disclosed in Schedule 3.10, or (c) Liabilities incurred under this Agreement or in connection with the transactions contemplated hereby. The Company has never effected or maintained any “off-balance sheet arrangement” (as defined in Item 303(c) of Regulation S-K of the U.S. Securities and Exchange Commission).

3.11. Taxes.

(a) The Company has timely filed all material Tax Returns it is required to have filed. Such Tax Returns are accurate, complete and correct in all material respects.

(b) The Company has timely paid all Taxes required to have been paid (whether or not shown as due on any Tax Returns) and have reserved in accordance with GAAP in the Most Recent Balance Sheet for all Taxes (whether or not shown on any Tax Return) that have accrued as of the balance sheet date.

39

(c) Except as set forth on Schedule 3.11(c):

(i) no written claim has been made by any taxing authority in any jurisdiction where the Company does not file Tax Returns that it is or may be subject to Tax by that jurisdiction;

(ii) no extensions or waivers of statutes of limitations with respect to the Tax Returns have been given by or requested from the Company; and

(iii) no written claim for assessment or collection of Taxes has been asserted against the Company which remains unpaid or unresolved, and there is no presently pending audit examination, refund claim, litigation, proceeding, proposed adjustment or matter in controversy with respect to any Taxes of or with respect to the Company.

(d) Except to the extent indicated in Schedule 3.11(d), all deficiencies asserted or assessments made against the Company as a result of any examinations by any taxing authority have been fully paid.

(e) There are no Encumbrances for Taxes (other than Permitted Encumbrances) upon the assets of the Company.

(f) The Company is not party to or bound by any Tax indemnity, Tax sharing, tax allocation or similar agreement.

(g) The Company is not party to or bound by any closing agreement, offer in compromise or other agreement with any taxing authority.

(h) (1) The Company has never been a member of an affiliated group of corporations, within the meaning of Section 1504 of the Code (or any predecessor provision or comparable provision of state, local or foreign law), or a member of a combined, consolidated or unitary group for state, local or foreign Tax purposes, other than the group of which the Company is the common parent;

(2) The Company has no Liability for Taxes of any Person (other than the Company) under Treasury Regulations Section 1.1502-6 (or any corresponding provision of state, local or foreign income Tax law), as transferee or successor, by Contract (excluding for purposes of this Section 3.11(h) Liability pursuant to customary provisions in Contracts not primarily relating to Taxes) or otherwise; and

(3) The Company has not engaged in a transaction that constitutes a “reportable transaction”, as such term is defined in Treasury Regulation Section 1.6011-4(b)(1), or a transaction that constitutes a “listed transaction”, as such term is defined in Treasury Regulation Section 1.6011-4(b)(2).

(i) The Company has not incurred any Liability for Taxes following the date of the Most Recent Balance Sheet other than Taxes incurred in the Ordinary Course of Business or Taxes incurred as a result of the transactions contemplated by Article II.

40

(j) The Company has never been a United States real property holding corporation within the meaning of Section 897(c)(2) of the Code.

(k) The Company has never been a “distributing corporation” or a “controlled corporation” in connection with a distribution described in Section 355 of the Code.

(l) The Company has withheld and paid all Taxes required to be withheld in connection with any amounts paid or owing to any employee, creditor, independent contractor or other third party.

(m) The Company has never elected to be treated as an “S corporation” within the meaning of Section 1362(a)(1) of the Code.

3.12. Environmental Matters. (a) To the Company’s Knowledge, there has been no disposal, release or threatened release of Hazardous Materials (as defined below) on, from, near or under the Leased Real Property that would be reasonably likely to form the basis of a material Environmental Claim against the Company, (b) no third party has used, generated, manufactured or stored on, under or about the Leased Real Property or transported to or from the Leased Real Property any Hazardous Materials in violation of applicable Environmental Laws, (c) there are no Environmental Claims pending or, to the Company’s Knowledge, threatened against the Company, (d) the Company is not subject to any Court Order, letter or memorandum by or with any Governmental Authority or Contract with any Person imposing any Liability under any Environmental Law; and (e) the Company has not retained or assumed, either contractually or by operation of law, any Liability or obligation that would reasonably be expected to have formed the basis of any Environmental Claim against the Company. For purposes of this Agreement, the terms “disposal,” “release” and “threatened release” shall have the definitions assigned thereto by the U.S. Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. Section 9601 et seq., as amended (“CERCLA”). For the purposes of this Section 3.12, “Hazardous Materials” shall mean any hazardous or toxic substance, material or waste which is regulated under, or defined as a “hazardous substance,” “pollutant,” “contaminant,” “toxic chemical,” “hazardous material,” “toxic substance” or “hazardous chemical” under any Environmental Law. “Environmental Law” shall mean all Applicable Laws relating to pollution or protection of human health or the environment, including, without limitation (i) CERCLA, (ii) the Emergency Planning and Community Right-to-Know Act, 42 U.S.C. Section 11001 et seq.; (iii) the U.S. Hazardous Materials Transportation Act, 49 U.S.C. Section 1801, et seq.; (iv) the U.S. Toxic Substances Control Act, 15 U.S.C. Section 2601 et seq.; (v) the U.S. Occupational Safety and Health Act of 1970, 29 U.S.C. Section 651 et seq.; and (vi) regulations promulgated under any of the above statutes.

3.13. Employee Benefits.

(a) Schedule 3.13(a) lists as of the date hereof all “employee benefit plans” (as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”)), and all other employee compensation and benefits plans, policies, programs, arrangements or payroll practices, including multiemployer plans within the meaning of Section 3(37) of ERISA, and each other stock purchase, stock option, restricted stock, severance, retention, employment, consulting, change-of-control, collective bargaining, bonus,

41

incentive, deferred compensation, employee loan, fringe benefit and any other benefit plan, agreement, program, policy, commitment or other arrangement, whether or not subject to ERISA (including any related funding mechanism now in effect or required in the future), whether formal or informal, oral or written, in respect of any present or former officers, directors, stockholders or other Workers of the Company or any of its ERISA Affiliates, in each case sponsored, maintained, contributed or required to be contributed to by the Company or any of its ERISA Affiliates or under which the Company or any of its ERISA Affiliates has any current or potential Liability (each a “Benefit Plan,” and collectively, the “Benefit Plans”). For each Benefit Plan, true and complete copies of, where applicable, (i) the three (3) most recent annual reports on Form 5500 (with schedules and attachments) and associated summary annual reports, (ii) the actuarial reports and results of all nondiscrimination tests for the last three (3) plan years, and (iii) any plan document (or, in the case of an unwritten Benefit Plan, a written description thereof), summary plan description (and any summaries of material modifications with respect thereto), trust agreement (and any other documents relating to the funding or payment of benefits under any Benefit Plan), employment agreement and other governing instrument, document or employee communication, have been delivered to Buyer as of the date hereof.

(b) No Benefit Plan is subject to Title IV or Section 302 of ERISA or Section 412 or 4971 of the Code. No Benefit Plan is a “multiple employer plan” as defined in Section 210(a) of ERISA or a “multiemployer plan” as defined in Section 3(37) of ERISA, and none of the Company or any ERISA Affiliate has withdrawn at any time from any multiemployer plan, or incurred any withdrawal Liability with respect to any multiemployer plan which remains unsatisfied, and no events have occurred and no circumstances exist that would reasonably be expected to result in any such Liability to the Company or any ERISA Affiliate.

(c) Each Benefit Plan has been established and administered in accordance with its terms, and in compliance in all material respects in accordance with the requirements of Applicable Law (including with the requirements of ERISA and the Code). All insurance premiums with respect to any of the Benefit Plans, and all contributions (including all employer contributions and employee salary reduction contributions) required to have been made under any of the Benefit Plans to any funds or trusts established thereunder or in connection therewith, have been made or paid by the due date thereof and all contributions or payments for any period ending on or before the Closing Date which are not yet due will have been paid or accrued prior to the Closing Date.

(d) Each Benefit Plan intended to qualify under Section 401(a) of the Code has obtained a favorable determination or opinion letter from the Internal Revenue Service (“IRS”) or may rely upon an opinion letter for a prototype plan and each such Benefit Plan has adopted all amendments necessary to comply with the Code on or before the remedial amendment period deadline specified for each such amendment pursuant to Section 401(b) of the Code or IRS promulgations. The Company has provided to Buyer a true and compete copy of the latest IRS determination or opinion letter with respect to each such Benefit Plan and nothing has since occurred that could cause the loss of such qualification or exemption and no such Benefit Plan has been operated in a manner which would reasonably be expected to cause it to be disqualified in operation. No Benefit Plan is or at any time was funded through a “welfare benefit fund” as defined in Section 419(e) of the Code, and no benefits under any Benefit Plan

42

are or at any time have been provided through a voluntary employees’ beneficiary association (within the meaning of Section 501(c)(9) of the Code) or a supplemental unemployment benefit plan (within the meaning of Section 501(c)(17) of the Code).

(e) No Benefit Plan has participated in, engaged in or been a party to any transaction that is prohibited under Section 4975 of the Code or Section 406 of ERISA (i) that is not exempt under Section 4975 of the Code or Section 408 of ERISA, respectively, or (ii) that could result in a material Liability to the Company or any ERISA Affiliate. With respect to any Benefit Plan, (i) neither the Company, nor any of its ERISA Affiliates has had asserted against it any material claim for taxes under Chapter 43 of Subtitle D of the Code and Section 5000 of the Code, or for material penalties under ERISA Sections 502(c), 502(i) or 502(l), nor, to the Company’s Knowledge, is there a basis for any such claim, and (ii) no officer, director or employee of the Company has committed a breach of any fiduciary responsibility or obligation imposed by Title I of ERISA that could result in a material Liability to the Company or any ERISA Affiliate. Other than routine claims for benefits, there is no claim or proceeding (including any audit or investigation) pending or, to the Company’s Knowledge, threatened, involving any Benefit Plan by any Person or any Governmental Authority.

(f) Schedule 3.13(f) sets forth a list as of the date hereof of all (i) employment agreements or letters with officers of the Company, (ii) agreements with consultants who are individuals obligating the Company to make, pursuant to which the Company has made, or pursuant to which it is reasonably likely that the Company will make, annual cash payments in an amount of fifty thousand dollars ($50,000) or more, (iii) Contracts, programs and policies of the Company under which the Company may be obligated to provide a Worker severance or any other compensation or benefits as a result of the transaction contemplated by this Agreement or upon termination of employment or any other relationship with the Company, (iv) plans, programs, agreements and other arrangements of the Company with or relating to its Workers that contain change in control provisions, and (v) all written agreements between the Company and any Worker of the Company and identifies each such Worker whose employment may be terminated on not less than three months notice without compensation. The Company has delivered to Buyer true and complete copies of all such agreements, plans, programs and other arrangements.

(g) Except as set forth on Schedule 3.13(g), neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will (either alone or in combination with another event) (i) result in any payment becoming due, or increase the amount of any compensation or benefits due, to any current or former Worker of the Company or with respect to any Benefit Plan; (ii) increase any benefits otherwise payable under any Benefit Plan; (iii) result in the acceleration of the time of payment or vesting of any such compensation or benefits; (iv) result in a non-exempt “prohibited transaction” within the meaning of Section 406 of ERISA or section 4975 of the Code; (v) result in the forgiveness in whole or in part of any outstanding loans made by the Company to any Person; or (vi) result in the payment of any amount that would, individually or in combination with any other such payment, not be deductible as a result of Section 280G of the Code.

43

(h) Except as set forth in Schedule 3.13(h), none of the Benefit Plans provide retiree health or life insurance benefits except as may be required by Section 4980B of the Code and Section 601 of ERISA or any other Applicable Law. There has been no violation of the “continuation coverage requirement” of “group health plans” as set forth in Section 4980B of the Code and Part 6 of Subtitle B of Title I of ERISA with respect to any Benefit Plan to which such continuation coverage requirements apply.

(i) Except as set forth in Schedule 3.13(i), the Company has reserved all rights necessary to amend or terminate each Benefit Plan without the consent of any other Person.

(j) Except as set forth in Schedule 3.13(j), no Benefit Plan or other contract between the Company and any “service provider” (within the meaning of Section 409A of the Code and the guidance issued thereunder) is a “nonqualified deferred compensation plan” within the meaning of Treasury Regulation section 1.409A-1(a)(1).

3.14. Compliance with Law. The operation of the business of the Company has been conducted in material compliance with all Applicable Laws, all Court Orders applicable to the Company or its business and all Permits required for the operation of the Company’s business. The Company has not received any notice to the effect that, or otherwise been advised that, it is not in compliance with any such Applicable Laws, Court Orders or Permits, and the Company does not know of any existing circumstances that are likely to result in violations of any of the foregoing.

3.15. Permits. Schedule 3.15 sets forth a complete list of all material Permits used in the operation of the Company’s business or otherwise held by the Company in connection with its business, all of which are valid and in full force and effect as of the date hereof, and accurate and complete copies of such Permits have been delivered to Buyer. The Company has all material Permits required in the operation of its business and to own, lease and operate its properties and assets, and such Permits are in full force and effect and are owned by the Company free and clear of all Encumbrances except Permitted Encumbrances. The Company is not in material Default, nor has it received any notice of any claim of Default, with respect to any such Permit. Such Permits will not be adversely affected by the completion of the transactions contemplated by this Agreement. No suspension or cancellation of any such Permits is pending or, to the Company’s Knowledge, threatened. To the Knowledge of the Company, no Governmental Authority is challenging the right of the Company to design, research, develop, pre-clinically or clinically test, manufacture, license, offer or sell any of its products or services.

3.16. Consents and Approvals. Except for the filing of notification, and expiration or early termination of the waiting period under, the HSR Act, as well as any required approval or notification under laws analogous to the HSR Act existing in foreign jurisdictions, no consent, approval or authorization of, or filing or registration with, any Governmental Authority or any other Person is required to be made, obtained or given by the Company in connection with the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated hereby.

44

3.17. Litigation. There is no action, suit, proceeding, claim, arbitration, audit of a Governmental Authority, criminal prosecution, unfair labor practice charge or complaint, examination or investigation (“Proceeding”) pending (or, to the Company’s Knowledge, threatened) against the Company, or relating to its activities, properties or assets or, to the Company’s Knowledge, against any officer, director or employee of the Company in connection with such officer’s, director’s or employee’s relationship with, or actions taken on behalf of, the Company. To the Company’s Knowledge, there is no factual or legal basis for any such Proceeding that would be reasonably expected to result in any such Proceeding that could result in material monetary damages or any equitable remedy. The Company is not a party to or subject to the provisions of any Court Order and there is no material Proceeding by the Company currently pending or which the Company intends to initiate.

3.18. Labor Matters.

(a) The Company is not bound by or subject to (and none of its assets or properties is bound by or subject to) any written or oral, express or implied, contract, collective bargaining agreement, commitment or arrangement with any labor union, and, to the Company’s Knowledge, no labor union has requested or has sought to represent any of the employees, representatives or agents of the Company, and no campaign is being conducted to solicit cards from employees of the Company by any labor union or labor organization.

(b) There is no strike, slowdown, work stoppage, lockout, or other labor dispute or union organizing activity, or any similar activity or dispute involving the Company, or, to the Company’s Knowledge, threatened. The Company has not, during the period from the Company’s inception through the date of this Agreement, received any material demand letters, civil rights charges, suits, drafts of suits, administrative or other claims from any of its employees.

(c) All individuals who are performing consulting or other services for the Company are correctly classified by the Company as either “independent contractors” or “employees” as the case may be and, at the Closing Date, will qualify for such classification with immaterial exceptions.

(d) The Company is in compliance in all material respects with all Applicable Laws respecting employment, termination of employment, employment practices, terms and conditions of employment, wages and hours, overtime, collective bargaining, employment discrimination, leaves of absence, immigration, civil rights, safety and health, workers’ compensation, pay equity, classification of employees, the collection and payment of withholding and/or social security Taxes, and other employment related Taxes. In addition, each Worker is in compliance with all applicable visa and work permit requirements. No visa or work permit held by a Worker will expire during the six month period beginning at the date of this Agreement.

(e) No claims, disputes, grievances, or controversies are pending or, to the Knowledge of the Company, threatened involving any Worker or group of Workers. No charges, investigations, administrative proceedings or formal complaints of discrimination (including discrimination based upon sex, age, marital status, race, national origin, sexual

45

orientation, disability or veteran status) are threatened or pending before the Equal Employment Opportunity Commission, the National Labor Relations Board, the U.S. Department of Labor, the U.S. Occupational Health and Safety Administration, the Workers Compensation Appeals Board, or any other Governmental Authority against the Company pertaining to any Worker.

(f) All employees of the Company are employed on an at-will basis, which means that their employment can be terminated at any time, with or without notice, for any reason or no reason at all. No employee of the Company has been granted the right to continued employment by the Company. Schedule 3.18(f) lists all employee manuals and handbooks, policy statements and agreements relating to the employment or other relationship of Workers with the Company as of the date of this Agreement and the Company has delivered to Buyer accurate and complete copies of the same.

(g) Schedule 3.18(g) sets forth an accurate and complete list of all (i) employees of the Company, including each employee’s name, title or position, present annual compensation (including bonuses, commissions and deferred compensation), accrued and unused paid vacation and other paid leave, years of service, interests in any incentive compensation plan, vested and unvested equity interests, and estimated entitlements to receive supplementary retirement benefits or allowances (whether pursuant to a contractual obligation or otherwise), (ii) individuals who are currently performing services for the Company who are classified as independent contractors, including the respective compensation of each consultant or independent contractor, and (iii) any employees or independent contractors of an Affiliate of the Company that perform services for the Company.

(h) The Company is in full compliance with the Worker Readjustment and Notification Act (the “WARN Act”) (29 U.S.C. §2101) and any applicable state laws or other Applicable Laws regarding redundancies, reductions in force, mass layoffs, and plant closings, including all obligations to promptly and correctly furnish all notices required to be given thereunder in connection with any redundancy, reduction in force, mass layoff, or plant closing to affected employees, representatives, any state dislocated worker unit and local government officials, or any other governmental authority. No reduction in the notification period under the WARN Act is being relied upon by the Company. Schedule 3.18(h) sets forth an accurate, correct and complete list of all employees terminated (except with cause, by voluntarily departure or by normal retirement), laid off or subjected to a reduction of more than 50% in hours or work during the three full calendar months preceding the date of this Agreement.

3.19. Intellectual Property.

(a) Schedule 3.19(a) sets forth a complete and accurate list of all (1) patents, patent applications and other rights granted by a Governmental Authority with respect to an invention issued or filed with any Governmental Authority, together with all reissues, divisions, continuations, continuations-in-part, revisions, extensions and reexaminations thereof, (2) trade names, common law trademarks, common law service marks, registered trademarks, registered service marks, and applications for trademark registration or service mark registration, (3) registered and unregistered copyrights and (4) domain name registrations and websites in each case owned, used or held for use by the Company in the conduct of its business, specifying as to each such item, as applicable (i) the owner(s) of the item, (ii) the jurisdictions in which the item is issued or registered or in which any application for issuance or registration has been filed, (iii) the respective issuance, registration, and application number of the item, and (iv) the date of application and issuance or registration of the item.

46

(b) Schedule 3.19(b) sets forth a complete and accurate list of all material licenses, sublicenses, consents and other agreements (whether written or otherwise) (i) pertaining to any Intellectual Property used by the Company in the conduct of its business, and (ii) by which the Company licenses or otherwise authorizes a third party to use, covenants not to sue under or grants an immunity from suit under any Intellectual Property of the Company. Neither the Company nor, to the Company’s Knowledge, any third party is in Default under any such license or other agreement in any material respect, and except as set forth on Schedule 3.19(b), each such license or other agreement is now and immediately following the Closing shall be in full force and effect. Any license, sublicense, consent or other agreement pertaining primarily to the development, manufacture, or use of Development Compounds is deemed “material” for purposes of this Section 3.19(b).

(c) To the Company’s Knowledge, the business operations of the Company do not and have not infringe(d), misappropriate(d) or otherwise violate(d) the Intellectual Property rights of any Person, or constitute unfair competition or trade practices under the laws of any jurisdiction. To the Company’s Knowledge, no Person has infringed, misappropriated or otherwise violated the Intellectual Property of the Company, and the Company has not filed or threatened in writing any claims alleging that a third party has infringed, misappropriated or otherwise violated any Intellectual Property of the Company. No third party has filed any or, to the Company’s Knowledge, threatened any claims alleging that the Company has infringed, misappropriated or otherwise violated any Person’s Intellectual Property rights. The Company has not given any indemnification, release or covenant to any third party against infringement, misappropriation or other violation of Intellectual Property of the Company. The Company has not requested (whether or not received) any opinion of patent counsel that concerns infringement, validity or enforceability of any Person’s patent that have not been disclosed to Buyer.

(d) Except as set forth thereon, all of the items listed in Schedule 3.19(a) are owned solely by the Company free and clear of all liens and encumbrances, and (i) are not the subject of any cancellation or reexamination proceeding or any other proceeding challenging their scope or validity, (ii) no opposition, extension of time to oppose, interference, rejection, or refusal to register has been filed in connection with any such application, (iii) to the Company’s Knowledge, are, as to registered patents and registered trademarks, valid and enforceable, and (iv) the ownership of the entire right, title and interest therein is recorded with the applicable Governmental Authority solely in the name of the Company. All fees, taxes, annuities and other payments associated with filing, prosecuting, issuing, recording, registering or maintaining any such Intellectual Property have been paid in full in a timely manner (including any permitted extensions) to the proper Governmental Authority, and except as set forth in Schedule 3.19(a), no such fees are due within the one year period following the date hereof. Except as set forth in Schedule 3.19(d), none of the Intellectual Property owned or controlled by the Company is the subject of any order, decree or injunction of any Governmental Authority, and the Company has not been the subject to any order, decree or injunction of any Governmental Authority in respect of any other Person’s Intellectual Property.

47

(e) None of the trade secrets or other material confidential or proprietary information of the Company has been disclosed to any Person unless such disclosure was necessary and made pursuant to an appropriate confidentiality agreement. To the Company’s Knowledge, there has not been any breach by any of the counterparties to any such agreement. The Company has taken commercially reasonable measures at least commensurate with those taken by similarly situated biotechnology companies to maintain the confidentiality of the trade secrets and other material confidential or other proprietary information and in each such case using not less than a reasonable degree of care under the circumstances.

(f) Except for any fees payable to a Governmental Authority to issue, register or maintain any of the Intellectual Property listed in Schedule 3.19(a) and for any payments required pursuant to a contract listed in Schedule 3.19(b), no payment of any kind is required to be made to any Person (including directors, officers, employees, consultants, contractors and agents of the Company) for the ownership or use of any Intellectual Property listed in Schedule 3.19(a). None of the Intellectual Property owned by the Company was developed with funding by any Governmental Authority and no Governmental Authority has any rights thereto.

(g) No Person has claimed any compensation from the Company for the loss of or unauthorized disclosure or transfer of personal data or information, and no facts or circumstances exist to the Company’s Knowledge that might give rise to such a claim.

3.20. Transactions with Certain Persons. No Related Party has or has had, either directly or indirectly, a material interest in: (a) any Person or entity which purchases from or sells, licenses or furnishes to the Company any goods, property, technology, intellectual or other property rights or (b) any Contract to which the Company is a party or by which it is bound or to which any of its properties or assets is subject. To the Knowledge of the Company, no event has occurred, and no circumstance or condition exists, that has resulted in, or would reasonably be expected to result in, any claim by an employee or director of the Company for indemnification or advancement of expenses related thereto pursuant to (i) the terms of the certificate of incorporation or bylaws of the Company, (ii) any indemnification agreement or other Contract between the Company and any such employee, or (iii) any Applicable Laws.

3.21. Insurance. Schedule 3.21 sets forth a complete and correct list of all insurance policies of the Company of any kind currently in force and also sets forth for each insurance policy the type of coverage, the name of the insureds, the insurer, the premium, the expiration date, the deductibles and loss retention amounts and the amounts of coverage. True, correct and complete copies of such insurance policies have been made available to Buyer. All such insurance policies are in full force and effect and insure the Company in reasonably sufficient amounts against normal risks usually insured against by persons operating similar businesses or properties of similar size in the localities where such businesses or properties are located. Such insurance policies are sufficient for compliance with Applicable Law and for compliance with any obligations under any Contract of the Company and are provided by reputable and nationally recognized insurers. The Company does not have any self-insurance or co-insurance programs. The Company is not in Default under any material provision of any such insurance policy and

48

the Company has not received notice of cancellation of any such insurance. No event relating specifically to the Company (as opposed to events affecting the pharmaceuticals industry in general) has occurred that is reasonably likely to result, after the date of this Agreement, in an increase in premiums under any insurance policies they maintain. To the Company’s Knowledge, no event has occurred, including the failure by the Company to give any notice or information or by giving any inaccurate or erroneous notice or information, which materially limits or impairs the rights of the Company under any such excess liability or protection and indemnity insurance policies.

3.22. Certain Business Practices. None of the directors, officers, agents or employees of the Company or any of their Affiliates has, in each case in connection with the Company’s business, (a) used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses, including expenses related to political activity, (b) made any unlawful payment to foreign or domestic government officials or employees or to foreign or domestic political parties or campaigns, made any bribes or kickback payments or violated any provision of the Foreign Corrupt Practices Act of 1977, as amended, (c) made any payment to any customer or supplier of the Company, or given any other consideration to any such customer or supplier in respect of the Company’s business that violates Applicable Law or (d) made any other unlawful payment.

3.23. No Brokers. Except as set forth on Schedule 3.23, none of the Company or any of its officers, directors or employees, has entered into nor will enter into any contract, agreement, arrangement or understanding with any broker, finder or similar agent or any Person which will result in an obligation of Buyer, the Company, or any of their respective Affiliates to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.

3.24. Books and Records. The Company has made and kept (and given Buyer access to) its true, correct and complete books and records and accounts, which, in reasonable detail, accurately and fairly reflect the activities of the Company. The minute books of the Company previously made available to Buyer accurately and adequately reflect in all material respects all action previously taken by the Stockholders, Board of Directors and committees of the Board of Directors of the Company. The copies of the stock book records of the Company previously made available to Buyer are true, correct and complete, and accurately reflect all transactions effected in the Equity Participations of the Company through and including the date hereof.

3.25. Bank Accounts. Schedule 3.25 contains a true, correct and complete list of all bank accounts maintained by the Company, including each account number and the name and address of each bank and the name of each Person who has signature power with respect to each such account or power of attorney to act on behalf of the Company.

3.26. FDA and Related Matters. (a) The Company has had no written or oral communications, including, but not limited to, Regulatory or Warning Letters and Section 305 Notices and similar letters or notices, with any Regulatory Authority. The Company is not subject to, and has not received notice of, any criminal, injunctive, seizure or civil penalty actions begun or threatened by any Regulatory Authority against the Company.

49

(b) The Company has no Knowledge (and has not been notified by a Company Partner) of any pending regulatory action of any sort (other than non-material routine or periodic inspections or reviews) against any of the Company or any Person that manufactures, develops or distributes Development Compounds or Development Products pursuant to a development, contract research, commercialization, manufacturing, supply or other collaboration arrangement with the Company (each, a “Company Partner”) by any Regulatory Authority. None of the Company or, to the Company’s Knowledge, any Company Partner, has committed or permitted to exist any material violation of the rules and regulations of any Regulatory Authority which has not been cured by the Company or, to the Company’s Knowledge, any Company Partner, or waived by the relevant Regulatory Authority.

(c) All Development Compounds and Development Products are being and have been developed, manufactured, used, processed, packaged, labeled, stored and tested by or on behalf of the Company in compliance in all material respects with all applicable requirements under all Applicable Laws. The Company is not conducting, and has not conducted, directly or through a Company Partner, any clinical trials of a Development Product. All preclinical trials conducted by or on behalf of the Company with respect to Development Compound and Development Products are being and have been conducted in compliance in all material respects with all Applicable Laws.

(d) None of the Company or, to the Company’s Knowledge, any of their respective agents or subcontractors, has been convicted of any crime or engaged in any conduct which could result in debarment or disqualification by any Regulatory Authority, and there are no proceedings pending or, to the Company’s Knowledge, threatened in writing that reasonably would reasonably be expected to result in criminal liability or debarment or disqualification by any Regulatory Authority.

(e) The Company has not marketed, sold, offered for sale, or distributed for sale any products. The Company does not have any information with respect to the safety or efficacy in humans of the Development Compounds or Development Products. The Company has not filed any INDs with respect to any Development Compounds.

(f) The Company has not received from any Regulatory Authority any (i) inspection reports, (ii) notices of adverse findings, warning, untitled letters, minutes of meetings or (iii) other correspondence from any Regulatory Authority concerning the Development Compounds or Development Products in which any Regulatory Authority asserted that the operations of the Company may not be in compliance with Applicable Laws or that Development Compounds or Development Products may not be safe, effective, or approvable.

(g) The Company has not received notice from any Company Partner of any material interruption of supply or manufacturing capacity, shortage of raw materials, components or other manufacturing problems that would have a material effect on the subsequent development (as such development is contemplated as of the date of this Agreement) of the Development Compounds or Development Products, nor to the Company’s Knowledge do any conditions exist that reasonably could be expected to lead to such manufacturing problems.

50

3.27. State Takeover Statutes. The Board of Directors of the Company has taken all action necessary to ensure that any restrictions on business combinations contained in the DGCL will not apply to the transactions contemplated hereby. No other “fair price”, “moratorium”, “control share acquisition” or other similar anti-takeover statute or regulation or any anti-takeover provision in the Company’s certificate of incorporation or bylaws is, or at the Closing will be, applicable to the Company, the Common Stock, the Preferred Stock, or the transactions contemplated by this Agreement.

3.28. Disclosure. This Agreement (including the Company Disclosure Schedule) does not, and none of the certificates delivered to Buyer in connection with the transactions contemplated hereby will, (i) contain any representation, warranty or information that is false or misleading with respect to any material fact, or (ii) omit to state any material fact necessary in order to make the representations, warranties and information contained and to be contained herein and therein (in the light of the circumstances under which such representations, warranties and information were or will be made or provided) not false or misleading. The Company makes no representations or warranties to Buyer regarding any projection or forecast regarding future results or activities or the probable success or profitability of the Company.

ARTICLE IV.

REPRESENTATIONS AND WARRANTIES EACH SELLER

Each Seller represents and warrants to Buyer, severally and not jointly, as to itself that the statements contained in this Article IV are true and correct as of the date hereof and as of the Closing (unless the particular statement speaks expressly as of a particular date, in which case it is true and correct only as of such date):

4.1. Organization of Certain Sellers. If such Seller is a corporation, limited liability company, limited partnership or trust or other entity, it is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization.

4.2. Authorization. Such Seller, and if such Seller is a trust, the trustee of such Seller, has the requisite power and authority to execute and deliver this Agreement, to perform his, her or its obligations hereunder, to own, hold, sell and transfer pursuant to this Agreement the Shares owned by such Seller and to consummate the transactions contemplated hereby. This Agreement and the performance by such Seller of its obligations hereunder have been duly authorized by all requisite action on the part of such Seller. This Agreement has been duly executed and delivered by such Seller and, assuming this Agreement constitutes the valid and binding obligation of the other Parties hereto, constitute the legal, valid and binding obligations of such Seller, enforceable against such Seller in accordance with their terms, except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights generally and except insofar as the availability of equitable remedies may be limited by Applicable Law.

51

4.3. No Conflict; Required Filings and Consents.

(a) The execution, delivery and performance of and compliance with this Agreement and the consummation of the transactions contemplated hereby will not (i) if such Seller is an entity conflict with, or result in any violation or breach of, any provision of the certificate or articles of incorporation, bylaws, limited liability or operating agreement, partnership agreement, trust agreement or similar organizational documents of such Seller, or (ii) assuming the consents and approvals referred to in Section 3.16 are duly obtained, result in a violation of, or be in conflict with or constitute, with or without the passage of time or the giving of notice or both, a Default under, result in a violation of, or conflict with any Applicable Laws, Court Orders or Permits applicable to such Seller or (iii) violate, conflict with, result in a material Default under, or give to any Person any rights of termination or acceleration under any Contract of such Seller, or result in the creation of any Encumbrance (other than a Permitted Encumbrance) upon any of the properties, assets or Equity Participations of the Company.

(b) No consent, approval, order or authorization of, or registration, declaration or filing with, any Governmental Authority is required by such Seller in connection with the execution and delivery of this Agreement or the consummation by such Seller of the transactions contemplated hereby.

4.4. No Brokers. Such Seller has not entered into nor will enter into any contract, agreement, arrangement or understanding with any broker, finder or similar agent or any Person which will result in an obligation of Buyer, the Company, or any of their respective Affiliates to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.

4.5. The Shares.

(a) Such Seller holds of record and owns beneficially the number of Shares, Company Options, Company Warrants and Company Notes, set forth opposite such Seller’s name on the Initial Allocation Schedule free and clear of any Encumbrances and as of the Closing Date will own of record and beneficially the number of Shares set forth opposite such Seller’s name on the Closing Allocation Schedule free and clear of any Encumbrances. Such Seller is not party to any Contract (other than this Agreement) obligating such Seller to sell, transfer, pledge or otherwise dispose of any Company Capital Stock or other Equity Participations of the Company. Except as set forth in Schedule 4.5, there is no Contract of such Seller:

(i) with respect to the sale or transfer of Equity Participations of the Company;

(ii) with respect to the voting of any Equity Participations of the Company;

(iii) granting any preemptive right, right of participation, right of maintenance or any similar right with respect to the Equity Participations of the Company;

(iv) granting any right of first refusal or similar right; or

52

(v) relating to the registration of, or restricting any Person from purchasing, selling, pledging or otherwise disposing of (or granting any option or similar right with respect to), any Equity Participations of the Company.

(b) Upon the Closing, Buyer will own all of such Seller’s Equity Participations of the Company free and clear of all Encumbrances, other than Encumbrances created by Buyer or arising out of the ownership of the Shares by Buyer.

ARTICLE V.

REPRESENTATIONS AND WARRANTIES OF BUYER

Buyer hereby represents and warrants to the Company that:

5.1. Organization. Buyer is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware with full power and authority to conduct its business as it is presently being conducted, and to own, lease or operate, as applicable, its assets and properties, and to perform all its obligations under its contracts. Buyer is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction where the character of its properties owned, leased or operated or the nature of its activities make such qualification necessary. Buyer is not in violation of its certificate of incorporation or bylaws.

5.2. Authorization. Buyer has all requisite power and authority, and has taken all action necessary, to execute, deliver and perform this Agreement, to consummate the transactions contemplated hereby and to perform its obligations hereunder. The execution and delivery of this Agreement and the consummation by Buyer of the transactions contemplated hereby have been duly approved Board of Directors of Buyer and no other proceeding on the part of Buyer is necessary to authorize this Agreement and the transactions contemplated hereby. This Agreement has been duly executed and delivered by Buyer and is the legal, valid and binding obligation of Buyer, enforceable against Buyer in accordance with its terms except as enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other laws affecting creditors’ rights generally and except insofar as the availability of equitable remedies may be limited by Applicable Law.

5.3. Compliance with Other Instruments. The execution, delivery and performance of and compliance with this Agreement and the consummation of the transactions contemplated hereby will not (i) result in a violation of, or be in conflict with or constitute a violation of, the certificate of incorporation or bylaws of Buyer, or (ii) assuming the consents and approvals referred to in Section 5.4 are duly obtained, result in a violation of, or be in conflict with or constitute, with or without the passage of time or the giving of notice or both, a Default under, result in a violation of, or conflict with any Applicable Laws, Court Orders or Permits applicable to Buyer, except for any such violation or Default which would not materially affect Buyer’s ability to perform any of its obligations hereunder or the consummation of the transactions contemplated by this Agreement.

53

5.4. Consents and Approvals. Except for the filing of notification, and expiration or early termination of the waiting period under, the HSR Act, as well as any required approval or notification under laws analogous to the HSR Act existing in foreign jurisdictions, no consent, approval or authorization of, declaration to, or filing or registration with, any Governmental Authority, or any other Person, is required to be made or obtained by Buyer in connection with the execution, delivery and performance by Buyer of this Agreement and the consummation of the transactions contemplated hereby.

5.5. Litigation. There are no Proceedings pending, or to the knowledge of Buyer, threatened against or affecting Buyer which has or might be reasonably expected to materially affect Buyer’s ability to perform any of its obligations hereunder or the consummation of the transactions contemplated by this Agreement.

5.6. No Brokers. Neither Buyer nor any of its respective partners, Representatives or Affiliates has entered into or will enter into any contract, agreement, arrangement or understanding with any broker, finder or similar agent or any Person which will result in the obligation of the Company or the Stockholders to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.

5.7. Available Funds. Buyer will have available to it as of the Closing all funds necessary for the payment to the Paying Agent of the Closing Payment Amount plus the Bonus Amount.

ARTICLE VI.

ADDITIONAL AGREEMENTS

6.1. Conduct of Business by the Company.

(a) Ordinary Course. During the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing, the Company shall (i) carry on its business in the Ordinary Course and in material compliance with all Applicable Law and (ii) use commercially reasonable efforts to preserve intact its present business organization, including the services of its key employees and the goodwill of its customers, lenders, distributors, suppliers, regulators and other Persons with whom it has business relationships.

(b) Required Consent. In addition, without limiting the generality of Section 6.1(a), without the prior written consent of Buyer, during the period from the date hereof and continuing until the earlier of the termination of this Agreement pursuant to its terms or the Closing, the Company shall not do any of the following:

(i) propose or adopt any amendments to the certificate of incorporation and bylaws of the Company;

(ii) adopt a plan of complete or partial liquidation or dissolution;

(iii) form a Subsidiary;

54

(iv) declare, set aside or pay any dividends on or make any other distributions (whether in cash, stock, equity securities or property) in respect of any Equity Participations;

(v) (A) adjust, split, combine or reclassify or otherwise amend the terms of the Company Capital Stock or authorize the issuance of any Equity Participations in respect of, in lieu of or in substitution for any Company Capital Stock, or (B) purchase, redeem or otherwise acquire, directly or indirectly, any Equity Participations, except for purchases, redemptions or other acquisitions of capital stock or other securities required under the terms of the plans, arrangements or contracts existing on the date hereof between the Company and any director, employee or consultant of the Company;

(vi) issue, deliver, grant, sell, authorize, pledge or otherwise encumber any Equity Participations, or subscriptions, rights, warrants or options to acquire any Equity Participations, or enter into other agreements or commitments of any character obligating it to issue any such Equity Participations, other than issuances of Common Stock upon the exercise of Company Options, Company Notes, Company Warrants or Preferred Stock outstanding on the date hereof in accordance with their terms or any agreement to which the Company is a party in effect as of the date hereof, each of which agreements have been disclosed to Buyer;

(vii) acquire or agree to acquire by merging or consolidating with, or by purchasing any Equity Participation or voting interest in or any assets of, or by any other manner, any business or any Person or division thereof, or otherwise acquire or agree to acquire any assets;

(viii) sell, lease or otherwise dispose of assets, including by merger, consolidation, asset sale or other business combination, except payment of invoices in the Ordinary Course of Business;

(ix) mortgage or pledge any of its assets (tangible or intangible), or create, assume or suffer to exist any Encumbrances thereupon other than Permitted Encumbrances;

(x) make any loans, advances or capital contributions to, or investments in, any other Person, which, individually, are not in excess of $5,000 and, in the aggregate, are not in excess of $25,000;

(xi) except as required by GAAP, make any material change in its methods or principles of accounting since the date of the last audited Financial Statements;

(xii) make or change any material election, change an annual accounting period, adopt or change any material accounting method, file any material amended Tax Return, enter into any closing agreement, settle any material Tax claim or assessment relating to the Company, or consent to any extension or waiver of the limitation period applicable to any material Tax claim or assessment relating to the Company, in each case if such election, adoption, change, amendment, agreement, settlement, surrender, consent or other action would have the effect of increasing the Tax Liability of the Company for any period ending after the Closing Date;

55

(xiii) revalue any of its assets other than in the Ordinary Course of Business;

(xiv) except as required by Applicable Law, Benefit Plans or Material Contracts binding on the Company as of the date hereof, (A) increase in any manner the amount of compensation or fringe benefits of, pay any bonus to or grant severance or termination pay to any Worker or any director of the Company, (B) make any increase in or commitment to increase, in any material respect, any benefits provided under any Benefit Plan (including any severance plan), adopt or amend or make any commitment to adopt or amend any Benefit Plan or make any contribution, other than regularly scheduled contributions, to any Benefit Plan, (C) waive any stock repurchase rights, accelerate, amend or change the period of exercisability of Company Options, (D) hire any employee at the level of vice president or above (or performing functions typically associated with an employee at the level of vice president or above) or with an annual base salary or severance in excess of $50,000, (E) enter into any employment, severance, termination or indemnification agreement with any executive officer or director of the Company or enter into any collective bargaining agreement, (F) grant any stock appreciation right, phantom stock award, stock-related award or performance award (whether payable in cash, shares or otherwise) to any Person (including any employee of the Company), or (G) enter into any agreement with any employee of the Company the benefits of which are (in whole or in part) contingent or the terms of which are materially altered upon the occurrence of a transaction involving the Company of the nature contemplated hereby;

(xv) grant any rights with respect to any Intellectual Property of the Company other than non-exclusive licenses to third party consultants and vendors in the Ordinary Course;

(xvi) enter into any written, oral or other agreement, contract, subcontract, settlement agreement, license, sublicense, or other legally binding commitment containing any non-competition or exclusivity restrictions on the Company;

(xvii) enter into any agreement or commitment the effect of which would be to grant to a third party following the Closing any license to any material Intellectual Property owned by Buyer or any of its Subsidiaries (other than the Company);

(xviii) disclose any of the Company’s material trade secrets outside of an appropriate confidentiality agreement;

(xix) incur any indebtedness for borrowed money or guarantee any such indebtedness of another Person, issue or sell any debt securities, warrants, calls or other rights to acquire any debt securities of the Company, guarantee any debt securities of another Person, enter into any “keep well” or other agreement to maintain any financial statement condition of any other Person (other than any wholly-owned Subsidiary of it) or enter into any arrangement having the economic effect of any of the foregoing, other than in connection with the financing of Ordinary Course trade payables or in connection with any agreement to which the Company is a party in effect as of the date hereof and which has been disclosed to Buyer;

56

(xx) make or commit to make capital expenditures in excess of an aggregate of $10,000 or fail to pay its obligations or satisfy its Liabilities as the same become due and payable;

(xxi) modify, amend or terminate any Material Contract currently in effect, or waive, release or assign any material rights or claims thereunder, other than renewals of contracts with contract research organizations existing as of the date of this Agreement in the Ordinary Course of Business;

(xxii) (A) waive, release, assign, settle or compromise any dispute, claim, suit, action or Proceeding, other than waivers, releases, assignments, settlements or compromises in the Ordinary Course of Business that involve only the payment of monetary damages not in excess of $50,000 individually or $250,000 in the aggregate, in any case without the imposition of equitable relief or any restrictions on the business and operations of, on, or the admission of any wrongdoing by, the Company, or (ii) commence a Proceeding;

(xxiii) enter into any Contract that, if entered into prior to the date hereof, would be a Material Contract required to be set forth on Schedule 3.7(a), other than in the Ordinary Course of Business in connection with contracts with contract research organizations or pursuant to any agreement to which the Company is a party in effect as of the date hereof and which has been disclosed to Buyer; or

(xxiv) agree in writing or otherwise to take any of the actions described in (i) through (xxiii) above.

6.2. Confidentiality; Access to Information; No Modification of Representations, Warranties or Covenants.

(a) Confidentiality.

(i) The Parties acknowledge that the Company and Buyer have previously executed a Non-Disclosure Agreement dated as of July 30, 2009 (as amended, the “Confidentiality Agreement”), which Confidentiality Agreement shall continue in full force and effect in accordance with its terms and each of Buyer and the Company shall hold, and shall cause its respective directors, officers, employees of the Company, agents and advisors (including attorneys, accountants, consultants, bankers and financial advisors) to hold, any information regarding the other Party confidential in accordance with the terms of the Confidentiality Agreement.

(ii) Until the date that is five years after the Closing, the Equityholders and the Equityholder Representative agree to, and shall cause their Affiliates and Representatives to: (a) treat and hold as confidential (and not disclose or provide access to any Person) all information relating to trade secrets, processes, patent applications, product development, price, customer and supplier lists, pricing and marketing plans, policies and strategies, details of Contracts, operations methods, product development techniques and all other confidential or proprietary information with respect to the Company, (b) in the event that a Equityholder or any of its Affiliates or Representatives becomes legally compelled to disclose any such information,

57

provide Buyer with prompt written notice of such requirement so that Buyer may seek a protective order or other remedy or waive compliance with this Section 6.2(a)(ii), and (c) in the event that such protective order or other remedy is not obtained, or Buyer waives compliance with this Section 6.2(a)(ii), furnish only that portion of such confidential information that is legally required to be provided and exercise its commercially reasonable efforts to obtain assurances that confidential treatment will be accorded such information; provided, however, that this sentence shall not apply to any information that (x) at the time of disclosure, is available publicly and was not disclosed in breach of this Agreement by a Equityholder or its Affiliates or Representatives, (y) is made available to the Equityholder or its Affiliates or Representatives by any third party which, to such Equityholder’s, Affiliate’s or Representative’s knowledge, does not have an obligation of confidentiality to Buyer or (z) was permitted to be disclosed with Buyer’s prior written consent; and provided further that, with respect to Intellectual Property of the Company, specific information shall not be deemed to be within the foregoing exception merely because it is embraced in general disclosures in the public domain. In addition, with respect to Intellectual Property of the Company, any combination of features shall not be deemed to be within the foregoing exception merely because the individual features are in the public domain unless the combination itself and its principle of operation are in the public domain.

(b) Access to Information. The Company shall, upon reasonable prior notice, afford Buyer and Buyer’s accountants, counsel and other Representatives reasonable access during normal business hours to its properties, books, records, personnel and Representatives during the period prior to the Closing to obtain all information concerning its business, including the status of product development efforts, properties, results of operations and personnel for purposes of this Agreement, as Buyer may reasonably request; provided, however, that the Company may restrict the foregoing access to the extent that (i) any Applicable Law, treaty, rule or regulation of any Governmental Authority applicable to such Party requires such Party to restrict or prohibit access to any such properties or information, or (ii) such access would be in breach of any confidentiality obligation, commitment or provision by which the Company is bound or affected, which confidentiality obligation, commitment or provision shall be disclosed to Buyer, provided that disclosure of such obligation, commitment or provision would not itself be the breach of an obligation or commitment to a third party. In addition, any information obtained from the Company pursuant to the access contemplated by this Section 6.2(b) shall be subject to the Confidentiality Agreement.

(c) No Modification of Representations and Warranties or Covenants. No information or knowledge obtained in any investigation or notification of a Party shall affect or be deemed to modify any representation or warranty contained herein, the covenants or agreements of the Parties hereto or the conditions to the obligations of the Parties hereto under this Agreement.

6.3. Public Disclosure. Without limiting any other provision of this Agreement, Buyer and the Company shall consult with each other before issuing, and provide each other the opportunity to review, comment upon and concur with, and agree on any press release or public statement with respect to this Agreement and the transactions contemplated hereby, and shall not issue any such press release or make any such public statement prior to such consultation and agreement, except as may be required by Applicable Law, provided that Buyer may make public

58

statements or disclosures that are not inconsistent with previous press releases, public disclosures or public statements made by Buyer and/or the Company in compliance with this Section 6.3. The Parties have agreed to the text of the joint press release announcing the execution of this Agreement.

6.4. Regulatory Filings; Reasonable Efforts.

(a) Regulatory Filings. Each of Buyer and the Company shall coordinate and cooperate with one another and shall each use commercially reasonable efforts to comply with, and shall each refrain from taking any action that would impede compliance with, all Applicable Laws, and as promptly as practicable after the date hereof, Buyer and the Company shall make all filings, notices, petitions, statements, registrations, submissions of information, application or submission of other documents required by any Governmental Authority, including (i) notification and report forms with the United States Federal Trade Commission and the Antitrust Division of the United States Department of Justice as required by the HSR Act and (ii) any other filings necessary to satisfy the closing condition set forth in Section 8.1(b), in connection with the transactions contemplated hereby. Each of Buyer and the Company shall cause all documents that it is responsible for filing with any Governmental Authority under this Section 6.4(a) to comply in all material respects with all Applicable Law.

(b) Exchange of Information. Buyer and the Company each shall promptly supply the other with any information which may be required in order to effectuate any filings or application pursuant to Section 6.4(a). Subject to Applicable Law relating to the exchange of information, the Confidentiality Agreement, and the preservation of any applicable attorney-client privilege, work-product doctrine, self-audit privilege, or other similar privilege, each of the Company and Buyer shall use commercially reasonable efforts to collaborate in reviewing and commenting on in advance, and to consult the other on, information relating to the Company, Buyer or any of its Subsidiaries, that appears in any filing made with, or written materials submitted to, any third party and/or any Governmental Authority in connection with any filing, investigation, or proceeding in connection with this Agreement or the transactions contemplated hereby (including under any antitrust or fair trade Applicable Law), provided that neither Party shall be required to provide the other with access to any competitively sensitive document that would be required to be provided in response to Item 4(c), and Buyer shall not be required to provide the Company with revenue information provided in response to Item 5, of any HSR Act filing (whether or not such filing is made). In connection with such collaboration, each of the Company and Buyer shall act reasonably and as promptly as practicable.

(c) Notification. Each of Buyer and the Company shall notify the other promptly upon the receipt of: (i) any comments from any officials of any Governmental Authority in connection with any filings made pursuant hereto and (ii) any request by any officials of any Governmental Authority for amendments or supplements to any filings made pursuant to, or information provided to comply in all material respects with, any Applicable Law. Whenever any event occurs that is required to be set forth in an amendment or supplement to any filing made pursuant to Section 6.4(a), Buyer or the Company, as the case may be, shall promptly inform the other of such occurrence and cooperate in filing with the applicable Governmental Authority such amendment or supplement.

59

(d) Reasonable Efforts. Upon the terms and subject to the conditions set forth herein, each of the Parties agrees to use commercially reasonable efforts to take, or cause to be taken, all reasonable actions, and to do, or cause to be done, and to assist and cooperate with the other Parties in doing, all things reasonably necessary, proper or advisable to consummate the transactions contemplated by this Agreement, including using commercially reasonable efforts to accomplish the following: (i) the taking of all reasonable acts necessary to cause the conditions precedent set forth in Article VIII to be satisfied; (ii) the obtaining of all necessary actions or nonactions, waivers, consents, approvals, orders and authorizations from Governmental Authorities and the making of all necessary registrations, declarations and filings with any Person (including registrations, declarations and filings with Governmental Authorities, if any); (iii) the obtaining of all necessary consents, approvals or waivers from third parties, including all necessary consents (provided, that the Parties shall discuss in good faith procedures to pursue third party consents with respect to the transactions contemplated hereby) (it being understood that failure to obtain any one or more such consents, in and of itself, shall not constitute a failure by the Company to comply with any of its covenants herein or a failure of a condition to Closing hereunder); (iv) the defending of any suits, claims, actions, investigations or proceedings, whether judicial or administrative, challenging this Agreement or the consummation of the transactions contemplated hereby (other than any suits, claims, actions, investigations or proceedings brought by a Governmental Authority); and (v) the execution or delivery of any additional instruments necessary to consummate the transactions contemplated by, and to fully carry out the purposes of, this Agreement. Notwithstanding anything herein to the contrary, neither Buyer nor any of its Affiliates shall be under any obligation to, nor, without Buyer’s prior written consent (which consent may be withheld in Buyer’s sole discretion), shall the Company, (A) make proposals, execute, agree or consent to or carry out agreements or submit to any Court Order or other injunction, ruling or decree of any Governmental Authority (1) providing for the sale or other disposition or holding separate of any assets of Buyer, any of its Affiliates or Subsidiaries (including, after the Closing, the Company) or any of their Affiliates, or the Company or the holding separate of any capital stock of any such Person, or imposing or seeking to impose any limitation on the ability of Buyer or any of its Affiliates, to own such assets or to acquire, hold or exercise full rights of ownership of capital stock of the Company, or (2) imposing or seeking to impose (x) any limitation whatsoever on the business activities of Buyer or any of its Affiliates or (y) any limitation on the business activities of the Company, or (B) otherwise take any step to avoid or eliminate any impediment which may be asserted or requested under any Applicable Law governing competition, monopolies or restrictive trade practices.

6.5. Notification of Certain Matters.

(a) By the Company. The Company shall promptly after obtaining Knowledge of such matter notify Buyer of any representation or warranty made by it contained in this Agreement becoming untrue or inaccurate, or any failure of the Company to comply with or satisfy in any material respect any covenant, condition or agreement to be complied with or satisfied by it under this Agreement, in each case, such that the conditions set forth in Section 8.3(a) or 8.3(b) would not be satisfied; provided, however, that the delivery of any notice pursuant to this Section 6.5(a) shall not limit or otherwise affect the remedies available hereunder to Buyer or the representations, warranties or covenants of the Company or the conditions to the obligations of Buyer.

60

(b) By Buyer. Buyer shall promptly after obtaining knowledge of such matter notify the Company of any representation or warranty made by it contained in this Agreement becoming untrue or inaccurate, or any failure of Buyer to comply with or satisfy in any material respect any covenant, condition or agreement to be complied with or satisfied by it under this Agreement, in each case, such that the conditions set forth in Section 8.2(a) or 8.2(b) would not be satisfied; provided, however, that the delivery of any notice pursuant to this Section 6.5(b) shall not limit or otherwise affect the remedies available hereunder to the Company or the representations, warranties or covenants of Buyer or the conditions to the obligations of the Company.

6.6. No Solicitation. (a) From the date of this Agreement until the earlier of (i) the Closing and (ii) the termination of this Agreement pursuant to Section 10.1, the Company agrees that neither it nor any of its Representatives, Affiliates, agents, officers or directors nor any Persons acting on behalf of the Company shall, directly or indirectly:

(i) initiate, solicit or encourage (including by way of providing information) or facilitate any inquiries, proposals or offers with respect to, or the making, announcement, submission or the completion of, an Acquisition Proposal;

(ii) participate or engage in any discussions or negotiations with, or furnish or disclose any non-public information relating to the Company, or otherwise cooperate with, facilitate or assist any Person in connection with an Acquisition Proposal;

(iii) approve, endorse or recommend any Acquisition Proposal;

(iv) enter into any letter of intent, agreement in principle, merger agreement, acquisition agreement, option agreement or other similar agreement relating to an Acquisition Proposal; or

(v) resolve, propose or agree to do any of the foregoing.

(b) The Company shall, and shall cause each of its Representatives, Affiliates, agents, officers or directors to, immediately cease any existing solicitations, discussions or negotiations with any Person (other than the Parties hereto) that has made or indicated an intention to make an Acquisition Proposal. The Company shall promptly request that each Person who has executed a confidentiality agreement with the Company in connection with such Person’s consideration of an Acquisition Proposal (other than the Parties hereto and their respective advisors) return or destroy all non-public information furnished to that Person by or on behalf of the Company. The Company shall promptly inform its Representatives, Affiliates, agents, officers or directors of the Company’s obligations under this Section 6.6. Any violation of or by any Representatives, Affiliates, agents, officers or directors of the Company shall be deemed to be a breach of this by the Company.

61

(c) The Company shall notify Buyer promptly (and in any event within twenty-four (24) hours) upon receipt by it or any of its Representatives of (i) any Acquisition Proposal or indication by any Person that it is considering making an Acquisition Proposal, (ii) any request for non-public information relating to the Company other than requests for information in the Ordinary Course of Business and unrelated to an Acquisition Proposal or (iii) any inquiry or request for discussions or negotiations regarding any Acquisition Proposal. The Company shall notify Buyer promptly (and in any event within twenty-four (24) hours) with the identity of such Person and a copy of such Acquisition Proposal, indication, inquiry or request (or, where no such copy is available, a description of such Acquisition Proposal, indication, inquiry or request), including any modifications thereto.

6.7. Takeover Statutes. If any takeover statute is or becomes applicable to this Agreement or the transactions contemplated by this Agreement, each of Buyer, the Company and their respective Boards of Directors shall (a) take all necessary action to ensure that such transactions may be consummated as promptly as practicable upon the terms and subject to the conditions set forth in this Agreement and (b) otherwise act to eliminate or minimize the effects of such takeover statute.

6.8. Closing Date Allocation Schedule. At least three (3) Business Days prior to the Closing, the Company shall deliver to Buyer the Closing Date Allocation Schedule, and thereafter through the Closing any interim updates to the Closing Date Allocation Schedule as necessary for the information reflected thereon to be accurate in all respects as of the Closing Date.

ARTICLE VII.

POST-CLOSING COVENANTS OF ALL PARTIES

7.1. Indemnification of Directors and Officers.

(a) [****]

(b) [****]

(c) [****]

(d) [****]

(e) [****]

7.2. Tax Matters.

(a) Cooperation. Without limiting any of the other provisions of this Section 7.2, the Parties shall cooperate fully, as and to the extent reasonably requested by any of them, in connection with the filing of Tax Returns pursuant to this Agreement and any audit, litigation or other proceeding with respect to Taxes. In this regard, the Buyer shall retain all books and records with respect to Tax matters of the Company which are or may be pertinent to any Tax

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

62

period beginning before the Closing Date until the expiration of the applicable statute of limitations and shall make them available to the Equityholder Representative in connection with any audit of the Company which could give rise to an indemnification obligation of any of the Equityholders. Promptly following Buyer’s request, the Equityholder Representative shall provide Buyer with any information that is available to it which is necessary for the preparation of any required statement to be furnished to the Equityholders or Tax Return to be filed by Buyer pursuant to Section 6043A of the Code, the regulations promulgated thereunder or the form prescribed by the United States Secretary of the Treasury thereunder.

(b) Transfer Taxes. All transfer, documentary, sales, use, stamp, registration and other such Taxes, and all conveyance fees, recording charges and other fees and charges (including any penalties and interest) incurred in connection with consummation of the transactions contemplated by this Agreement, if any, shall be borne and paid 50% by Buyer and 50% shall be deemed to be Transaction Expenses. The Equityholder Representative or Buyer (as required by Applicable Law) shall prepare and timely file all Tax Returns required to be filed in respect of any such Taxes.

(c) Tax Returns.

(i) The Equityholder Representative shall prepare all income Tax Returns of the Company for any Tax period ending on or before the Closing Date that are due before the Closing Date and shall submit a copy of such Tax Return to Buyer for review and approval at least thirty (30) days before the due date for filing such Tax Return. Such Tax Returns shall be prepared consistently with past practice.

(ii) Buyer, at its own expense (which expense, for the avoidance of doubt, shall not be subject to indemnification by the Equityholders) shall prepare all Tax Returns of or relating to the Company for the Straddle Period that are due after the Closing consistently with past practice and shall provide a copy of each such Tax Return to the Equityholder Representative at least thirty (30) days before the due date for filing such Tax Return for the Equityholder Representative’s review and approval. With respect to Tax Returns relating to any Tax period ending on or before the Closing Date or relating to any Straddle Period, Buyer shall consider in good faith all reasonable written comments made by the Equityholder Representative with respect to such Tax Returns and such Tax Returns shall be filed as finally prepared by Buyer.

(d) Tax Refunds. All refunds of Taxes of the Company for any Pre-Closing Tax Period received or realized after the Closing Date (including any such amounts that could have been refunded but are credited against Taxes for a Post-Closing Tax Period in lieu of being refunded) shall be for the Equityholders’ account (the “Tax Refund Amount”) and shall be paid to the Equityholder Representative for distribution to the Equityholders within five (5) days of receipt, except to the extent such refunds were reflected as an asset in the calculation of Closing Date Net Working Capital.

63

(e) Tax Claims. Buyer shall promptly inform the Equityholder Representative of the receipt by Buyer or its Affiliates (including the Company after the Closing) of notice of any audit, claim, inquiry, examination or other proceeding relating to Taxes with respect to which Buyer intends to seek indemnification under Article IX (a “Tax Claim”). The Equityholders shall not be relieved of their indemnification obligations hereunder if such notice is not delivered promptly except to the extent the Equityholders are materially prejudiced thereby. The Equityholder Representative shall have the right to control the conduct, defense and settlement or compromise of any Tax Claim relating to a Tax period ending on or before the Closing Date. Buyer shall execute, or cause the Company to execute, any such powers of attorney or other documents that may be required to give effect to the prior sentence. If the Equityholder Representative does not elect to control the conduct of such Tax Claim, Buyer shall have the right to control such Tax Claim, provided, however, that Buyer shall keep the Equityholder Representative fully informed of the progress of such Tax Claim, permit the Equityholder Representative to participate in the conduct of the defense of such Tax Claim and shall not settle or compromise such Tax Claim without the Equityholder Representative’s prior written consent. Notwithstanding anything in Article IX to the contrary, this Section 7.2(e), and not Section 9.4, shall govern the conduct of Tax Claims.

7.3. Employee Benefits.

(a) Offers of Employment. No less than five (5) days prior to the Closing, Buyer shall use commercially reasonable efforts to extend a written offer of employment with Buyer, a Subsidiary of Buyer or the Company to each employee set forth on Schedule C (“Continuing Employees”), effective on the Closing. Each such written offer of employment shall include (i) the same or superior base salary or base wage rate as provided to such Company employee by the Company as of immediately prior to the Closing, (ii) cash bonus and other incentive compensation opportunities substantially similar in the aggregate as those provided to similarly situated employees of Buyer and (iii) an appropriate retention bonus to be paid by Buyer upon the treatment of the first human patient with a PARP Development Compound or PARP Development Product in a clinical study. Nothing in this subsection (a), expressed or implied, shall confer upon any of the Continuing Employees any right to employment or continued employment for any specified period, of any nature or kind whatsoever under or by reason of this Agreement and the employment of all the Continuing Employees shall remain “at will.” Subject to Applicable Law, prior to the Closing, the Company shall take all necessary actions to terminate the employment of all employees of the Company, effective as of immediately prior to the Closing, other than the Continuing Employees. Consistent with the requirements set forth in Code Section 4980B and Part 6 of Subtitle B of Title I of ERISA (“COBRA”), the Company’s group health plan (or the Buyer’s group health plan if the Company’s plan is not continued after the Closing) shall make COBRA continuation coverage available to each such employee who is eligible for COBRA and was covered under the Company’s group health plan on the day prior to the employee’s last day of employment and each such employee’s “qualified beneficiaries” (within the meaning of COBRA).

(b) Benefits. Buyer agrees that all Continuing Employees shall be eligible to participate in either, at the sole discretion of Buyer: (i) Buyer’s employee benefit plans and programs, including any equity incentive plan, pension plan, defined benefit plan, defined contribution plan, Section 401(k) plan, bonus plan, profit sharing plan, severance plan, medical plan, dental plan, life insurance plan, time-off programs and disability plan, in each case to the same extent as similarly situated employees of Buyer; or (ii) such Benefit Plans as are continued

64

by the Company following the Closing Date, or are assumed by Buyer (for the purposes of this Section 7.3 only, the plans referred to in clauses “(i)” and “(ii)” of this sentence being referred to as “Specified Buyer Benefit Plans”) to the extent necessary so that Continuing Employees are offered benefits substantially similar in the aggregate to those offered to similarly situated employees of Buyer as of the Closing. Participation by Continuing Employees in the Specified Buyer Benefit Plans shall be subject to the terms and conditions of the applicable plan, and the plan sponsor’s right to amend or terminate the plan for any or no reason and without notice to employees.

(c) Eligibility; Service Credit. From and after the Closing, each Continuing Employee shall (to the extent permitted by Applicable Law) be credited under each Specified Buyer Benefit Plan with his or her years of services with the Company before the Closing for purposes of vesting, eligibility, and level of benefits (except for purposes of eligibility under the Buyer’s employee stock purchase plan, benefit accrual under a defined benefit pension plan or where such credit would result in a duplication of benefits) to the same extent as such Continuing Employee was entitled, before the Closing, to credit for such service with the Company under any similar Benefit Plan in which such Continuing Employee participated immediately prior to the Closing. In addition, and without limiting the generality of the foregoing, Buyer shall (to the extent that such limitation would not apply with respect to substantially similar plans maintained by the Company prior to the Closing) use its commercially reasonable efforts to (i) cause to be waived any eligibility requirements or pre-existing condition limitations, and (ii) to the extent practicable, give effect, in determining any deductible maximum out of pocket limitations, to amounts paid by such Continuing Employees during the plan year in which the Closing occurs.

(d) 401(k) Plan Termination. At least five (5) Business Days prior to the Closing Date, the Company shall take (or cause to be taken) all actions reasonably necessary or appropriate pursuant to resolutions of the Company’s Board of Directors to terminate, effective no later than the day prior to the Closing Date, any Benefit Plan that contains a cash or deferred arrangement intended to qualify under Section 401(k) of the Code (a “Company 401(k) Plan”). The Company shall provide to Buyer prior to the Closing Date written evidence of the adoption by the Company’s Board of Directors of resolutions authorizing the termination of such Company 401(k) Plan (the form and substance of which resolutions shall be subject to the prior review and approval of Buyer, which approval shall not be unreasonably withheld or delayed).

(e) This Section 7.3 shall be binding upon and inure solely to the benefit of each of the Parties to this Agreement, and nothing in this Section 7.3, expressed or implied, is intended to confer upon any other Person any rights or remedies of any nature whatsoever under or by reason of this Section 7.3. Without limiting the foregoing, no provision of this Section 7.3 shall create any third party beneficiary rights in any current or former employee, director or consultant of the Company in respect of continued employment or service (or resumed employment or service) or any other matter. Nothing in this Section 7.3 is intended to amend any Benefit Plan, or interfere with Buyer’s, the Company’s, or the Company’s right from and after the Closing to amend or terminate any Benefit Plan or the employment or provision of services by any director, employee, independent contractor or consultant.

65

7.4. Development and Commercialization of the Development Products.

(a) Following the Closing, and for up to a maximum period of [****], Buyer and the Company shall (i) use Milestone Diligence Efforts to [****]. “Milestone Diligent Efforts” means [****].

(b) Buyer shall notify Equityholder Representative if Buyer chooses not to proceed with further efforts to obtain Regulatory Approval of or commercialize any PARP Development Products.

(c) [****]

ARTICLE VIII.

CONDITIONS TO OBLIGATIONS

8.1. Conditions to the Obligations of Each Party. The respective obligations of each Party to consummate the transactions contemplated by this Agreement shall be subject to the satisfaction at or prior to the Closing Date of the following conditions:

(a) No Order. No Governmental Authority of competent jurisdiction shall have enacted, issued, promulgated, enforced or entered any statute, rule, regulation, executive order, decree, injunction or other Court Order which (i) is in effect and (ii) has the effect of otherwise prohibiting or preventing the consummation of the transactions contemplated hereby.

(b) Regulatory Approvals/HSR Act. If applicable, all waiting periods under the HSR Act relating to the transactions contemplated hereby will have expired or terminated early.

8.2. Conditions to the Company’s Obligations. The obligations of the Company to consummate the transactions provided for hereby are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by the Company:

(a) Representations and Warranties. Each of (i) the representations and warranties of Buyer in Section 5.1 (Organization) and Section 5.2 (Authorization) shall be true and correct in all respects as of the date hereof and as of the Closing as though made on and as of the Closing (except that those representations and warranties which address matters only as of a particular date need only be true and correct as of such date), and (ii) all other representations and warranties of Buyer contained in this Agreement shall be true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) in all material respects as of the date hereof and as of the Closing as though made on and as of the Closing (except that those representations and warranties which address matters only as of a particular date need only be true and correct in accordance with this subclause (ii) as of such date).

(b) Covenants. Buyer shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it on or prior to the Closing Date. The Company shall have received a certificate with respect to the foregoing signed on behalf of Buyer, with respect to the covenants of Buyer, by an authorized executive officer of Buyer.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

66

(c) Escrow Agreement. The Company shall have received the Escrow Agreement, signed on behalf of Buyer, the Escrow Agent and the Equityholder Representative.

8.3. Conditions to the Obligations of Buyer. The obligations of Buyer to consummate the transactions provided for hereby are subject to the satisfaction, on or prior to the Closing Date, of each of the following conditions, any of which may be waived by Buyer:

(a) Representations and Warranties. Each of the representations and warranties (i) of the Company in Section [****] shall be true and correct in all respects as of the date hereof and as of the Closing as though made on and as of the Closing (except that those representations and warranties which address matters only as of a particular date need only be true and correct as of such date), and (ii) all other representations and warranties of the Company and each Seller contained in this Agreement shall be true and correct (without giving effect to any limitation as to “materiality” or “Material Adverse Effect” set forth therein) in all material respects as of the date hereof and as of the Closing as though made on and as of the Closing (except that those representations and warranties which address matters only as of a particular date need only be true and correct in accordance with this subclause (ii) as of such date).

(b) Covenants. The Company shall have performed or complied in all material respects with all agreements and covenants required by this Agreement to be performed or complied with by it at or prior to the Closing Date. Buyer shall have received a certificate to such effect signed on behalf of the Company by an authorized executive officer of the Company.

(c) Company Material Adverse Effect. Since the date of this Agreement, there shall not have been any Material Adverse Effect on the Company.

(d) Deliveries. Buyer shall have received the following:

(i) a copy of the Escrow Agreement, signed by the Equityholder Representative and the Escrow Agent;

(ii) stock certificates evidencing the Shares duly endorsed in blank, or accompanied by stock powers duly executed in blank, in form satisfactory to Buyer;

(iii) a certificate of the Secretary or an Assistant Secretary of the Company certifying the names and signatures of the officers or directors of the Company authorized to sign this Agreement and the other documents to be delivered hereunder;

(iv) a certificate of the Chief Executive Officer of the Company certifying, with respect to the Company, as to the matters set forth in Sections 8.3(a), 8.3(b), 8.3(c), 8.3(e), 8.3(f) and 8.3(g);

(v) the resignations, effective as of the Closing, of all of the directors and officers of the Company;

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

67

(vi) a copy of (A) the certificate of incorporation, as amended, of the Company, certified by the Secretary of State of Delaware, as of a date not earlier than five business days prior to the Closing and accompanied by a certificate of the Secretary or Assistant Secretary of the Company, dated as of the Closing, stating that no amendments have been made to such certificate of incorporation since such date, and (B) the bylaws of the Company, certified by the Secretary or Assistant Secretary of the Company; and

(vii) good standing certificates for the Company from the Secretary of State of Delaware and from the Secretary of State in each other jurisdiction in which the properties owned or leased by the Company, or the operation of its business in such jurisdiction, requires the Company to qualify to do business as a foreign corporation, in each case dated as of a date not earlier than five business days prior to the Closing and accompanied by bring-down telegrams dated as of the Closing.

(e) Consents and Approvals. The Company shall have received (i) all Permits from and consents of Governmental Authorities that are required for the consummation of the transactions contemplated hereby, and (ii) an executed Option Holder Consent Agreement in the form attached hereto as Exhibit C from each holder of a Company Option.

(f) Series A Preferred Stock Agreements. Each of the Series A Preferred Stock Agreements shall have been terminated, or by their terms shall be terminated as of the Closing.

(g) Company Notes, Company Warrants and Company Options. Prior to the Closing, all Company Notes shall have converted into Series A Preferred Stock or been cancelled. Prior to the Closing, all Company Warrants shall have been exercised in full or cancelled. Prior to or Concurrently with the Closing, all Company Options shall have been exercised in full or cancelled.

(h) FIRPTA. The Company shall have delivered to Buyer an affidavit dated as of the Closing Date, made under penalty of perjury and in form and substance required under Treas. Reg. § 1.1445-2(c)(3) in a form reasonably acceptable to Buyer.

ARTICLE IX.

INDEMNIFICATION

9.1. Survival of Representations. The representations and warranties contained herein shall survive the Closing until [****] thereafter; provided, however, that: (i) the representations and warranties set forth in [****] shall survive until [****] and (ii) the representations and warranties set forth in [****] shall survive the Closing until the earlier of [****]. Any claims under this Agreement with respect to a breach of a representation and warranty must be asserted by written notice within the applicable survival period contemplated by this Section 9.1, and if such a notice is given, the survival period for such representation and warranty shall continue until the claim is fully resolved. The right to indemnification or other remedy based on the representations, warranties, covenants and agreements herein will not be affected by any investigation conducted with respect to, or any knowledge (or capable of being acquired) at any time, whether before or after the execution and delivery of this Agreement, with respect to the accuracy or inaccuracy of or compliance with, any such representation, warranty, covenant or agreement.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

68

9.2. Indemnification.

(a) (i) Subsequent to the Closing, subject to the limitations described below in Section 9.5 and the other provisions of this Article IX, each of Buyer and its respective Affiliates (including, after the Closing, the Company) and each of its respective officers, directors, employees, stockholders and agents (the “Buyer Indemnified Parties”) shall be indemnified and reimbursed by the Equityholders [****], from and against any and all damage, claim, loss, cost, Liability or expense, including interest, penalties, reasonable attorneys’ fees and expenses of investigation, response action, removal action or remedial action (collectively, “Damages”) incurred by such Buyer Indemnified Party that arise out of, or relate to [****].

(ii) Subsequent to the Closing, subject to the limitations described below in Section 9.5 and the other provisions of this Article IX, Buyer shall indemnify and reimburse each Equityholder and each of their respective representatives, heirs and Affiliates (the “Company Indemnified Parties” and collectively with the Buyer Indemnified Parties, the “Covered Parties”) from and against any and all Damages asserted against, suffered, sustained, accrued or incurred by such Company Indemnified Party arising out of or relating to [****].

(b) The term “Damages” as used in this Article IX is not limited to matters asserted by third parties against the Covered Parties, but includes Damages incurred or sustained by such Persons in the absence of third-party claims, and payments by a Covered Party shall not be a condition precedent to recovery, and shall be net (as contemplated by the last sentence of this Section 9.2(b)) of [****]. “Net Tax Benefit” means, [****].

9.3. Notice of Claims.

(a) Any Covered Party seeking indemnification hereunder shall, within the relevant limitation period provided for in Section 9.1 above, if applicable, give to the Party which is obligated pursuant to this Article IX to provide indemnification as set forth herein (the “Indemnifying Party”) a notice (a “Claim Notice”) describing in reasonable detail the facts giving rise to any claims for indemnification hereunder and shall include in such Claim Notice (if then known) the amount or the method of computation of the amount of such claim, and a reference to the provision of this Agreement or any agreement, certificate or instrument executed pursuant hereto or in connection herewith upon which such claim is based; provided, that a Claim Notice in respect of any action at law or suit in equity by or against a third Person as to which indemnification shall be sought shall be given promptly after the action or suit is commenced; and provided further, that failure to give such notice shall not affect such Covered Party’s right to indemnification hereunder except to the extent the Indemnifying Party shall have been materially prejudiced by such failure.

(b) The Indemnifying Party shall have twenty (20) days following receipt of any Claim Notice pursuant hereto to (i) agree to the amount or method of determination set forth in the Claim Notice to pay such amount to (A) a Buyer Indemnified Party in immediately

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

69

available funds solely from the Escrow Account or upon offset of a Future Payment Amount pursuant to Section 9.5(d), or (B) a Company Indemnified Party in immediately available funds or (ii) to provide such Covered Party with notice that they disagree with the amount or method of determination set forth in the Claim Notice and thereafter comply with the dispute resolution provisions set forth in Section 2.11(h).

9.4. Third Person Claims. If a claim by a third Person is made against a Covered Party, and if such party intends to seek indemnity with respect thereto under this Article IX, such Covered Party shall promptly notify the Indemnifying Party in writing of such claims, setting forth such claims in reasonable detail. The failure to give such notice shall not affect such Covered Party’s right to indemnification hereunder except to the extent the Indemnifying Party shall have been materially prejudiced by such failure. With respect to any claim for Damages relating solely to the payment of money damages and that will not result in the Covered Party becoming subject to injunctive or other relief or otherwise adversely affect the business or reputation of Buyer or any of its Affiliates (including, after the Closing, the Company) in any manner and, in the case of a Buyer Indemnified Party, if the amount of the claim does not exceed the amount then held in the Indemnification Escrow Account, the Indemnifying Party shall have twenty (20) days following receipt of such notice to deliver to the Covered Party a written acknowledgement that such claim is an indemnifiable claim for which it is Liable under this Article IX, that it will undertake, conduct and control (in accordance with the terms hereof), through counsel of their own choosing (provided that such counsel must be reasonably acceptable to the Covered Party) and at their own expense, the settlement or defense thereof, and the Covered Party shall cooperate with them in connection therewith; provided that the Covered Party may participate in such settlement or defense through counsel chosen by such Covered Party and paid at its own expense, provided further that, if in the reasonable opinion of counsel for the Covered Party, there is a reasonable likelihood of a conflict of interest between the Indemnifying Party and the Covered Party, the Indemnifying Party shall be responsible for reasonable fees and expenses of one counsel to such Covered Party in connection with such defense. So long as the Indemnifying Party is reasonably contesting any such claim in good faith, the Covered Party shall not pay or settle any such claim without the consent of the Equityholder Representative with respect to claims where the Equityholders are the Indemnifying Party and Buyer where Buyer is the Indemnifying Party. If the Indemnifying Party does not notify the Covered Party within such twenty (20) days, the Covered Party shall have the right to undertake, at the Indemnifying Party’s cost, risk and expense, the defense, compromise or settlement of the claim but shall not thereby waive any right to indemnity therefor pursuant to this Agreement. The Indemnifying Party shall not, except with the consent of the Covered Party, enter into any settlement that is not exclusively monetary and shall be paid entirely by the Indemnifying Party and does not include as an unconditional term thereof the giving by the person or persons asserting such claim to all Covered Parties of an unconditional release from all Liability with respect to such claim or consent to entry of any judgment. Notwithstanding the foregoing, the Indemnifying Party shall not be entitled to control any claim relating to Taxes of Buyer or its Subsidiaries, or the Company for any Tax period ending after the Closing Date and shall not be entitled to settle, either administratively or after the commencement of litigation, any claim for Taxes which could adversely affect the Liability of Buyer or its Subsidiaries, or the Company for Taxes for any Tax period (or portion thereof) after the Closing Date, without the prior written consent of Buyer.

70

9.5. Limitation on Indemnity; Payments Out of Milestone Payment Amounts.

(a) Notwithstanding anything expressed or implied in this Article IX to the contrary, no Covered Party shall be entitled to make a claim for indemnification pursuant to Section 9.2(a)(i)(1) of this Agreement unless and until the aggregate of all Damages suffered by such Covered Parties and agreed upon in accordance with Section 9.3(b) hereunder exceeds $[****] (the “Deductible Amount”), whereupon, provided the other requirements of this Article IX have been complied with, only Damages exceeding the Deductible Amount shall become due and payable. Notwithstanding the foregoing, no Deductible Amount shall apply to (i) the Company’s representations and warranties set forth in [****].

(b) To the extent permitted by Law, any payment made by a Person indemnifying a Covered Party pursuant to this Article IX shall be treated on the Parties’ Tax Returns as an adjustment to the Purchase Price for all Tax purposes.

(c) In the event a claim for indemnification or reimbursement under this Article IX shall have been finally determined in which the indemnified party is Buyer, (i) the amount of the related Damages (after taking into account the limitations of Section 9.5(a)) shall be paid [****].

(d) If, following depletion or release of the Indemnification Escrow Account to the Equityholders, an amount has been claimed by a Buyer Indemnified Party pursuant to Section 9.2(a)(i) (whether or not finally determined to be owed by the Equityholders), and if the Future Payment Amounts have not yet been fully paid pursuant to Section 2.1, Buyer may set-off such amounts claimed against the Future Payment Amounts (if required to be paid pursuant to Section 2.1), on a dollar for dollar basis, notwithstanding any objection by the Equityholder Representative, subject to the limitations set forth in Section 9.5(a). The exercise of such right of set-off by Buyer in good faith, whether or not the claim is ultimately determined to be justified, will not constitute a breach of this Agreement. Once a claim is finally determined in accordance with this Agreement, if the Damages relating to such claim are determined to be less than the amount set-off against the Future Payment Amounts, Buyer shall notify the Equityholder Representative. Thereafter, the Equityholder Representative shall prepare a Future Payment Allocation Schedule showing the portion of such amount to be paid to each Equityholder and deliver such Future Payment Allocation Schedule to Buyer. Within ten (10) Business Days following Buyer’s receipt of such Future Payment Allocation Schedule, Buyer shall pay to each Equityholder the portion of such amount set forth opposite such Equityholder’s name on such Future Payment Allocation Schedule in immediately available funds by check or by wire transfer to such bank account or accounts as may be specified on such Future Payment Allocation Schedule. [****]

(e) Each Equityholder waives, and acknowledges and agrees that such Equityholder shall not have and shall not exercise or assert (or attempt to exercise or assert), any right of contribution, right of indemnity or other right or remedy against Buyer or the Company, or any of their respective directors, officers, employees, Affiliates, agents, attorneys, Representatives, assigns or successors, for any indemnification claims asserted by any Buyer Indemnified Parties in connection with any indemnification obligation or any other Liability to which such Equityholder may become subject under or in connection with this Agreement, it being acknowledged and agreed that the representations, warranties, covenants and agreements of the Company and Equityholders are solely for the benefit of the Buyer Indemnified Parties.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

71

9.6. Remedies. Subsequent to the Closing, the remedies in this Article IX shall be the sole and exclusive remedies of the Parties with respect to any breach of the respective representations, warranties, covenants and agreements pursuant to this Agreement or otherwise arising out of this Agreement, regardless of the theory or cause of action pled, and the sole remedies of the Buyer Indemnified Parties shall be by means of deductions from the Indemnification Escrow Account and Buyer’s right of offset set forth in Section 9.5(d) except for the remedies of specific performance, injunction and other equitable relief; provided, however, that no Party hereto shall be deemed to have waived any rights, claims, causes of action or remedies, and the Deductible Amount or the Cap Amount shall not limit any recovery related thereto, if and to the extent actual fraud, intentional misrepresentation or willful misconduct is proven on the part of a Party by another Party hereto or such rights, claims, causes of action or remedies may not be waived under Applicable Law. For the avoidance of doubt, Buyer acknowledges that its claims arising from fraud of Equityholder(s), in such Equityholder(s)’s capacity as a Stockholder, can only be brought against such Equityholder(s) who has committed such fraud or aided and abetted such fraud. For the purposes of this Section 9.6, there shall be deemed “willful misconduct” by a Party only if such Party had actual knowledge at the time of taking an action or omitting to take an action, that such action or omission constituted a breach of such Party’s covenants or obligations under the Agreement.

ARTICLE X.

TERMINATION, AMENDMENT AND WAIVER

10.1. Termination. This Agreement may be terminated at any time prior to the Closing, by action taken or authorized by the Board of Directors of the terminating Party or Parties:

(a) by mutual written consent duly authorized by the Boards of Directors of Buyer and the Company;

(b) by either the Company or Buyer if the Closing shall not have occurred by February 28, 2010 (the “End Date”); provided, however, that the right to terminate this Agreement under this Section 10.1(b) shall not be available to any Party whose action or failure to act has been a principal cause of or resulted in the failure of the Closing to occur on or before such date and such action or failure to act constitutes a breach of this Agreement;

(c) by either the Company or Buyer if a Governmental Authority shall have issued an Court Order, decree or ruling or taken any other action (including the failure to have taken an action), in any case having the effect of permanently restraining, enjoining or otherwise prohibiting the Closing, which order, decree, ruling or other action is final and nonappealable;

(d) by the Company, upon a breach of any representation, warranty, covenant or agreement on the part of Buyer set forth in this Agreement, or if any representation or warranty of Buyer shall have become untrue, in either case such that the conditions set forth in Section 8.2(a) or Section 8.2(b) would not be satisfied as of the time of such breach or as of the

72

time such representation or warranty shall have become untrue, provided that if such inaccuracy in Buyer’s representations and warranties or breach by Buyer is curable by Buyer prior to the End Date through the exercise of reasonable efforts, then the Company may not terminate this Agreement under this Section 10.1(d) prior to thirty (30) days following the receipt of written notice from the Company to Buyer of such breach (it being understood that the Company may not terminate this Agreement pursuant to this Section 10.1(d) if it shall have materially breached this Agreement or if such breach by Buyer is cured so that such conditions would then be satisfied); or

(e) by Buyer, upon a breach of any representation, warranty, covenant or agreement on the part of the Company set forth in this Agreement, or if any representation or warranty of the Company shall have become untrue, in either case such that the conditions set forth in Section 8.3(a) or Section 8.3(b) would not be satisfied as of the time of such breach or as of the time such representation or warranty shall have become untrue, provided that if such inaccuracy in the Company’s representations and warranties or breach by the Company is curable by the Company prior to the End Date through the exercise of reasonable efforts, then Buyer may not terminate this Agreement under this Section 10.1(e) prior to thirty (30) days following the receipt of written notice from Buyer to the Company of such breach (it being understood that Buyer may not terminate this Agreement pursuant to this Section 10.1(e) if it shall have materially breached this Agreement or if such breach by the Company is cured so that such conditions would then be satisfied).

10.2. Notice of Termination; Effect of Termination. Any termination of this Agreement under Section 10.1 above shall be effective immediately upon the delivery of a valid written notice of the terminating Party to the other Party hereto. In the event of the termination of this Agreement as provided in Section 10.1, this Agreement shall be of no further force or effect, except (i) as set forth in Section 6.2(a) this Section 10.2, Section 10.3 and Article XI, each of which shall survive the termination of this Agreement and (ii) nothing herein shall relieve any Party from Liability for any breach of this Agreement. No termination of this Agreement shall affect the obligations of the Parties contained in the Confidentiality Agreement, all of which obligations shall survive termination of this Agreement in accordance with their terms.

10.3. Expenses. All fees and expenses incurred in connection with this Agreement and the transactions contemplated hereby, including fees and expenses of financial advisors, financial sponsors, legal counsel and other advisors, shall be paid by the Party incurring such expenses whether or not the transactions contemplated hereby are consummated.

ARTICLE XI.

MISCELLANEOUS

11.1. Binding Effect; Assignment. This Agreement shall be binding upon and inure to the benefit of the Parties hereto and their successors and permitted assigns, in accordance with the terms hereof. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the Parties hereto, in whole or in part (whether by operation of law or otherwise), without the prior written consent of the other Parties, and any attempt to make any such assignment without such consent shall be null and void, except that (a) Buyer may assign,

73

in its sole discretion, any or all of its rights, interests and obligations under this Agreement to any entity that is wholly-owned directly by Buyer without the consent of the Company and (b) Buyer may assign, in its sole discretion, any or all of its rights, interests and obligations under this Agreement to any entity that will acquire substantially all of Buyer’s assets by merger, stock purchase, asset purchase or otherwise. Subject to the foregoing, this Agreement shall be binding upon and inure to the benefit of the Parties hereto and their respective successors and assigns, and no other Person shall have any right, benefit or obligation hereunder.

11.2. Notices. Unless otherwise provided herein, any notice, request, instruction or other document to be given hereunder by any Party to the other shall be in writing and delivered in person or by courier, by facsimile transmission or mailed by registered or certified mail, postage prepaid, return receipt requested (such mailed notice to be effective on the date of such receipt is acknowledged), as follows:

If to Buyer:

BioMarin Pharmaceutical Inc.

105 Digital Drive

Novato, CA 94949

Attn: Chief Executive Officer

Fax: (415) 382-7889

With a copy (which shall not constitute notice) to:

BioMarin Pharmaceutical Inc.

105 Digital Drive

Novato, CA 94949

Attn: General Counsel

Fax: (415) 382-7889

If to the Company:

LEAD Therapeutics, Inc.

999 Bayhill Dr, Suite 130

San Bruno, CA 94066

Attn: Peter Myers

Fax: (925) 253-2450

With a copy (which shall not constitute notice) to:

Latham & Watkins LLP

140 Scott Drive

Menlo Park, CA 94025

Attn: Alan C. Mendelson

Fax: (650) 463-2600

74

If to the Equityholder Representative:

Arthur Pappas

c/o A.M. Pappas & Associates, LLC

P.O. Box 110287

Research Triangle Park, NC 27709

Or (for Fedex deliveries)

2520 Meridian Parkway

Suite 400

Durham, NC 27713

Fax: (919) 998-3302

With a copy (which shall not constitute notice) to:

Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.

2500 Wachovia Capitol Center

P.O. Box 2611

Raleigh, NC 27602

Attn: Gerald F. Roach

Fax: (919) 821-6800

Any Party may, from time to time, designate any other address to which any such notice to such Party shall be sent. Any such notice shall be deemed to have been delivered upon receipt.

11.3. Choice of Law. This Agreement shall be construed, interpreted and the rights of the Parties determined in accordance with the laws of the State of Delaware, as applied to agreements among Delaware residents entered into and wholly to be performed within the State of Delaware (without reference to any choice of law rules that would require the application of the laws of any other jurisdiction).

11.4. Entire Agreement; Amendments and Waivers. This Agreement, together with the Confidentiality Agreement and the other documents and instruments referred to herein and all exhibits and schedules hereto, constitutes the entire agreement among the Parties pertaining to the subject matter hereof and supersedes all prior agreements, understandings, negotiations and discussions, whether oral or written, of the Parties. This Agreement may be supplemented, modified or amended by action by each Party hereto, which in the case of the Company and Buyer shall be action taken by or on behalf of the Board of Directors of such Party. No supplement, modification or other amendment or waiver of this Agreement shall be binding unless executed in writing by the Party to be bound thereby. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provision hereof (whether or not similar), nor shall such waiver constitute a continuing waiver unless otherwise expressly provided.

75

11.5. Counterparts. This Agreement may be executed by facsimile and in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

11.6. Severability. If any provision of this Agreement is deemed or held to be illegal, invalid or unenforceable, this Agreement shall be considered divisible and inoperative as to such provision to the extent it is deemed to be illegal, invalid or unenforceable, and in all other respects this Agreement shall remain in full force and effect; provided, however, that if any provision of this Agreement is deemed or held to be illegal, invalid or unenforceable the Parties agree to replace such illegal, invalid or unenforceable provision with a provision that is legal, valid and enforceable that achieves the original intent of the Parties as closely as possible. Further, should any provision contained in this Agreement ever be reformed or rewritten by any judicial body of competent jurisdiction, such provision as so reformed or rewritten shall be binding upon all Parties hereto.

11.7. Schedules. The Schedules and the Exhibits referenced in this Agreement are a material part hereof and shall be treated as if fully incorporated into the body of the Agreement.

11.8. No Third Party Beneficiaries. Nothing expressed or referred to in this Agreement, other than pursuant to Article II and Section 7.1, will be construed to give any Person other than the Parties to this Agreement (and their successors and assigns) any legal or equitable right, remedy, or claim under or with respect to this Agreement or any provision of this Agreement.

11.9. Specific Performance. The Parties hereto agree that irreparable damage would occur in the event any provision of this Agreement was not performed in accordance with the terms hereof and that the Parties shall be entitled to seek specific performance of the terms hereof, in addition to any other remedy at law or equity without the necessity of demonstrating the inadequacy of monetary damages.

11.10. No Strict Construction. The Parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties hereto, and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement.

11.11. Submission to Jurisdiction; Waivers; Consent to Service of Process. Except as otherwise provided in this Agreement, each Party hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement or for recognition and enforcement of any judgment in respect hereof brought by another party hereto or its successors or assigns shall be brought exclusively in the Court of Chancery in the State of Delaware to the fullest extent permitted by Applicable Law and, to the extent not so permitted, in any court sitting in the State of Delaware, and each of the Parties hereto hereby (x) irrevocably submits with regard to any such action or proceeding for itself and in respect to its property, generally and unconditionally, to the exclusive personal jurisdiction of the aforesaid courts in the event any dispute arises out of this Agreement or any transaction contemplated hereby, (y) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (z) agrees that it will not bring any action relating to this Agreement or any transaction

76

contemplated hereby in any court other than the aforesaid courts. Any service of process to be made in such action or proceeding may be made by delivery of process in accordance with the notice provisions contained in Section 11.2. Nothing in this Agreement will affect the right of any Party to this Agreement to serve process in any other manner permitted by Applicable Law. Each of the Parties hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) the defense of sovereign immunity, (b) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to serve process in accordance with this Section 11.11, (c) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (d) to the fullest extent permitted by Applicable Law that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper and (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

11.12. WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

11.13. Release.

(a) As an inducement to Buyer to enter into this Agreement and consummate the transactions contemplated hereby and for other good and sufficient consideration, each of the Equityholders, with the intention of binding himself, herself or itself and each of such Equityholder’s heirs, executors, administrators and assigns (the “Releasors”), does hereby release, acquit and forever discharge Buyer and the Company, and each of their past and present Affiliates, Subsidiaries, and Representatives, and all Persons acting by, through, under, or in concert with such Persons (the “Releasees”), of and from any and all manner of action or actions, cause or causes of action, suits, arbitrations, demands, debts, contracts, agreements, promises, Liability, Damages, or loss of any nature whatsoever, known or unknown, suspected or unsuspected, fixed or contingent, direct, derivative, vicarious or otherwise, whether based in contract, tort, or other legal, statutory, or equitable theory of recovery, each as though fully set forth at length herein, (hereinafter, a “Claim”), which the Releasors now have or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, act, omission or thing whatsoever in any way arising out of, based upon, or relating to Equityholder’s ownership of Shares or other equity interest in the Company; provided, however, that nothing set forth in this

77

Section 11.13 shall (i) affect the ability of any of such Equityholder to bring a Claim under this Agreement, (ii) release, acquit or discharge any rights to indemnification to which any Equityholder may be entitled under the Company’s certificate of incorporation or bylaws as in effect on the date hereof or under any employment agreement and/or indemnification agreement between such Equityholder and the Company or (iii) affect the ability of any of the Equityholders to bring a Claim with respect to any ordinary course of employment rights or any Contracts with Buyer or the Company that remain in effect after the Closing. Notwithstanding the foregoing, nothing in this Agreement shall be interpreted to release Buyer from any of its obligations to the Equityholders under this Agreement.

(b) Each Equityholder represents and warrants to the Company and Buyer that there has been no assignment or other transfer of any interest in any Claim which such Equityholder may have against any of the Releasees, and each Equityholder agrees to indemnify and hold the Releasees harmless from any Liability, Claims or attorneys’ fees or expenses incurred as a result of any Person asserting any such assignment or transfer of any rights or Claims under any such assignment or transfer from such party.

(c) Each Equityholder represents and warrants to the Company and Buyer that it has not filed, nor has as of the date hereof, any Claims against any of the Releasees. Each Equityholder agrees that if such Equityholder hereafter commences, joins in, or in any manner seeks relief through any suit arising out of, based upon, or relating to any of the Claims released hereunder, or in any manner asserts against the Releasees any of the Claims released hereunder, including, without limitation, through any motion to reconsider, reopen or appeal the dismissal of the suit or action, then such Equityholder will pay to the Releasees against whom such claim(s) is asserted all Damages incurred by such Releasees in defending or otherwise responding to said Claim.

(d) Notwithstanding anything to the contrary herein, the release set forth in this Section 11.13 shall have no force and effect until the Closing.

(e) EACH EQUITYHOLDER ACKNOWLEDGES THAT HE, SHE OR IT IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

EACH EQUITYHOLDER, BEING AWARE OF SAID CODE SECTION, HEREBY EXPRESSLY WAIVES ANY RIGHTS HE, SHE OR IT MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.

[remainder of page intentionally left blank]

78

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement or caused this Agreement to be duly executed on their respective behalf, by their respective officers thereunto duly authorized, all as of the day and year first above written.

BIOMARIN PHARMACEUTICAL INC.
By:	/s/ Jean-Jacques Bienaimé
	Name:	Jean-Jacques Bienaimé
	Title:	Chief Executive Officer

LEAD THERAPEUTICS, INC.
By:	/s/ Peter L. Myers
	Name:	Peter L. Myers
	Title:	Chief Executive Officer

EQUITYHOLDER REPRESENTATIVE:
By:	/s/ Arthur Pappas
	Arthur Pappas, as Equityholder Representative

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

SELLERS
	PROQUEST INVESTMENTS IV, L.P.
By:	ProQuest Associates IV LLC, its General Partner
By:	/s/ Alain B. Schreiber, MD
Name:	Alain B. Schreiber
Title:	Managing Member
	PROQUEST MANAGEMENT LLC
By:	/s/ Alain B. Schreiber
Name:	Alain B. Schreiber
Title:	Managing Partner

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

SELLERS
	A. M. PAPPAS LIFE SCIENCE VENTURES III, LP
By:	AMP&A Management III, LLC, its General Partner
By:	/s/ Ford S. Worthy
Name:	Ford S. Worthy
Title:	Partner
	PV III CEO FUND, LP
By:	AMP&A Management III, LLC, its General Partner
By:	/s/ Ford S. Worthy
Name:	Ford S. Worthy
Title:	Partner

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

SELLERS
	MUSTANG VENTURES I, L.P.
By:
By:	/s/ Robert McCormack
Name:	Robert C. McCormack, Jr.
Title:	Managing Director

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

SELLERS
CHINA GATEWAY LIFE SCIENCE (HOLDINGS) LTD. (HK)
Print Name: Michael Hui
Title: CEO
Signature:	/s/ Michael Hui
Address:
Attn: Mr. Michael Hui
Chief Executive Officer
No. 3 Building, 720 Cailun Road
Zhangjiang High Tech Park, Pu Dong New Area
Shanghai China

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

SELLERS

/s/ Shuang Qiao

Shuang (Sofie) Qiao

/s/ Leonard E. Post

Leonard Post

/s/ Peter L. Myers

Peter Myers

/s/ Daniel Chu

Daniel Chu

/s/ Charles Hsu

Charles Hsu

/s/ Zhengying Pan

Zhengying Pan

/s/ Xiaoyi Xiao 2/4/2010

Xiaoyi Xiao

/s/ David K. Hanabusa

David Hanabusa

SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT

EXHIBIT A

Form of Escrow Agreement

ESCROW AGREEMENT

THIS ESCROW AGREEMENT (this “Agreement”) dated as of February             , 2010 by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“Buyer”), Arthur Pappas, acting in his capacity as agent and attorney-in-fact (the “Representative”) for certain equity holders of LEAD Therapeutics, Inc., a Delaware corporation (the “Company”), and Wells Fargo Bank, N.A., as escrow agent (the “Escrow Agent”).

RECITALS

WHEREAS, pursuant to the Stock Purchase Agreement dated as of February             , 2010 (the “Purchase Agreement”) by and among Buyer, the Company, each of the parties listed on Schedule A thereto (each, a “Seller”) and the Representative, Buyer will purchase, and each Seller will collectively sell, all of the capital stock of the Company and the Company will become a wholly owned subsidiary of Buyer. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed thereto in the Purchase Agreement. All interest or other income earned from the investment of the Escrow Funds or any portion thereof (all such interest or other income, the “Earnings”) shall be retained as additional amounts in the Escrow Account (as defined below), except as provided in Section 3(b).

Buyer will deliver or cause to be delivered to the Escrow Agent an amount in cash equal to the sums of [****] (the “Indemnification Escrow Amount”) and [****] (the “Working Capital Escrow Amount”) at the Closing pursuant to Section 2.5 and Section 2.6, respectively, of the Purchase Agreement, which amounts (together with any Earnings thereon, the “Escrow Funds”), are to be held in escrow by the Escrow Agent pursuant hereto and released in accordance with the terms hereof.

NOW, THEREFORE, the parties agree as follows:

SECTION 1. Escrow Funds Subject to Agreement. The Escrow Agent hereby agrees to act as escrow agent subject to the terms of this Agreement. The Escrow Agent shall accept delivery of, hold and safeguard the Escrow Funds in two escrow accounts specifically established for each of the Indemnification Escrow Amount and the Working Capital Escrow Amount (respectively, the “Indemnification Escrow Account” and the “Working Capital Escrow Account”, and collectively, the “Escrow Account”) and maintained for the purpose outlined below pursuant to the terms hereof.

SECTION 2. Investment of Escrow Funds.

(a) Upon written direction by the parties, the Escrow Funds shall be invested by the Escrow Agent in Permitted Investments. The term “Permitted Investments” means the following investments so long as they have maturities of ninety (90) days or less: (a) direct obligations of or obligations unconditionally guaranteed by the United States or by any Person controlled or supervised by or acting as an instrumentality of the United States or by any Person controlled or supervised by or acting as an instrumentality of the United States pursuant to authority granted by Congress, provided such obligations are backed by the full faith and credit of the United States; (b) obligations issued or guaranteed by any state or political subdivision

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

thereof, in each case, rated either AAA or higher, or MIG 1 or higher, by Moody’s Investors Service, Inc. (“Moody’s”) or AAA or higher, or an equivalent, by Standard & Poor’s Corporation (“Standard & Poor’s”), both of New York, New York, or their successors; (c) commercial or finance paper which is rated either Prime-1 or higher or an equivalent by Moody’s or A-1 or higher or an equivalent by Standard & Poor’s or their successors; and (d) certificates of deposit, time deposits or money market deposit accounts of banks or trust companies, organized under the Laws of the United States and having minimum equity of $500,000,000, which certificates of deposit are insured by the Federal Deposit Insurance Corporation (“FDIC”). The Escrow Agent shall be entitled to rely upon the written certification of Buyer and the Representative as to the characterization of the investment as a Permitted Investment, and shall have no liability to ascertain whether or not the investment is a Permitted Investment. In the absence of such written directions, the Escrow Agent shall invest the Escrow Funds in the money market accounts of Wells Fargo that are insured by the FDIC as set forth in Exhibit A. Until disbursement pursuant to the terms hereof, Earnings will be deposited into the Escrow Account and invested with the Escrow Funds. The Escrow Agent shall not be accountable for any losses resulting from the sale or depreciation in the market value of such investments thereof, unless such loss results from the Escrow Agent’s gross negligence, fraud or willful misconduct.

(b) The Escrow Agent is hereby authorized and directed to sell or redeem any Permitted Investments as it deems necessary to make any payments or distributions required under this Escrow Agreement. The Escrow Agent shall have no responsibility or liability for any loss which may result from any investment or sale of investment made pursuant to this Escrow Agreement. The Escrow Agent is hereby authorized, in making or disposing of any Permitted Investment, to deal with itself (in its individual capacity) or with any one or more of its affiliates, whether it or any such affiliate is acting as agent of the Escrow Agent or for any third person or dealing as principal for its own account. The parties acknowledge that the Escrow Agent is not providing investment supervision, recommendations, or advice.

SECTION 3. Tax Treatment and Reporting.

(a) The parties hereto agree that Buyer shall be treated for Tax purposes as the owner of all amounts held in the Escrow Account unless and until such amounts are released therefrom, in which case such amounts shall be treated for Tax purposes as having been paid by Buyer to the party to whom such amounts are released.

(b) The parties hereto agree that, for Tax reporting purposes and to the extent required by the Internal Revenue Service (“IRS”), Earnings in any Tax year shall be treated as having been realized by Buyer for United States federal income tax purposes. Unless otherwise required by law, the parties hereto agree that, for United States federal income tax purposes, Buyer shall report Earnings as its income and shall report related expenses as its expense, provided that within five (5) Business Days following the end of each calendar quarter, Escrow Agent shall release forty-five percent (45%) of the Earnings relating to each such calendar quarter to Buyer and such Earnings shall no longer be part of the Escrow Account. The Escrow Agent annually shall file required information returns (if any) with the IRS and provide payee statements to Buyer documenting such Earnings.

2

(c) Any disbursement of amounts in the Escrow Account to Equityholders shall be treated for United States federal income tax purposes as consisting, in part, of imputed interest in accordance with the Code and Treasury Regulations promulgated thereunder. The Representative shall calculate the imputed interest with respect to each Equityholder and provide such calculations to the Escrow Agent. Escrow Agent shall then timely file information statements with the IRS and provide payee statements to Equityholders documenting each Equityholder’s share of the imputed interest or any payment made hereunder. The Escrow Agent shall inform Buyer that the Escrow Agent filed such information returns and provided such payee statements.

(d) Buyer and, on behalf of the Equityholders, the Representative agree to provide the Escrow Agent with certified tax identification numbers by furnishing appropriate IRS Forms W-9 and such other forms and documents that the Escrow Agent may reasonably request to complete any information returns and payee statements (collectively, the “Tax Reporting Documentation”) prior to any distribution to Buyer or the Equityholders. The parties hereto understand that, in the event the Tax Reporting Documentation is not provided to the Escrow Agent, the Code or similar state tax laws may require withholding of a portion of any interest or other payments made to Buyer or the Equityholders. To the extent that amounts are so withheld by the Escrow Agent, such withheld amounts shall be treated for all purposes of this Agreement as having been paid to Buyer or the Equityholders, as appropriate, in respect of whom such deduction and withholding was made by the Escrow Agent.

SECTION 4. Working Capital Escrow Fund. Upon receipt by the Escrow Agent of a written notice from Buyer or the Representative setting forth how amounts in the Working Capital Escrow Account are to be distributed and released, accompanied by either (i) an executed written agreement between Buyer and the Representative with respect to such distribution and release or (ii) a written decision of the Neutral Arbitrator with respect to such distribution and release, the Escrow Agent shall:

(a) promptly pay to Buyer from the Working Capital Escrow Account and, to the extent the Working Capital Escrow Amount is insufficient, the Indemnification Escrow Account, the Net Working Capital Deficiency Amount, if any; and

(b) promptly following the delivery of a Future Payment Allocation Schedule to Buyer with respect to such release by the Representative pursuant to Section 2.6(b) of the Purchase Agreement, release any remaining amounts in the Working Capital Escrow Account from the Working Capital Escrow Account to each Equityholder in accordance with such Future Payment Allocation Schedule.

SECTION 5. Indemnification Escrow Fund.

(a) Notices of Claims and Dispute Notices.

(i) With respect to any indemnification claim of a Buyer Indemnified Party (a “Buyer Claim”) that Buyer reasonably believes exists, or reasonably expects will exist, Buyer may deliver to the Escrow Agent a written notice (a “Notice of Claim”), which shall set forth in reasonable detail (to the extent known) the nature of such Buyer Claim, the amount of Damages indemnifiable pursuant to the Stock Purchase Agreement (the “Indemnifiable Damages”) that have been paid or incurred, a good faith estimate of the amount of Indemnifiable Damages reasonably expected to be incurred and the provision(s) of the Stock Purchase Agreement on which the indemnification claim is based. Buyer shall deliver a copy of the Notice of Claim to the Representative at the same time that it delivers such Notice of Claim to the Escrow Agent.

3

(ii) The Escrow Agent shall pay to Buyer, or such Person designated by Buyer, therefrom the amount set forth in a Notice of Claim as soon as practicable, but no earlier than thirty-one (31) days following receipt by the Escrow Agent of such Notice of Claim; provided, however, that if within the period of thirty (30) days following receipt by the Escrow Agent of such Notice of Claim, the Escrow Agent shall have received from the Representative a written notice (a “Dispute Notice”) stating that the Representative disputes the validity or the amount specified in such Notice of Claim or any portion thereof (a “Disputed Amount”) and providing in reasonable detail the reasons therefor, the Escrow Agent shall not pay any such Disputed Amount (but shall pay any amount specified in such Notice of Claim that is not in dispute) to Buyer, or such Person designated by Buyer, other than pursuant to Section 3(b) of this Agreement. The Representative shall deliver a copy of each Dispute Notice to Buyer at the same time that the Representative delivers such Dispute Notice to the Escrow Agent.

(iii) If the Escrow Agent shall not have received a Dispute Notice with respect to the amount specified in a Notice of Claim, or a portion thereof, within the period of thirty (30) days following its receipt of such Notice of Claim, the Representative and the Equityholders shall be forever barred and precluded from contesting in any manner or forum whatsoever the distribution of the Escrow Funds on account of such amount not so disputed (except to dispute the delivery by Buyer of a Notice of Claim to the Representative), and the Escrow Agent shall pay such amount to Buyer, or such Person designated by Buyer in writing, in accordance with the preceding paragraph (ii) of this Section 5(a).

(iv) Notwithstanding the foregoing, the Escrow Agent may pay to Buyer, or any Person designated by Buyer in writing, the amount set forth in a Notice of Claim earlier than thirty-one (31) days following receipt by the Escrow Agent of such Notice of Claim, provided that the Buyer delivers to the Escrow Agent a Notice of Claim executed by both Buyer and the Representative authorizing the Escrow Agent to release such specified amount of the Escrow Funds to Buyer. In the event that the Representative authorizes the Escrow Agent to release such specified amount of the Escrow Funds by executing a Notice of Claim with Buyer, the Representative and the Equityholders shall be forever barred and precluded from contesting in any manner or forum whatsoever the distribution of the Escrow Funds on account of such amount absent fraud or intentional misrepresentation.

(b) Disputed Amounts. Upon receipt by the Escrow Agent of a written notice (a “Resolution Notice”) from Buyer or the Representative with respect to a Disputed Amount specifying the amount of such Disputed Amount to which Buyer is entitled, accompanied by either (i) an executed written agreement between Buyer and the Representative with respect to such Disputed Amount or (ii) an award, judgment, decree or order of a court of competent jurisdiction pursuant to Section 5(c) below, the Escrow Agent shall pay to Buyer, or such Person designated by Buyer, from the Indemnification Escrow Account the amount to which Buyer is entitled, if any.

4

(c) Dispute Resolution. In the event of a Disputed Amount, the Buyer and the Representative shall in good faith negotiate to settle such Disputed Amount. If no resolution is reached within thirty (30) days after delivery of the Dispute Notice to the Escrow Agent, either party may bring suit in any court of competent jurisdiction (subject to the limitations set forth in Section 11.11 and Section 11.12 of the Purchase Agreement) with respect to such Disputed Amount. The non-prevailing party in any such dispute shall bear all fees, costs and expenses related to such dispute, including the reasonable attorneys’ fees and costs incurred by the other party.

(d) Release of the Indemnification Escrow Fund.

(i) Promptly following the close of business on the date that is [****] (the “Distribution Date”), the Buyer will notify the Representative of the positive difference, if any, between (A) the Indemnification Escrow Amount plus Earnings thereon remaining in the Indemnification Escrow Account and (B) the sum of (i) the aggregate amount of the payments, if any, previously made to Buyer, the Equityholders or the Escrow Agent out of the Escrow Funds (other than pursuant to Section 3(b) or Section 4) in accordance with the terms of this Agreement, (ii) any amounts that the Escrow Agent is required to pay but has not yet paid to Buyer or a Person designated by Buyer, pursuant to Sections 5(a) or 5(b), (iii) the Withheld Amounts (as defined below) (such positive difference, if any, the “Initial Release Amount”), and (iv) the Earnings released from the Indemnification Escrow Account pursuant to Section 3(b). As soon as practicable, after the Distribution Date, the Representative will provide a Future Payment Allocation Schedule prepared in accordance with the Purchase Agreement showing the allocation of the Initial Release Amount among the Equityholders. Promptly following the receipt of such Future Payment Allocation Schedule, the Escrow Agent will release the Initial Release Amount, if any, to the Equityholders by wire transfer or certified check, in accordance with the Future Payment Allocation Schedule prepared by the Representative. The term “Withheld Amounts” shall mean the aggregate amount of (x) all Disputed Amounts not paid or otherwise resolved by such date and (y) all other amounts specified in Notices of Claims received by the Escrow Agent as of such date and not paid as of such date from the Escrow Funds unless, as of such date, the Escrow Agent is required to pay such amounts pursuant to Sections 5(a) or 5(b). The amounts described in clause (B)(ii) of this Section 5(d)(i) shall be paid by the Escrow Agent to Buyer, or a Person designated by Buyer, pursuant to Sections 5(a) or 5(b) as the case may be, and the amounts described in clause (B)(iii) of this Section 5(d)(i) shall remain Escrow Funds held by, and to be paid out by, the Escrow Agent in accordance with the terms of this Agreement.

(ii) If, after the Distribution Date, the Escrow Agent is required to pay all or a portion of the amounts remaining in the Escrow Account to Buyer pursuant to Section 5(a) or 5(b), then the Escrow Agent shall make such payment to Buyer in accordance with such Section 5(a) or 5(b).

(iii) Upon receipt by the Escrow Agent after the Distribution Date of a Resolution Notice that any claims as to all or any portion of the Withheld Amounts as of the Distribution Date have been resolved (“Resolved Withheld Amounts”), accompanied by (A) an executed written agreement between Buyer and the Representative with respect to such Resolved Withheld Amounts or (B) an award,

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

5

judgment, decree or order of the arbitrator pursuant to Section 5(c) with respect to such Withheld Amounts, the Escrow Agent shall release such Resolved Withheld Amounts from the Escrow Account, as instructed in the joint written notice or order, to Buyer or to the Equityholders by wire transfer or certified check, in accordance with a Future Payment Allocation Schedule prepared by the Representative pursuant to the Purchase Agreement, but only to the extent the Withheld Amounts remaining in the Indemnification Escrow Account exceed the sum of (1) the aggregate amount of Buyer Claims that the Escrow Agent is required to pay but has not yet paid to Buyer or a person designated by Buyer pursuant to Section 5(a) or 5(b) plus (2) all other Withheld Amounts then remaining in the Indemnification Escrow Account.

(iv) Any amounts paid or otherwise released to the Representative hereunder, when made, shall be deemed to have been paid in full satisfaction of the rights of the Equityholders to receive such payments as set forth in the Purchase Agreement and hereunder.

SECTION 6. Administrative Provisions.

(a) Buyer and the Representative shall have the right to inspect and obtain copies of the records of the Escrow Agent pertaining to the Escrow Account and to receive monthly reports of the status of the Escrow Funds. The Escrow Agent shall send to Buyer and the Representative monthly reports detailing the amount of the Escrow Funds in the Escrow Agent’s possession, any release of the Escrow Funds in the preceding month and the status of any claims pending for the release of any of the Escrow Funds.

(b) The Escrow Agent may resign as escrow agent by notice to the other parties hereto (the “Resignation Notice”) effective upon appointment of a successor Escrow Agent. If, prior to the expiration of sixty (60) Business Days after the delivery of the Resignation Notice, the Escrow Agent shall not have received written instructions from Buyer and the Representative designating a banking corporation or trust company organized either under the laws of the United States or of any state as successor escrow agent and consented to in writing by such successor escrow agent, the Escrow Agent may apply to a court of competent jurisdiction to appoint a successor escrow agent. Alternatively, if the Escrow Agent shall have received such written instructions, it shall promptly transfer the Escrow Funds to such successor escrow agent. Upon the appointment of a successor escrow agent and the transfer of the Escrow Funds, and any other records, including without limitation, tax-related information, relating to the Escrow Funds or this Agreement by the resigning Escrow Agent to the successor escrow agent, the duties of such resigning Escrow Agent hereunder shall terminate.

(c) Each of Buyer and the Representative hereby agrees to pay the Escrow Agent reasonable compensation for its services hereunder in accordance with the “Schedule of Fees” attached hereto as Exhibit B and to reimburse the Escrow Agent for all expenses, disbursements and advances incurred or made by it in the performance of its duties hereunder and to indemnify and hold the Escrow Agent harmless from and against any and all taxes, expenses (including reasonable counsel fees), assessments, liabilities, claims, damages, actions, suits or other charges incurred by or assessed against it for anything done or omitted by it in the performance of its duties hereunder, except as a result of its own gross negligence or willful misconduct. Buyer and the Representative, on behalf of the Equityholders, shall share equally in all payments owing under this Section 6(c), although liability for such payments if not paid in a timely

6

manner shall be the responsibility of the party responsible therefore. The Representative’s portion of such payments shall be funded from the Escrow Fund (without any requirement of any written instruction or directive from the Representative), and Buyer agrees to execute a Notice of Claim pursuant to Section 5(a) of this Agreement authorizing the Escrow Agent to release such portion of the Representative’s payments to the Escrow Agent. The agreement contained in this Section 6(c) shall survive any termination of the duties of the Escrow Agent hereunder.

(d) THE ESCROW AGENT SHALL NOT BE LIABLE, DIRECTLY OR INDIRECTLY, FOR ANY (I) DAMAGES, LOSSES OR EXPENSES ARISING OUT OF THE SERVICES PROVIDED HEREUNDER, OTHER THAN DAMAGES, LOSSES OR EXPENSES WHICH HAVE BEEN FINALLY ADJUDICATED TO HAVE DIRECTLY RESULTED FROM THE ESCROW AGENT’S GROSS NEGLIGENCE OR WILLFUL MISCONDUCT, OR (II) SPECIAL, INDIRECT OR CONSEQUENTIAL DAMAGES OR LOSSES OF ANY KIND WHATSOEVER (INCLUDING WITHOUT LIMITATION LOST PROFITS), EVEN IF THE ESCROW AGENT HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES AND REGARDLESS OF THE FORM OF ACTION.

(e) The Escrow Agent shall have no duties or responsibilities, including, without limitation, a duty to review or interpret the Purchase Agreement, except those expressly set forth herein, and no implied duties shall be read into this Agreement. It may consult with counsel, shall be fully protected with respect to any action taken or omitted in good faith on advice of counsel and shall have no liability hereunder except for gross negligence, fraud or willful misconduct. The Escrow Agent shall have no responsibility as to the validity, collectibility or value of the Escrow Funds or for investment losses related thereto, provided the Escrow Funds have been invested in accordance with Section 2 above, and it may rely on any notice, instruction, certificate, statement, request, consent, confirmation, agreement or other instrument which it reasonably believes to be genuine and to have been signed or presented by a proper person or persons. If the Escrow Agent shall be uncertain as to its duties or rights hereunder or shall receive instructions from any of the undersigned with respect to the Escrow Funds, which, in its opinion, are in conflict with any of the provisions of this Escrow Agreement, it shall be entitled to refrain from taking any action until it shall be directed otherwise in writing by the other parties hereto or by order of a court of competent jurisdiction or the Escrow Agent may file an interpleader action in any court of competent jurisdiction, and upon the filing thereof, the Escrow Agent shall be relieved of all liability as to the Escrow Funds and shall be entitled to recover attorneys’ fees, expenses and other costs incurred in commencing and maintaining any such interpleader action. Notwithstanding any provision to the contrary contained in any other agreement between any of the parties hereto, the Escrow Agent shall have no interest in the Escrow Funds except as provided in this Escrow Agreement and shall hold such funds in trust in accordance herewith.

7

(f) All notices, consents and other communications under this Escrow Agreement shall be in writing and shall, except as otherwise provided herein, be deemed to have been received when (i) delivered by hand, (ii) sent by facsimile (with receipt confirmed), provided that a copy is mailed by certified mail, return receipt requested, or (iii) when received by the addressee, if sent by Express Mail, Federal Express or other express delivery service (receipt requested), in each case, at the appropriate addresses and facsimile numbers as set forth below:

If to Escrow Agent:
	Wells Fargo Bank, N.A.
	Corporate Trust & Escrow Services
	707 Wilshire Boulevard, 17th Floor
	Los Angeles, CA 90017
	Attention: Tom Orlina
	Telephone: (213) 614-4117
	Facsimile:  (213) 625-4406
Wire Instructions:	Indemnification Escrow Account
	Working Capital Escrow Account
If to Buyer:	BioMarin Pharmaceutical Inc.
	105 Digital Drive
	Novato, CA 94949
	Attn: Chief Executive Officer
	Fax: (415) 382-7889
with a copy to:
	BioMarin Pharmaceutical Inc.
	105 Digital Drive
	Novato, CA 94949
	Attn: General Counsel
	Fax: (415) 382-7889
If to the Representative:	Arthur Pappas
	c/o A.M. Pappas & Associates, LLC
	P.O. Box 110287
	Research Triangle Park, NC 27709
Or (for Fedex deliveries)
	2520 Meridian Parkway
	Suite 400
	Durham, NC 27713
	Fax: (919) 998-3302
with a copy (which shall not constitute notice) to:
	Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P.
	2500 Wachovia Capitol Center
	P.O. Box 2611
	Raleigh, NC 27602
	Attn: Gerald F. Roach
	Fax: (919) 821-6800

8

(or to such other addresses and facsimile numbers as a party may designate as to itself by notice to the other parties in accordance with this Section 6(f)). Concurrently with the execution of this Escrow Agreement, the Buyer shall deliver to the Escrow Agent authorized signers’ forms in the form of Exhibit C to this Escrow Agreement.

(g) Nothing in this Agreement shall be construed to limit the right of Buyer, the Representative or any of the Equityholders under any provision of the Purchase Agreement.

(h) This Agreement, including the validity hereof and the rights and obligations of the parties hereunder, shall be construed in accordance with and governed by the laws of the State of Delaware applicable to contracts made and to be performed entirely in the State of Delaware (without giving effect to the conflicts of laws provisions thereof).

(i) Any corporation or association into which the Escrow Agent may be converted or merged, or with which it may be consolidated, or to which it may sell or transfer all or substantially all of its corporate trust business and assets as a whole or substantially as a whole, or any corporation or association resulting from any such conversion, sale, merger, consolidation or transfer to which the Escrow Agent is a party, shall be and become the successor escrow agent under this Escrow Agreement and shall have and succeed to the rights, powers, duties, immunities and privileges as its predecessor, without the execution or filing of any instrument or paper or the performance of any further act.

(j) This Escrow Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original instrument and all of which together shall constitute a single agreement.

(k) All covenants and agreements set forth in this Agreement and made by or on behalf of any of the parties hereto shall bind and inure to the benefit of the successors, heirs and assigns of such party, whether or not so expressed. None of the parties may assign or transfer any of their respective rights or obligations under this Agreement without the consent in writing of the other parties hereto, except as otherwise provided herein and provided that Buyer may assign or transfer its rights and obligations hereunder in connection with a change of control of Buyer or its permitted successors or assigns, or to any other permitted assignee under the Purchase Agreement.

(l) In the event that any one or more of the provisions contained herein is held invalid, illegal or unenforceable in any respect for any reason in any jurisdiction, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions hereof shall not be in any way impaired or affected, it being intended that each of the parties’ rights and privileges shall be enforceable to the fullest extent permitted by law, and any such invalidity, illegality and unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.

9

(m) Except as specifically set forth or referred to herein, nothing herein expressed or implied is intended or shall be construed to confer upon or give to any person other than Buyer, any Buyer Indemnified Party, the Representative, the Equityholders, the Escrow Agent and their respective permitted successors and assigns any rights or remedies under or by reason of this Agreement or any other certificate, document, instrument or agreement executed in connection herewith.

(n) This Agreement shall terminate upon the disbursement by the Escrow Agent of all the Escrow Funds in accordance with this Agreement; provided, however, that the provisions of Section 6(c) hereof shall survive such termination. This Agreement may be amended only with the written consent of all parties hereto. No waiver of any right or remedy hereunder shall be valid unless the same shall be in writing and signed by the party giving such waiver.

[SIGNATURE PAGE FOLLOWS]

10

IN WITNESS WHEREOF, the undersigned have executed this Escrow Agreement as of the date first written above.

WELLS FARGO BANK, N.A.,

as Escrow Agent

By:

Name:

Title:

BIOMARIN PHARMACEUTICAL INC.

By:

Name:

Title:

REPRESENTATIVE

Arthur Pappas

EXHIBIT A

Direction for Investment of Cash Balances

Wells Fargo Money Market Deposit Accounts

Direction to use the following Wells Fargo Money Market Deposit Accounts for Cash Balances for the following account(s):

Account Name:

Account Number(s):

You are hereby directed to deposit, as indicated below, or as we shall direct further in writing from time to time, all cash in the Account(s) in the following money market deposit account of Wells Fargo Bank, National Association (Bank):

    Wells Fargo Money Market Deposit Account (MMDA)

I understand that amounts on deposit in the MMDA are insured, subject to the applicable rules and regulations of the Federal Deposit Insurance Corporation (FDIC), in the basic FDIC insurance amount of $100,000 per depositor, per insured bank. This includes principal and accrued interest up to a total of $100,000.

We acknowledge that we collectively have full power to direct investments of the Account(s).

We understand that we may change this direction at any time and that it shall continue in effect until revoked or modified by us by written notice to you.

BIOMARIN PHARMACEUTICAL INC.

By:

Name:

Title:

REPRESENTATIVE

Arthur Pappas

EXHIBIT B

SCHEDULE OF FEES

Wells Fargo Corporate Trust

707 Wilshire Blvd – 17^th Floor

Los Angeles, CA 90017

John Deleray (JD/TC)

213.614.3351 – office

213.760.0363 – mobile

213.614.3355 - fax

Wells Fargo Corporate Trust Services

Fee Schedule for Escrow Agent for the

BioMarin/LEAD Cash Escrow

Escrow Agent Acceptance and Administrative Fee: $ 3,000.00

Fees as they relate to Wells Fargo Bank acting in the capacity of Escrow Agent – includes creation and examination of the Escrow Agreement; acceptance of the Escrow appointment; setting up of Escrow Account(s) and accounting records; and coordination of receipt of funds for deposit to the Escrow Account.

Also includes ordinary administration services by Escrow Agent – includes daily routine account management; investment transactions; cash transaction processing (including wires and check processing); monitoring claim notices pursuant to the agreement; disbursement of the funds in accordance with the agreement; and mailing of trust account statements to all applicable parties.

Tax reporting is included for up to Twenty (20) entities. Should additional reporting be necessary, a $25 per reporting charge will be assessed.

This fee is Payable in advance, at the time of Escrow Agreement execution. Fee will not be prorated in case of early termination.

Should this Escrow Account be in existence for more than [****], an Annual Fee of $2,000.00 will be assessed.

Out-of-Pocket Expenses: At Cost

We only charge for out-of-pocket expenses in response to specific tasks assigned by the client. Therefore, we cannot anticipate what specific out-of-pocket items will be needed or what corresponding expenses will be incurred. Possible expenses would be, but are not limited to, express mail and messenger charges, travel expenses to attend closing or other meetings. There are no charges for indirect out-of-pocket expenses.

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

EXHIBIT C

CERTIFICATE AS TO AUTHORIZED SIGNATURES

The specimen signatures shown below are the specimen signatures of the individuals who have been designated as authorized representatives of BioMarin Pharmaceutical, Inc. and are authorized to initiate and approve transactions of all types for the escrow account or accounts established under the Escrow Agreement to which this Exhibit C is attached, on behalf of BioMarin Pharmaceutical, Inc.

Name / Title	Specimen Signature
Name Title	Signature
Name Title	Signature
Name Title	Signature
Name Title	Signature

EXHIBIT B

RELEASE OF ALL CLAIMS AGREEMENT

This Release of All Claims (“Agreement”) is made by and between LEAD Therapeutics, Inc., a Delaware corporation (the “Company”) and                              (“Releasor”) based on the following facts:

a. The Company has offered, and Releasor has accepted, payment of the sum set forth in Section 1 below in exchange for a general release of all claims.

b. Through this Agreement, Releasor intends to release all known and unknown claims that Releasor could assert against any released parties pursuant to Section 2 below, other than those claims expressly excluded.

WHEREFORE, the Company and Releasor agree as follows:

1. In consideration of the promises and representations of Releasor as described in this Agreement, the Company will pay Releasor the gross sum of $                        as set forth on the Participating Service Provider Certificate (as the terms Bonus Amount and Participation Service Provider Certificate are defined in that certain Stock Purchase Agreement, dated February __, 2010, by and among BioMarin, the Company, the parties listed on Schedule A thereto and Arthur Pappas, acting in his capacity as Equityholder Representative (“Stock Purchase Agreement”)), less federal and state withholdings (“Consideration”). The Company shall provide Releasor with the Consideration within one week after the later of: (a) Effective Date as defined in Section 4(e) below; or (b) the final determination of the Net Working Capital Excess Amount or Net Working Capital Deficiency Amount as defined in the Stock Purchase Agreement. Releasor acknowledges that Releasor would not be entitled to receive any portion of the Consideration absent this Agreement.

2. Except for the rights and obligations expressly set forth herein, Releasor, for Releasor and for each of Releasor’s past and present agents, assigns, transferees, heirs, spouses, relatives, executors, attorneys, administrators, employees, predecessors, affiliates, successors, insurers, and representatives (“Releasors”), hereby releases and discharges the Company, BioMarin Pharmaceutical Inc. (“BioMarin”), and their respective past and present agents, assigns, transferees, attorneys, administrators, officers, directors, stockholders, employees, predecessors, subsidiaries, parents, affiliates, successors, insurers, and representatives (“Releasees”) from any and all claims and causes of action, known or unknown, which Releasors now have or may have against any of the Releasees arising through the Effective Date. This release is intended to be interpreted broadly and is intended to include, without limitation, all common law claims (including but not limited to: breach of contract, breach of the covenant of good faith and fair dealing, wrongful discharge in violation of public policy, infliction of emotional distress, negligence, invasion of privacy, interference with contractual relationship, defamation and fraud), as well as any statutory claims (including but not limited to claims arising under: the Age Discrimination in Employment Act as amended, 29 U.S.C. § 621 et seq.; Title VII of the Civil Rights Act of 1964, as amended by the Civil Rights Act of 1991, 42 U.S.C. § 2000 et seq.; the Civil Rights Act of 1866, 42 U.S.C. § 1981; the Family and Medical Leave Act of 1993, 29 U.S.C. § 2601 et seq.; the Americans with Disabilities Act of 1990, 42 U.S.C. § 12101 et seq.; the False Claims Act , 31 U.S.C. § 3729 et seq.; the Fair Labor Standards Act, 29 U.S.C. § 215 et seq.,

-1-

the Worker Adjustment and Retraining Notification Act, 29 U.S.C. § 2102 et seq., as well as claims under the California Fair Employment and Housing Act, Cal. Govt. Code § 12900 et seq.; the California False Claims Act, Cal. Govt. Code § 12650 et seq.; the California Corporate Criminal Liability Act, Cal. Penal Code § 387; or under the California Labor Code or under any other state or local law governing employment), any claim for unpaid wages or any discretionary bonus, or any other claim whatsoever arising out of Releasor’s engagement by the Company or the termination of Releasor’s relationship with the Company, other than those that cannot be released as a matter of law. Releasor and the Company expressly acknowledge and agree that neither the Company nor Releasor would enter into this Agreement but for the representation and warranty that Releasor is hereby releasing any and all claims of any nature whatsoever, known or unknown, whether statutory or at common law, which Releasor now has or could assert directly or indirectly against any of the Releasees (other than as expressly set forth herein). Notwithstanding the generality of the foregoing, Releasor does not release the following claims and/or rights, if applicable to such Releasor:

a. Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;

b. Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;

c. Claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of the federal law known as the Consolidated Omnibus Budget Reconciliation Act (COBRA) or benefits under the Company's written employee benefit plans governed by the Employee Retirement Income Security Act (ERISA) in which Releasor is a participant;

d. Claims to severance or bonus payments pursuant to Releasor’s written employment agreement in effect immediately prior to the Closing (as defined in the Stock Purchase Agreement) or paid time off/vacation pursuant to the Company's applicable written policies in effect immediately prior to the Closing;

e. Claims to indemnity under California Labor Code Section 2802;

f. Rights under the indemnification provisions of the Company’s certificate of incorporation or bylaws as in effect on the Closing Date (as defined in the Agreement), the Agreement or any indemnification agreement between Releasor and the Company or BioMarin;

g. Rights under the Company’s or BioMarin’s directors’ and officers’ liability insurance policies; and

h. Rights to consideration payable pursuant to Article II of the Stock Purchase Agreement.

-2-

3. Releasor waives all the benefits and rights granted by California Civil Code section 1542, and any other applicable similar state laws, which provides:

A general release does not extend to claims which the creditor

does not know or suspect to exist in his or her favor at the time

executing the release, which, if known by him or her must have

materially affected his or her settlement with the debtor.

4. This Agreement is intended to release and discharge any claims of Releasor under the Age Discrimination and Employment Act. To satisfy the requirements of the Older Workers’ Benefit Protection Act, 29 U.S.C. section 626(f), the parties agree as follows:

a. Releasor acknowledges that Releasor has read and understands the terms of this Agreement.

b. Releasor acknowledges that Releasor has been advised to consult with an attorney, if desired, concerning this Agreement and has received all advice Releasor deems necessary concerning this Agreement.

c. Releasor acknowledges that Releasor has been given forty-five days from receipt of this Agreement to consider whether or not to enter into this Agreement (“Execution Deadline”), has taken as much of this time as necessary to consider whether to enter into this Agreement, and has chosen to enter into this Agreement freely, knowingly and voluntarily.

d. The eligibility requirements, job titles and ages of all individuals eligible or selected to participate in this program in exchange for a release, and the ages of all individuals in the same job classification or organizational unit who have not been made a similar offer are listed on the form attached as Appendix A, and is incorporated by this reference as though fully set forth herein.

e. The Effective Date of this Agreement shall be as follows: (a) where Releasor has not yet turned forty years of age as of the date this Agreement is provided to Releasor, this Agreement shall become effective on the date it is first signed by Releasor; or (b) where Releasor is forty or more years of age as of the date this Agreement is provided to Releasor, for a seven day period following the execution of this Agreement by Releasor, Releasor may revoke this Agreement by delivering a written revocation to Company’s Chief Executive Officer or General Counsel at the following address:

BioMarin Pharmaceutical Inc.

105 Digital Drive

Novato, CA 94949

Attn: Chief Executive Officer/General Counsel

Fax: (415) 382-7889

, and this Agreement shall not become effective and enforceable until the revocation period has expired. If Releasor does not sign this Agreement and provide the Company with an executed copy of the Agreement on or before the Execution Deadline or revokes the Agreement before the Effective Date, Releasor shall not receive the Consideration or any other compensation Releasor would not otherwise be entitled to in the absence of this Agreement.

-3-

5. Releasor acknowledges and agrees that Releasor has no pending lawsuit, administrative charge or complaint against the Company or any of the other Releasees, in any court or with any governmental agency. Releasor also agrees that, to the extent permitted by law, Releasor will not allow any lawsuit, administrative charge or complaint to be pursued on Releasor’s behalf against any of the Releasees. Releasor further agrees that Releasor will not participate, cooperate or assist in any litigation against the Releasees in any manner, to the extent permitted by law. If lawfully subpoenaed by a court of this jurisdiction, Releasor agrees to provide the Company written notice of such a subpoena within five (5) days of receipt.

6. Releasor agrees that Releasor will not disparage, defame or otherwise detrimentally comment upon the Releasees, including their business practices or products, in any manner. Releasor acknowledges that such comment shall cause serious damage to the Company.

7. Releasor represents and warrants that Releasor has not heretofore assigned, transferred or purported to assign or transfer to any other person or entity any rights, claims or causes of action herein released and discharged, and no other person or entity has any interest in the matters herein released and discharged. Furthermore, Releasor shall indemnify and hold the Company and all persons or entities released herein harmless from and against any rights, claims or causes of action which have been assigned or transferred contrary to the foregoing representations, or in violation of the foregoing warranties, and shall hold such persons or entities harmless from any and all loss, expense and/or liability arising directly or indirectly out of the breach of any of the foregoing representations or warranties.

8. This Agreement is a compromise and settlement of disputed claims being released herein, and therefore this Agreement does not constitute an admission of liability on the part of the Company or any Releasees, or an admission, directly or by implication, that the Company or any of the Releasees has violated any law, rule, regulation, policy or any contractual right or other obligation owed to any party.

9. This Agreement may be pled as a full and complete defense and may be used as the basis for an injunction against any action, suit, or proceeding that may be prosecuted, instituted, or attempted by Releasor or the Company in breach thereof.

10. This Agreement shall be construed in accordance with, and be deemed governed by, the laws of the State of California, and the Company and Releasor agree that the proper forum and venue for any action brought arising out of or relating in anyway to this Agreement shall be in San Francisco, California.

11. Releasor agrees that this Agreement has been negotiated by the parties, and that no provision contained herein shall be interpreted against any party because that party drafted the provision.

12. This Agreement contains the entire agreement between the parties on the subjects addressed in this Agreement and replaces any other prior agreements between the parties on these subjects. This Agreement may only be modified in a written document signed by the Company’s Chief Executive Officer.

-4-

13. Releasor and the Company represent and warrant that they are not relying, and have not relied, on any representations or statements, verbal or written, made by any other with regard to the facts involved in this controversy or with regard to their rights or asserted rights arising out of alleged claims or the execution and terms of this Agreement, except as provided herein. Releasor and the Company have consulted with an attorney regarding the terms of this Agreement and have entered into this Agreement freely, willingly and without any coercion or duress.

14. The Company and Releasor shall execute any and all further documents that may be required to effectuate the purposes of this Agreement.

15. This Agreement shall be binding upon and shall inure to the benefit of the Company and Releasor and to their respective representatives, successors, heirs, agents and assigns.

16. This Agreement may be executed in counterparts, and if so executed each such counterpart shall have the force and effect of an original. Photocopies of such signed counterparts may be used in lieu of the originals for any purpose.

17. In the event any provision of this Agreement shall be found unenforceable by a court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefits contemplated herein to the fullest extent permitted by law. If a deemed modification is not satisfactory in the judgment of such court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.

18. No breach of any provision of this Agreement can be waived unless in writing. Waiver of any one breach shall not be deemed to be a waiver of any other breach of the same or any other provision of this Agreement.

19. Each individual signing this Agreement directly and expressly warrants that he/she has been given and has received and accepted authority to sign and execute the documents on behalf of the party for whom it is indicated he/she has signed, and further has been expressly given and received and accepted authority to enter into a binding agreement on behalf of such party with respect to the matters concerned herein and as stated herein.

[Signature Page Follows]

-5-

WE, THE UNDERSIGNED, HAVE READ THE FOREGOING AND, HAVING BEEN ADVISED BY COUNSEL, FULLY UNDERSTAND AND AGREE TO ITS TERMS,

Dated:                                 , 2010
	[Releasor]

	LEAD Therapeutics, Inc.
Dated:                                 , 2010
	By:
	Its:

-6-

APPENDIX A

I. PROGRAM REQUIREMENTS.

In order to receive the consideration set forth in the attached Agreement, Releasor must meet the following requirements:

A. Execute and provide the Company with the attached Agreement on or before the Execution Deadline, and not revoke the Agreement for a period of seven days after its execution, if applicable.

B. Selected for participation in the program by the Company.

The Company selected individuals for participation in this program based on position held, duties performed, contributions to the Company, and performance.

II. JOB TITLES AND AGES OF ALL EMPLOYEES WHO ARE AND ARE NOT ELIGIBLE TO PARTICIPATE IN THE PROGRAM.

ELIGIBLE TO PARTICIPATE		NOT ELIGIBLE TO PARTICIPATE
Position	Age	Position	Age

-7-

EXHIBIT C

OPTION HOLDER CONSENT AGREEMENT

THIS OPTION HOLDER CONSENT AGREEMENT (this “Agreement”), dated as of                         , 2010, is entered into by and among BioMarin Pharmaceutical Inc., a Delaware corporation (“Buyer”), LEAD Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned holder (the “Option Holder”) of options to acquire shares of common stock of the Company (the “Company Options”).

RECITALS

WHEREAS, pursuant to that certain Stock Purchase Agreement (the “Stock Purchase Agreement”) dated as of February __, 2010 by and among Buyer, the Company, the parties listed on Schedule A thereto (each a “Seller” and collectively the “Sellers”), and Arthur Pappas, acting in his capacity as representative of the equityholders of the Company (the “Equityholder Representative”), Sellers will sell, assign, transfer, convey and deliver, or cause to be sold, assigned, transferred, conveyed and delivered, to Buyer, and Buyer shall purchase from the Sellers, all of the shares of capital stock of the Company;

WHEREAS, capitalized terms used herein and not defined shall have the meaning ascribed to such terms in the Stock Purchase Agreement;

WHEREAS, the Option Holder is the owner of the Company Options listed on Schedule A hereto; and

WHEREAS, the Option Holder wishes to (a) consent to the treatment of the Company Options as set forth in the Stock Purchase Agreement and to waive all notice requirements contained in any other agreement related to the Company Options, (b) approve and appoint the Equityholder Representative as set forth in the Stock Purchase Agreement, and (c) be bound by and comply with the obligations of the Equityholders as set forth in the Stock Purchase Agreement and the Escrow Agreement.

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

ARTICLE I CONSENT

Section 1.1 Receipt of Stock Purchase Agreement. The Option Holder acknowledges that it has reviewed the Stock Purchase Agreement and the attachments thereto (including the Escrow Agreement), and has had ample opportunity to discuss with representatives of the Company any questions relating to the Company, the Stock Purchase Agreement and the transactions contemplated by the Stock Purchase Agreement and the Escrow Agreement.

Section 1.2 Company Options. The Option Holder acknowledges, agrees and consents that, notwithstanding anything to the contrary contained in the agreements or instruments regarding the Company Options held by the Option Holder, each Company Option held by the Option Holder granted under the Company Option Plan or otherwise, whether or not currently vested or

exercisable immediately prior to the Closing Date, and which remains outstanding immediately prior to the Closing Date, will, at the Closing, be cancelled, no longer be outstanding and cease to represent the right to acquire shares of Common Stock, and in consideration for such cancellation, the Option Holder will have the right to receive the amounts payable with respect to such Company Options pursuant to Section 2.1 of the Stock Purchase Agreement.

Section 1.3 Waiver of Notice Requirement. The Option Holder waives all notice requirements which it may have or may be entitled to have with respect to its Company Options in regards to the Stock Purchase Agreement and the transactions contemplated thereby, including with respect to the treatment of its Company Options.

Section 1.4 Appointment of Equityholder Representative. The Option Holder irrevocably constitutes and appoints, effective as of the Closing, together with his permitted successors, the Equityholder Representative, as its true and lawful agent, proxy and attorney-in-fact, to execute and deliver the Stock Purchase Agreement and the Escrow Agreement on its behalf and exercise all or any of the powers, authority and discretion conferred on him under the Stock Purchase Agreement, the Escrow Agreement and any documents related to the transaction contemplated hereby and thereby. The power of attorney granted in this Section 1.4 (i) is coupled with an interest and is irrevocable; (ii) may be delegated by the Equityholder Representative; and (iii) shall survive the dissolution, death or incapacity of the Option Holder.

Section 1.5 Indemnification Obligations. The Option Holder irrevocably agrees to, and shall be bound by and comply with, all of the indemnification obligations of the Equityholders set forth in the Stock Purchase Agreement and the Escrow Agreement including the Equityholders’ agreement to indemnify and reimburse the Buyer Indemnified Parties as set forth in Article IX of the Stock Purchase Agreement, it being understood that the Option Holder shall be an Equityholder for all purposes under the Stock Purchase Agreement and the Escrow Agreement.

Section 1.6 Escrow. The Option Holder irrevocably agrees to be bound by and comply with the Escrow Agreement and all of the arrangements and provisions of the Stock Purchase Agreement relating thereto, including the deposit of the Indemnification Escrow Amount and Working Capital Escrow Amount into escrow.

Section 1.7 Equityholder Representative Reimbursement. The Option Holder irrevocably agrees to be bound by and comply with the Equityholders’ obligations with respect to the Equityholder Representative’s Fund Amount as set forth in the Stock Purchase Agreement, including the deposit of the Equityholder Representative’s Fund Amount into the Equityholder Representative’s Fund. The Option Holder acknowledges that the Equityholders indemnify and defend the Equityholder Representative and hold the Equityholder Representative harmless against any loss, damage, cost, Liability or expense incurred without fraud, gross negligence or willful misconduct by the Equityholder Representative and arising out of or in connection with the acceptance, performance or administration of the Equityholder Representative’s duties under this Stock Purchase Agreement. The Option Holder acknowledges that all expenses incurred by the Equityholder Representative in connection with the performance of its duties as Equityholder Representative shall be borne and paid by the Equityholders.

ARTICLE II REPRESENTATIONS AND WARRANTIES

Section 2.1 Power and Capacity. The Option Holder represents and warrants that: (a) it has full power and authority to execute and deliver this Agreement and to perform its obligations hereunder, (b) the execution and delivery of this Agreement by the Option Holder and the performance of its obligations hereunder have been duly authorized by all necessary action on the part of the Option Holder, and (c) this Agreement has been duly executed and delivered by the Option Holder and constitutes a valid and binding obligation of the Option Holder enforceable against the Option Holder in accordance with its terms.

ARTICLE III MISCELLANEOUS

Section 3.1 Entire Agreement. This Agreement, together with the Stock Purchase Agreement and the Escrow Agreement, contains the entire understanding of the parties with respect to the subject matter hereof and supersedes all previous oral and written communications, agreements and understandings between the parties with respect to the subject matter herein, including any agreements or instruments in respect of the Company Options. No change, modification or amendment of this Agreement shall be binding unless made in writing and signed by authorized representatives of all parties.

Section 3.2 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. This Agreement may be executed and delivered by facsimile transmission, and a facsimile of this Agreement or of a signature of a party will be effective as an original.

Section 3.3 Applicable Law; Submission to Jurisdiction. Except as otherwise provided in this Agreement, each party hereto irrevocably agrees that any legal action or proceeding with respect to this Agreement or for recognition and enforcement of any judgment in respect hereof brought by another party hereto or its successors or assigns shall be brought exclusively in the Court of Chancery in the State of Delaware to the fullest extent permitted by Applicable Law and, to the extent not so permitted, in any court sitting in the State of Delaware, and each of the Parties hereto hereby (x) irrevocably submits with regard to any such action or proceeding for itself and in respect to its property, generally and unconditionally, to the exclusive personal jurisdiction of the aforesaid courts in the event any dispute arises out of this Agreement or any transaction contemplated hereby, (y) agrees that it will not attempt to deny or defeat such personal jurisdiction by motion or other request for leave from any such court and (z) agrees that it will not bring any action relating to this Agreement or any transaction contemplated hereby in any court other than the aforesaid courts. Each of the parties hereto hereby irrevocably waives, and agrees not to assert, by way of motion, as a defense, counterclaim or otherwise, in any action or proceeding with respect to this Agreement, (a) the defense of sovereign immunity, (b) any claim that it is not personally subject to the jurisdiction of the above-named courts for any reason other than the failure to serve process in accordance with Applicable Law, (c) that it or its property is exempt or immune from jurisdiction of any such court or from any legal process commenced in such courts (whether through service of notice, attachment prior to judgment, attachment in aid of execution of judgment, execution of judgment or otherwise), and (d) to the fullest extent permitted by Applicable Law that (i) the suit, action or proceeding in any such court is brought in an inconvenient forum, (ii) the venue of such suit, action or proceeding is improper and (iii) this Agreement, or the subject matter hereof, may not be enforced in or by such courts.

Section 3.4 WAIVER OF TRIAL BY JURY. EACH PARTY HERETO HEREBY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.

Section 3.5 Waiver of Rights. The failure of a party to assert any right or remedy upon the breach of any provision of this Agreement shall not be deemed to be a waiver of any present or future right hereunder, unless said waiver is made in writing and signed by the party against whom enforcement is sought.

[Signature Page Follows]

IN WITNESS WHEREOF, each party has caused this Agreement to be duly executed on its behalf by its duly authorized officer as of the date first written above.

BIOMARIN PHARMACEUTICAL INC.

By:

Name:

Title:

LEAD THERAPEUTICS, INC.

By:

Name:

Title:

OPTION HOLDER

Signature:

Name:

SCHEDULE A

Option Holder Number of Company Options

Schedule A

ProQuest Investments IV, L.P.

ProQuest Management LLC

A.M. Pappas Life Science Ventures III, LP

PV III CEO Fund, LP

Mustang Ventures I, L.P.

China Gateway Life Science (Holdings) Ltd. (HK)

Shuang Qiao

Peter Myers

Leonard Post

Charles Hsu

Zhengying Pan

Xiaoyi Xiao

Daniel Chu

David Hanabusa

Schedule B

Initial Allocation Schedule (as of date of Stock Purchase Agreement)

Equityholder Name	Equityholder Address	Series A Preferred Stock	Company Notes (Principal Amount + Accrued and Unpaid Interest)	Number of Shares of Series A Preferred Stock into which Company Notes are Convertible	Common Stock	Series A Preferred Stock Warrants	Company Warrants Exercise Price		Common Stock Options	Company Options Exercise Price		ISO / NSO	Service Provider Status	Portion of Closing Payment		Pro Rata Allocation of Escrow Amount
ProQuest Investments IV, LP	[****]	6,000,000	[****]	3,007,937		1,428,571	$	1.00							[****]		[****]
A.M. Pappas Life Science Ventures III, LP	[****]	2,824,404	[****]	1,415,938	235,367	672,477	$	1.00							[****]		[****]
PV III CEO Fund, LP	[****]	175,596	[****]	88,030	14,633	41,809	$	1.00							[****]		[****]
Mustang Ventures I, L.P.	[****]	1,200,000	[****]	601,587		285,714	$	1.00							[****]		[****]
China Gateway Life Science (Holdings) Ltd. (HK)	[****]	300,000	[****]	150,395		71,429	$	1.00							[****]		[****]
ProQuest Management, LLC	[****]				250,000									$	—	$	—
Shuang Qiao	[****]				549,282				480,000	$	0.10	ISO	Employee	$	—	$	—
Peter Myers	[****]				280,500				619,500	$	0.10	ISO	Employee	$	—	$	—
Leonard Post	[****]				280,500				480,000	$	0.10	ISO	Employee	$	—	$	—
Charles Hsu	[****]				363,000									$	—	$	—
Zhengying Pan	[****]				5,208									$	—	$	—
Xiaoyi Xiao	[****]				6,510									$	—	$	—
Daniel Chu	[****]				97,500				247,500	$	0.10	ISO	Employee	$	—	$	—
David Hanabusa	[****]				30,000									$	—	$	—
Yuqiao Shen	[****]								160,000	$	0.10	ISO	Employee	$	—	$	—
Amy Pfeiffer	[****]								12,000	$	0.10	ISO	Employee	$	—	$	—
Bing Wang	[****]								90,000	$	0.10	ISO	Employee	$	—	$	—
Ying Feng	[****]								40,000	$	0.10	ISO	Employee	$	—	$	—

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Closing Date Allocation Schedule

Equityholder Name	Equityholder Address	Series A Preferred Stock	Common Stock	Series A Preferred Stock Warrants	Common Stock Options	Portion of Closing Payment		Pro Rata Allocation of Escrow Amount		Payment Method (Wire or Check)	Wire Transfer / Check Delivery Instructions	W-8 / W-9 Delivered
ProQuest Investments IV, LP	[****]	9,007,937		1,428,571			[****]		[****]	Wire	[****]
A.M. Pappas Life Science Ventures III, LP	[****]	4,240,342	235,367	672,477			[****]		[****]	Wire	[****]	W-9
PV III CEO Fund, LP	[****]	263,626	14,633	41,809			[****]		[****]	Wire	[****]	W-9
Mustang Ventures I, L.P.	[****]	1,801,587		285,714			[****]		[****]	Wire	[****]
China Gateway Life Science (Holdings) Ltd. (HK)	[****]	450,395		71,429			[****]		[****]	Wire	[****]
ProQuest Management, LLC	[****]		250,000			$	—	$	—	Wire	[****]
Shuang Qiao	[****]		549,282		480,000	$	—	$	—	Wire	[****]
Peter Myers	[****]		280,500		619,500	$	—	$	—	Check
Leonard Post	[****]		280,500		480,000	$	—	$	—	Check
Charles Hsu	[****]		363,000			$	—	$	—	Check
Zhengying Pan	[****]		5,208			$	—	$	—	Check
Xiaoyi Xiao	[****]		6,510			$	—	$	—	Check
Daniel Chu	[****]		97,500		247,500	$	—	$	—	Check
David Hanabusa	[****]		30,000			$	—	$	—	Check
Yuqiao Shen	[****]				160,000	$	—	$	—	Check
Amy Pfeiffer	[****]				12,000	$	—	$	—	Check
Bing Wang	[****]				90,000	$	—	$	—	Check
Ying Feng	[****]				40,000	$	—	$	—	Check

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Schedule C

Leonard Post

Daniel Chu

Jerry Shen

Bing Wang

Ying Feng

Hong Wang

LEAD THERAPEUTICS INC.

SCHEDULE 1.1(a)

Assumed Current Liabilities

[****]

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Lead Therapeutics, Inc

Estimated Closing Date Balance Sheet

	Feb 15, 10
ASSETS
Current Assets
Checking/Savings
Bank of China	12,265.86
ML - Institutional Fund A	1,416,505.00
ML - WCMA Money Fund	20,351.02
Petty Cash	290.45
Total Checking/Savings	1,449,412.33
Other Current Assets
China Personal Tax Prepaid	11,785.05
Employee Advances	—
Pre-paid Expense	27,807.45
Total Other Current Assets	39,592.50
Total Current Assets	1,489,004.83
Fixed Assets
Fixed Assets
Accumulated Depreciation	(46,679.16	)
Fixed Assets Purchased	70,818.16
Total Fixed Assets	24,139.00
Net Tenant Improvements
Tenant Improvements	18,257.60
TI-Accumulated Amortization	(16,377.70	)
Total Net Tenant Improvements	1,879.90
Total Fixed Assets	26,018.90
TOTAL ASSETS	1,515,023.73
LIABILITIES & EQUITY
Liabilities
Current Liabilities
Accounts Payable
Accounts Payable	143,884.56
Total Accounts Payable	143,884.56
Other Current Liabilities
401(k) Payable	—
AP Accrual	750,000.00
China Personal Tax Payable	—
Convertible Note (BioMarin)	3,027,123.29
Convertible Notes (Shareholders)	5,269,369.85
Direct Deposit Liabilities	—
EPRS Liability	94.00
Hypo-Tax Equalization Sch Prep	10,000.00
Payroll Liabilities	291,000.00
PTO Accrual	92,085.79
Safe Harbor Co. Contribution	6,639.45
Total Other Current Liabilities	9,446,312.38
Total Current Liabilities	9,590,196.94
Total Liabilities	9,590,196.94
Equity
Common Stock Summary
APIC-EPRS	(94.00	)
APIC-ESBC (Options)	91,659.55
APIC-ESBC (Restricted)	2,976.26
APIC-NSBC (Options)	5,739.83
APIC-NSBC (Restricted)	255.00
Common Stock
Charles Hsu	11,055.00
Daniel Chu	975.00
David Hanabusa	3,000.00
Leonard Post	2,805.00
Pappas Life Science V. III, LP	2,353.67
Peter Myers	2,805.00
ProQuest Investments IV, LP	2,500.00
PV III CEO Fund, LP	146.33
Shuang Qiao	6,617.82
Xiaoyi Xiao	104.17
Zhengying Pan	83.33
Total Common Stock	32,445.32
Total Common Stock Summary	132,981.96
Preferred Stock Summary
APIC-Series A Accretion	(83,250.12	)
Cost of Pref. Equity, Series A	(77,356.72	)
Series A Preferred Stock
China Gateway Life Science	300,000.00
Mustang Ventures I, L.P.	1,200,000.00
Pappas Life Science V. III, LP	2,824,404.00
ProQuest Investments IV, L.P.	6,000,000.00
PV III CEO Fund, LP	175,596.00
Total Series A Preferred Stock	10,500,000.00
Total Preferred Stock Summary	10,339,393.16
Retained Earnings	(17,242,760.99	)
Net Income	(1,304,787.34	)
Total Equity	(8,075,173.21	)
TOTAL LIABILITIES & EQUITY	1,515,023.73

Lead Therapeutics, Inc

Detail of Trade AP

February 15, 2010

[****]

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Lead Therapeutics, Inc

Unrecorded Liabilities

February 15, 2010

[****]

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

Lead Therapeutics, Inc

2/1/10 - 2/15/10 Payroll, Bonus, and Change of Control Payments

[****]

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

LEAD Therapeutics, Inc.

Balance Sheet

As of February 15, 2010

	Jan 31, 10	Feb 15, 10
ASSETS
Current Assets
Checking/Savings							Jan	Feb
Bank of China	20,065.86	12,265.86				Current Assets	1,505,811.49	1,489,004.83
ML - Institutional Fund A	1,416,505.00	1,416,505.00				Current Liabilities	750,634.80	1,293,703.80
ML - WCMA Money Fund	20,351.02	20,351.02
Petty Cash	290.45	290.45				Working Capital	755,176.69	195,301.03
Total Checking/Savings	1,457,212.33	1,449,412.33	(7,800.00	)	c
Other Current Assets						Adjustments
China Personal Tax Prepaid	8,985.05	11,785.05				Change of Control Payments	—	210,000.00	b
Employee Advances	0.00	0.00				February Payroll 2/1/10 - 2/10/15	—	87,069.00	sum a
Pre-paid Expense	39,614.11	27,807.45				February Operating Expenses	—	16,806.66	sum c
Total Other Current Assets	48,599.16	39,592.50	(9,006.66	)	c	February Operating Costs - Accounts Payable Accrual	—	246,000.00	d
Total Current Assets	1,505,811.49	1,489,004.83
Fixed Assets						Working Capital	755,176.69	755,176.69
Fixed Assets
Accumulated Depreciation	-46,054.16	-46,679.16
Fixed Assets Purchased	70,818.16	70,818.16
Total Fixed Assets	24,764.00	24,139.00
Net Tenant Improvements
Tenant Improvements	18,257.60	18,257.60
TI-Accumulated Amortization	-16,109.70	-16,377.70
Total Net Tenant Improvements	2,147.90	1,879.90
Total Fixed Assets	26,911.90	26,018.90
TOTAL ASSETS	1,532,723.39	1,515,023.73
LIABILITIES & EQUITY
Liabilities
Current Liabilities
Accounts Payable
Accounts Payable	143,884.56	143,884.56
Total Accounts Payable	143,884.56	143,884.56	—
Other Current Liabilities							Payroll Detail
401(k) Payable	0.00	0.00					81,000.00	a
AP Accrual	504,000.00	750,000.00	246,000.00		d - also see AP accrual detail		210,000.00	b
China Personal Tax Payable	0.00	0.00
Debt from BioMarin	3,020,958.91	3,027,123.29					291,000.00	e -also see payroll detail
Debt from Shareholders	5,252,931.49	5,269,369.85
Direct Deposit Liabilities	0.00	0.00
EPRS Liability	125.00	94.00	(31.00	)	a
Hypo-Tax Equilization Sch Prep	10,000.00	10,000.00	—
Payroll Liabilities	0.00	291,000.00	291,000.00		e - also see payroll tab
PTO Accrual	88,385.79	92,085.79	3,700.00		a
Safe Harbor Co. Contribution	4,239.45	6,639.45	2,400.00		a
Total Other Current Liabilities	8,880,640.64	9,446,312.38	526,262.34
Total Current Liabilities	9,024,525.20	9,590,196.94
Total Liabilities	9,024,525.20	9,590,196.94
Equity
Common Stock Summary
APIC-EPRS	-125.00	-94.00
APIC-ESBC (Options)	90,249.55	91,659.55
APIC-ESBC (Restricted)	2,976.26	2,976.26
APIC-NSBC (Options)	5,739.83	5,739.83
APIC-NSBC (Restricted)	255.00	255.00
Common Stock
Charles Hsu	11,055.00	11,055.00
Daniel Chu	975.00	975.00
David Hanabusa	3,000.00	3,000.00
Leonard Post	2,805.00	2,805.00
Pappas Life Science V. III, LP	2,353.67	2,353.67
Peter Myers	2,805.00	2,805.00
ProQuest Investments IV, LP	2,500.00	2,500.00
PV III CEO Fund, LP	146.33	146.33
Shuang Qiao	6,617.82	6,617.82
Xiaoyi Xiao	104.17	104.17
Zhengying Pan	83.33	83.33
Total Common Stock	32,445.32	32,445.32
Total Common Stock Summary	131,540.96	132,981.96
Preferred Stock Summary
APIC-Series A Accretion	-83,250.12	-83,250.12
Cost of Pref. Equity, Series A	-77,356.72	-77,356.72
Series A Preferred Stock
China Gateway Life Science	300,000.00	300,000.00
Mustang Ventures I, L.P.	1,200,000.00	1,200,000.00
Pappas Life Science V. III, LP	2,824,404.00	2,824,404.00
ProQuest Investments IV, L.P.	6,000,000.00	6,000,000.00
PV III CEO Fund, LP	175,596.00	175,596.00
Total Series A Preferred Stock	10,500,000.00	10,500,000.00
Total Preferred Stock Summary	10,339,393.16	10,339,393.16
Retained Earnings	-17,242,760.99	-17,242,760.99
Net Income	-719,974.94	-1,304,787.34	(584,812.40	)
Total Equity	-7,491,801.81	-8,075,173.21
TOTAL LIABILITIES & EQUITY	1,532,723.39	1,515,023.73

LEAD Therapeutics, Inc.

Profit & Loss

November 1, 2009 through February 15, 2010

	Nov 09	Dec 09	Jan 10	Feb 1 - 15, 10	TOTAL
Ordinary Income/Expense
Expense
****Payroll Expenses
Bonus	0.00	0.00	0.00	97,000.00	97,000.00
Salaries	146,308.21	149,338.32	141,658.32	194,000.00	631,304.85
****Payroll Expenses - Other	93.89	24.91	93.88	0.00	212.68
Total ****Payroll Expenses	146,402.10	149,363.23	141,752.20	291,000.00	728,517.53
***Fringe Benefits
401(k) Safe Harbor Employer Con	47,000.00	3,023.00	1,966.58	2,400.00	54,389.58
CA - Unemployment Company	0.00	0.00	2,205.00	0.00	2,205.00
Dental Insurance	1,267.00	1,267.00	1,267.00	1,267.00	5,068.00
Emp Stk Based Comp (Options)	2,803.14	2,803.14	2,803.14	1,410.00	9,819.42
Employee Copays	-406.62	-1,219.86	-813.24	0.00	-2,439.72
Federal Unemployment	0.00	0.00	504.00	0.00	504.00
HRA Expense	13,500.00	0.00	0.00	0.00	13,500.00
Life Insurance	5,030.22	2,138.46	2,138.46	1,069.46	10,376.60
Medical Insurance	12,583.00	12,583.00	12,583.00	5,658.00	43,407.00
Medicare Company	1,029.11	3,186.48	2,014.70	0.00	6,230.29
Payroll Processing Fees	0.01	0.00	0.00	0.00	0.01
PTO Accrual Expense	0.00	12,346.81	6,093.74	3,700.00	22,140.55
Social Security Company	525.85	879.03	8,614.60	0.00	10,019.48
Total ***Fringe Benefits	83,331.71	37,007.06	39,376.98	15,504.46	175,220.21
**People Related Expenses
Consulting
Bus Dev	39,300.00	-2,175.00	0.00	0.00	37,125.00
G&A Consulting	5,460.80	7,942.48	9,597.51	2,500.00	25,500.79
IT Consulting	593.75	2,000.00	1,500.00	1,000.00	5,093.75
PARP - Development	33,750.00	25,457.00	41,440.00	17,000.00	117,647.00
Public Relations	0.00	1,372.00	0.00	0.00	1,372.00
Total Consulting	79,104.55	34,596.48	52,537.51	20,500.00	186,738.54
Contractors (CRO’s)
Cyp 17-Bio	2,000.00	0.00	0.00	0.00	2,000.00
Cyp 17-Chem	93,500.00	129,166.67	110,166.67	60,500.00	393,333.34
Glyco-Bio	33,020.00	0.00	0.00	0.00	33,020.00
PARP-Bio	53,568.00	41,269.00	17,000.00	8,000.00	119,837.00
PARP-Chem	92,500.00	46,200.00	62,500.00	31,500.00	232,700.00
PARP-Development	229,436.00	10,119.70	89,666.25	26,000.00	355,221.95
Total Contractors (CRO’s)	504,024.00	226,755.37	279,332.92	126,000.00	1,136,112.29
Legal Fees
Corporate	91,000.00	111,464.41	77,909.25	65,000.00	345,373.66
Patents	84,182.08	40,556.05	55,609.92	32,000.00	212,348.05
Total Legal Fees	175,182.08	152,020.46	133,519.17	97,000.00	557,721.71
Total **People Related Expenses	758,310.63	413,372.31	465,389.60	243,500.00	1,880,572.54
*Operations
Apartment Rent	1,713.53	0.00	0.00	0.00	1,713.53
Bank Service Charges	90.00	240.00	210.00	0.00	540.00
Conferences & Seminars	725.00	1,450.00	0.00	0.00	2,175.00
Dues and Subscriptions	2,050.00	4,050.00	0.00	2,000.00	8,100.00
Investors’ Expenses	8,055.93	15,576.88	1,686.38	0.00	25,319.19
Lab Supplies
Cyp17 - Chem	0.00	3,910.27	2,779.77	0.00	6,690.04
Glyco-Chem	1,341.70	1,548.00	0.00	0.00	2,889.70
PARP-Bio	718.19	0.00	0.00	0.00	718.19
Total Lab Supplies	2,059.89	5,458.27	2,779.77	0.00	10,297.93
Licenses and Permits	105.00	0.00	0.00	0.00	105.00
Miscellaneous	375.99	0.00	20.15	0.00	396.14
Postage and Delivery	186.78	600.05	249.88	0.00	1,036.71
Printing and Reproduction	9.43	447.93	0.00	0.00	457.36
Taxes
China Rep Office Business Tax	18,969.96	0.00	0.00	0.00	18,969.96
China Rep Office Corporate Tax	9,494.55	0.00	0.00	0.00	9,494.55
State	0.00	42.86	1,000.00	0.00	1,042.86
Total Taxes	28,464.51	42.86	1,000.00	0.00	29,507.37
Travel & Entertainment
Airfare, Rail, Etc.	4,263.51	2,459.98	0.00	0.00	6,723.49
Auto Rental, taxi	676.05	371.78	234.47	0.00	1,282.30
Cell Phones	82.43	0.00	0.00	0.00	82.43
Lodging	1,860.81	2,620.67	0.00	0.00	4,481.48
Meals and Entertainment	303.64	15,530.02	113.85	0.00	15,947.51
Parking, toll, etc.	185.50	84.00	0.00	0.00	269.50
Phone Cards	611.55	674.84	0.00	0.00	1,286.39
Travel & Entertainment - Other	0.00	2,405.25	888.40	0.00	3,293.65
Total Travel & Entertainment	7,983.49	24,146.54	1,236.72	0.00	33,366.75
Total *Operations	51,819.55	52,012.53	7,182.90	2,000.00	113,014.98
Facilities
Amortization of TI’s	536.99	536.99	536.99	268.00	1,878.97
Equipment Rental	229.43	0.00	469.36	0.00	698.79
Facility Cost Allocation	0.00	0.00	0.00	0.00	0.00
Liability Insurance	0.00	0.00	41.00	0.00	41.00
Office Rent
999 Bayhill Drive Office Rent	7,456.20	7,456.20	7,625.20	3,812.20	26,349.80
China Office Expenses	2,513.79	0.00	0.00	2,500.00	5,013.79
Total Office Rent	9,969.99	7,456.20	7,625.20	6,312.20	31,363.59
Office Supplies	854.88	5,886.80	1,230.38	3,000.00	10,972.06
Repairs	0.00	900.00	0.00	0.00	900.00
Telephone & Internet
Analog Land Phones	662.23	703.23	679.64	0.00	2,045.10
Analog Phone-Long Distance	145.52	101.09	68.30	0.00	314.91
Conference Call Service	652.95	153.19	240.45	0.00	1,046.59
Depreciation, Fixed Assets	1,250.00	1,250.00	1,250.00	625.00	4,375.00
Email Hosting	240.40	251.35	0.00	0.00	491.75
Internet	200.97	-200.97	0.00	0.00	0.00
Telephone & Internet - Other	0.00	255.25	244.45	0.00	499.70
Total Telephone & Internet	3,152.07	2,513.14	2,482.84	625.00	8,773.05
Utilities
Gas and Electric	0.00	11.85	0.00	0.00	11.85
Utilities - Other	0.00	23.73	43.22	0.00	66.95
Total Utilities	0.00	35.58	43.22	0.00	78.80
Total Facilities	14,743.36	17,328.71	12,428.99	10,205.20	54,706.26
Total Expense	1,054,607.35	669,083.84	666,130.67	562,209.66	2,952,031.52
Net Ordinary Income	-1,054,607.35	-669,083.84	-666,130.67	-562,209.66	-2,952,031.52
Other Income/Expense
Other Income
Cash & Share Dividends	65.20	270.17	3.64	0.00	339.01
Interest Income	0.00	0.00	5.52	0.00	5.52
Other Income	0.00	1.70	0.71	0.00	2.41
Total Other Income	65.20	271.87	9.87	0.00	346.94
Other Expense
Interest Expense	32,876.71	33,972.61	53,836.28	22,602.74	143,288.34
Other Expenses	189.57	-35,292.11	17.86	0.00	-35,084.68
Total Other Expense	33,066.28	-1,319.50	53,854.14	22,602.74	108,203.66
Net Other Income	-33,001.08	1,591.37	-53,844.27	-22,602.74	-107,856.72
Net Income	-1,087,608.43	-667,492.47	-719,974.94	-584,812.40	-3,059,888.24

Schedule 1.1(b)

Sample Future Payment Allocation Schedule*

Equityholder Name

Equityholder Address

Series A Preferred Stock [1]

Common Stock [1]

Series A Preferred Stock Warrants [1]

Common Stock Options [1]

Escrow Distribution Amount [2]

Equity- holder Represen- tative Fund Distribution [3]

First Subseq- uent PARP Payment Amount [4]

Dose Escalation Study Milestone [4]

Second Subseq -uent PARP Payment Amount [4]

Third Subseq- uent PARP Payment Amount [4]

Fourth Subseq- uent PARP Payment Amount [4]

Non-PARP Phase 2 Payment Amount [4]

Non-PARP Phase 3 Payment Amount [4]

Non-PARP Sub- licensing Payment Amount [5]

Payment Method (Wire or Check)

Wire Transfer / Check Delivery Instructions

W-8 / W-9 Delivered

ProQuest Investments IV, LP

[****]

9,007,937

1,428,571

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

A.M. Pappas Life Science Ventures III, LP

[****]

4,240,342

235,367

672,477

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

W-9

PV III CEO Fund, LP

[****]

263,626

14,633

41,809

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

W-9

Mustang Ventures I, L.P.

[****]

1,801,587

285,714

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

China Gateway Life Science (Holdings) Ltd. (HK)

[****]

450,395

71,429

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

ProQuest Management, LLC

[****]

250,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

Shuang Qiao

[****]

549,282

480,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Wire

[****]

Peter Myers

[****]

280,500

619,500

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Leonard Post

[****]

280,500

480,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Charles Hsu

[****]

363,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Zhengying Pan

[****]

5,208

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Xiaoyi Xiao

[****]

6,510

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Daniel Chu

[****]

97,500

247,500

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

David Hanabusa

[****]

30,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Yuqiao Shen

[****]

160,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Amy Pfeiffer

[****]

12,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Bing Wang

[****]

90,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

Ying Feng

[****]

40,000

$

—

$

—

[****]

[****]

[****]

[****]

[****]

[****]

[****]

[****]

Check

NOTES:

* Assumes no Unallocated Bonus Amount and no Working Capital Excess Amount will be distributed to Equityholders.

[1] Capitalization numbers presented based on the following assumptions:

• No Company Options or Company Warrants outstanding as of the date of the Agreement have been exercised.

• Closing Date is February 10, 2010.

• All the Company Notes have been converted to shares of Series A Preferred Stock immediately prior to the Closing.

• All Company Warrants or Company Options outstanding as of the date of the Agreement are exchanged for a portion of the Payable Consideration pursuant to the Agreement.

• No transfers of Equity Participations have occurred after the date of the Agreement.

[2] Assumes distribution of the full Indemnification Escrow Amount and Working Capital Escrow Amount, and in each case, does not account for earnings thereon.

[3] Assumes full distribution of Equityholder Representative Fund Amount and does not account for earnings.

[4] Assumes full payment of each Milestone Payment Amount (with no offsets by Buyer pursuant to the Agreement).

[5] Assumes up front consideration paid for Non-PARP Sublicensing Milestone is [****]

[****] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.

EX-31.1

Exhibit 31.1

CERTIFICATION

I, Jean-Jacques Bienaimé, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2010

/s/    JEAN-JACQUES BIENAIMÉ

Jean-Jacques Bienaimé

Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION

I, Jeffrey H. Cooper, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioMarin Pharmaceutical Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: April 30, 2010

/s/    JEFFREY H. COOPER

Jeffrey H. Cooper

Senior Vice President, Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

We, Jean-Jacques Bienaimé and Jeffrey H. Cooper, hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that BioMarin Pharmaceutical Inc.’s Quarterly Report on Form 10-Q for the period ended March 31, 2010, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and the information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/    JEAN-JACQUES BIENAIMÉ

Jean-Jacques Bienaimé

Chief Executive Officer

April 30, 2010

/s/    JEFFREY H. COOPER

Jeffrey H. Cooper

Senior Vice President, Chief Financial Officer

April 30, 2010